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Chapter 1 – General introduction
‘‘ I’ve told her that she can’t have kids, but she won’t accept that. ‘When I grow up
I’m going to have a boy and a girl.’’’ 
- Parent of a young female with Turner syndrome [1]
‘‘ Every once in a while, you know, when you’re holding a kid and they’re snuggling up
to your neck, I really thought: I wish I could have kids. I wish I had the choice.’’
- 31-year-old female with Turner syndrome [1]
‘‘Womengetflowersandtheygethonouredbecausethey’reamother,butIdon’t–you
know, I feel, does that make them a complete woman because they were able to have 
children? And I couldn’t, so I must be incomplete.’’
- 40-year-old female with Turner syndrome [1]
Turner syndrome (TS) is characterised by the partial or complete absence of a second 
X chromosome in some cell lines (i.e. mosaicism) or all cells. In most females, this 
results in early menopause and infertility. Infertility is the most painful challenge endured 
by females with TS, regardless of their age [1, 2]. Adolescent patients mentioned being 
extremely upset and disappointed at the time of diagnosis, and adult patients felt 
deprived of an important part of womanhood and reproductive choice [1]. The inability 
to bear a biological child remained, for many, a burden throughout their life, even 
though the majority of adult females with TS embraced alternative options to become 
a parent such as adoption [1]. 
Genotype
Typically, humans are born with 46 chromosomes arranged in 23 pairs. The first 22 
pairs of chromosomes are called the autosomes and the 23rd pair includes the sex 
chromosomes ‘X’ and ‘Y’.  The X and Y chromosome are called sex chromosomes 
because they determine the person ‘s biological sex. Most women have a 46, XX 
chromosome pattern and most men 46, XY. Divergence from the normal number of 
X and Y chromosomes is called sex chromosome aneuploidy (SCA). One of the most 
common SCA in humans is TS with a birth frequency of approximately 1 in 2,500 
live-born girls [3-5]. 
Genotypes associated with TS and their prevalence are listed in Table 1. Approximately 
40-50 percent of females with TS have a 45,X (monosomy X or “classic TS”) genotype 
[6]. The X chromosome is derived from the mother in two-thirds of patients and from 
the father in the remaining one-third [7]. This means that either an X or a Y chromosome 
is lost during early foetal life.
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45, X with one or more other cell lines (45, X mosaicism) is found in approximately 
one-half of all patients with TS (e.g., 45, X / 46, XX). 45, X mosaicism results from sex 
chromosome nondisjunction occurring during the foetal development [8, 9]. The 
degree of mosaicism may differ among different tissues. Furthermore, the absence of 
46, XX mosaicism in a peripheral blood sample does not always rule out the presence 
of 46, XX mosaicism in other tissues. 
In a small percentage of TS patients, a cell line with Y chromosomal content can be 
identified. The presence of Y chromosomal content is of medical importance because 
it might result in virilisation and increased gonadal tumour risk. In these patients, 
prophylactic gonadectomy is recommended.
The remaining group of females with TS has a structural anomaly of the X chromosome. 
Examples are isochromosome Xq (46, X, I (X) q), ring chromosome X (rX) and a 
deletion of a portion of the short arm of the X chromosome [del(X)p].
Table 1. Genotypes associated with Turner syndrome and their prevalence.
Genotype Percent 
of females with 
TS (%)
Description
45, X 40 to 50 Monosomy X
45, X / 46, XX 15 to 25 46, XX Mosaicism
45, X / 47, XXX; 
45, X / 46, XX/ 47, XXX
3 Mosaicism with “Triple X”
45, X /46, XY 10 to 12 Mixed gonadal dysgenesis
46, XX, del(p22.3) 10 to 12 Deletion Xp22.3
46, X, r (X) / 46, XX 10 to 12 Ring X chromosome
46, X I (Xq); 
46, X, idic (Xp)
(~10) Isochromosome Xq; 
Isodicentric Xp
X-autosome translocation, unbalanced Rare Various
46, XX, del(q24) Rare Not TS; premature ovarian 
insuffiency
46, X, idic (X)(q24) Rare Not TS; isodicentric Xq24
Copyright©2017BioScientificaLtd.Basedon:GravholtCH,AndersenNH,ConwayGS,etc.Clinicalpractice
guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati 
InternationalTurnerSyndromeMeeting.EurJEndocrinol2017;177:G1.
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Phenotype
A reduction of the X chromosomal content may affect the foetal development of 
almost all organs, leading to numerous clinical manifestations [10]. The clinical 
manifestations vary among girls with TS [11], and seem to be largely depending on the 
percentage of normal 46, XX cells, as patients with a ‘full-blown’ 45, X karyotype 
generally have a more severe phenotype [10].
The most common phenotypic features of TS are short stature and gonadal dysfunction. 
Other clinical features include cardio-aortic malformations, renal anomalies, hearing 
problems, and dysmorphic signs such as neck webbing, cubitus valgus and lymphoedema 
[11]. Although neurocognitive problems are common, females with TS generally have a 
normal range of cognitive abilities and intelligence [2]. Some of them will experience 
learning difficulties at school, particularly related to visual-spatial abilities, motor 
coordination, and mathematics [1]. Many adult women with TS are well-educated, 
employed, and are living a normal social life with stable relationships [2]. However, 
more often than females in the general population, females with TS are experiencing 
problems with social interaction or intimate relationships, mostly based on their 
concerns of being accepted despite their diagnosis [1]. 
Diagnosis
The majority of girls receives the diagnosis TS before the age of 5 because of growth 
retardation [11]. In some cases, TS is diagnosed prenatally, e.g. in case of cystic hygroma 
or intra-uterine growth retardation, or postnatally, e.g. in case of dysmorphic signs or 
congenital cardiac malformations. Occasionally, the diagnosis TS is concluded in 
adolescence because of delayed puberty or primary/secondary amenorrhoea.
In routine care, the diagnosis of TS is based on the genetic analysis of 20-30 peripheral 
blood lymphocytes [12]. On indication, the chromosome evaluation is expanded with 
FISH analysis on buccal cells. For instance, to identify a Y chromosome cell line in order 
to prevent the occurrence of a gonadoblastoma, and discuss prophylactic gonadectomy.
However, new insights recommend to perform buccal cell FISH in all patients with TS 
[13], to obtain a better global chromosomal evaluation, and, thus better care and 
follow-up.
History
Prior to the availability of karyotyping, TS was reported as a clinical syndrome. The American 
endocrinologist Henri Turner published a case series in 1938, where he described the 
occurrence of short stature, sexual immaturity, neck webbing, and deformity of the
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elbows (cubitus valgus) in seven independent cases [14]. A few years earlier, the German 
paediatrician Otto Ulrich described an eight-year-old girl with a similar phenotype [2].
Gonadal function 
Females with TS are at risk of premature ovarian insufficiency and have minimal chances 
of spontaneous conception. In addition, the likelihood of healthy offspring in females 
with TS is decreased as compared to the general population, because of an increased 
risk for miscarriage [15], and a slightly higher chance of giving birth to a child with a 
congenital disorder [15, 16]. Recent studies have shown that spontaneous pregnancies 
in females with TS are rare and occur in 2.0 – 7.6% of patients [15, 17-20]. As TS is 
related with an increased risk of foetal and maternal complications [11], strict monitoring 
by a team of high-care obstetricians, cardiologists and anaesthesiologists is paramount 
during pregnancy.
Approximately one-third of females with TS will have a sufficient ovarian reserve to 
experience a spontaneous onset of puberty, and up to 16.1% will experience one or 
more spontaneous menstruation cycles [21-23]. A recent study reports even higher 
rates for the spontaneous onset of puberty and menstruation in females with TS [24]. 
Nevertheless, most females with TS will be confronted with primary or secondary 
amenorrhea before reaching adulthood. If these females have a desire for parenthood 
in the future, they are depending on assisted reproductive technologies (ART), such as 
oocyte donation, or alternative options to become a parent such as adoption or fostering. 
However, interview studies with females with TS and their parents show a strong need 
for new options, such as fertility preservation (FP) [1, 25]. 
Fertility preservation
Fertility preservation includes the cryopreservation of the patient’s own gametes, 
either by preserving mature oocytes or ovarian tissue containing primordial follicles. 
Cryopreservation of mature oocytes (OC) is is an established fertility preservation 
approach but can be performed only in post pubertal females, as it requires ovarian 
activity and psychological maturity. This means that OC would be limited to a small 
percentage of females with TS only, i.e. girls with a spontaneous onset of menstruation 
who are emotionally mature enough to undergo the procedure.
The second technique, ovarian tissue cryopreservation (OTC), has the disadvantage 
that it requires surgery, most preferably a laparoscopic ovarian biopsy, ovarian wedge 
resection, or a unilateral ovariectomy. However, OTC can be performed regardless of 
the patient’s age or pubertal development, and thus appears to be a promising technique 
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to preserve the fertility of young girls with TS [25]. It provides the possibility to store 
(some of the) primordial follicles within the ovarian tissue before their premature 
disappearance. 
The efficacy of OTC in other patient groups has been well described, and over the past 
decades, several guidelines have been developed. Retransplantation of cryopre-
served-thawed ovarian cortical tissue in these patients has resulted in restoration of 
ovarian function [26, 27], pregnancies, and healthy offspring [28-33]. 
Recently, a Swedish study group proved that primordial follicles can be found in the 
laparoscopic ovarian biopsies from young girls with TS [34]. However, if OTC in females 
with TS will also lead to healthy offspring is currently still unknown. Hence, exploring 
the feasibility and efficacy of OTC in females with TS seems a logical next step [35]. 
Ideally, a clinical trial should be enrolled to explore the feasibility and efficacy of OTC 
in young females with TS. However, caution should be exercised, because this research 
will involve young children and OTC requires laparoscopic surgery under general 
anaesthesia with a possible risk of complications [36].
Aims and outline of this thesis
The aim of this thesis was to explore the various challenges of OTC in young females 
with TS. This thesis serves as groundwork for an international prospective cohort study 
(TurnerFertility trial, CCMO NL57738.000.16, ClinicalTrial ID NCT03381300). The 
following research questions will be addressed in this thesis:
I. What is currently known about the presence of follicles in the ovaries of young females 
with TS? (Chapter 2: In the literature)
II. What is current state of art regarding (experimental) FP outcomes in females with TS? 
(Chapter 2: In the literature)
III. Canwe optimize the efficacy ofOTC by using a non-invasive imaging technique to
determine the density of follicles in human ovarian cortex fragments that are intended 
for fertility restoration? (Chapter 3: Laboratory aspect)
IV. Which ethical aspects should be considered regarding OTC in young females with TS? 
(Chapter 4: Ethical aspect)
V. What is the standpoint of an international expert panel regarding OTC in young females 
with TS? (Chapter 4: Ethical aspect)
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VI. Which research should be performed to better inform TS patients about the feasibility 
andefficacyofOTC?(Chapter 5: Clinical aspect)
VII. Is it possible to determine the X chromosomal content of various ovarian cells in young 
patients with TS? (Chapter 6: Genetic aspect)
VIII. What is the X chromosomal content of the ovarian cells in young patients with TS? 
(Chapter 6: Genetic aspect)
IX. Is the X chromosomal content of the ovarian cells in young females with TS correlated 
with the X chromosomal content of other cell types? (Chapter 6: Genetic aspect)
X. Is FP also feasible in patients with 45, X monosomy? (Chapter 7: Patient-specific aspect)
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Infertility is a major concern for females with Turner syndrome (TS), regardless of their 
age. While fertility preservation is now routinely offered to girls and young women 
with cancer, there are currently no recommendations on fertility preservation in girls 
and young women with TS who generally face an even higher risk for infertility. Despite 
the lack of international guidelines, preservation procedures have been performed 
experimentally in females with TS.
Methods 
A systematic literature search based on the PRISMA-P methodology for systematic 
reviews was performed in order to collect all published data on fertility preservation 
options in females with TS between January 1980 and April 2018.  A total number of 
67 records were included in this review. The records were screened for information 
regarding cryopreservation of mature oocytes and ovarian tissue in females with TS. 
Two ongoing trials on fertility preservation in young females with TS were also included.
Results
Cryopreservation of oocytes or ovarian tissue has been performed experimentally in 
> 150 girls and adolescents with TS over the last 16 years. The efficacy of fertility 
preservation options in females with TS is still unknown due to the lack of follow-up 
data.
Conclusion
The efficacy of fertility preservation procedures in females with TS is still unknown. 
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Introduction
Turner syndrome (TS) is a condition in which a female is partly or completely missing 
one sex chromosome. It is the most common chromosomal abnormality in females, 
affecting 1 on 2,500 live-born girls [1-3]. The complete or partial loss of one sex 
chromosome in females leads to dysmorphic features and a constellation of physical 
findings that often includes short stature, cardiac and renal abnormalities, and infertility. 
Intelligence is generally normal among females with TS, but neurocognitive and 
psychosocial sequelae are common. 
For many years, it was thought that girls with TS were born infertile due to non-functional 
ovaries. However, scientists questioned this theory as increasing numbers of 
spontaneous pregnancies in females with TS were described. In 2002, a Swedish study 
group reported that primordial follicles were found in the ovaries of 8 out of 9 patients 
with TS who underwent a laparoscopic ovarian biopsy [4]. However, the number of 
follicles found was significantly lower as compared to the follicular density in unaffected 
girls undergoing laparoscopic ovarian biopsy. This new insight led to the hypothesis that 
a complete or partial loss of one sex chromosome in females causes an accelerated 
degeneration of germ cells, starting at the 13th week of fetal age [5-7]. In the general 
population, females are born with an ovarian reserve of approximately 1-2 million 
oocytes. This number is reduced to approximately 300.000 at puberty and continues 
to decrease throughout life until menopause is reached [8]. Due to the rapid loss of the 
ovarian reserve, most females with TS reach menopause during childhood or 
adolescence. The timeline at which this occurs is less clear, and may be different for 
each individual patient with TS [6]. Recent studies have shown that spontaneous 
pregnancies in females with TS are rare and occur in 2.0 – 7.6% of patients [9-13]. 
Approximately one-third of females with TS will have a sufficient ovarian reserve to 
experience a spontaneous onset of puberty, and up to 16.1% will experience one or 
more spontaneous menstruation cycles [8, 14, 15]. A recent study  reports even higher 
rates for the spontaneous onset of puberty and menstruation in females with TS [16]. 
However, the majority of females with TS will be confronted with primary or secondary 
amenorrhea before reaching adulthood.
Dealing with infertility can be one of life’s most stressful experiences, and interview 
studies [17, 18] have shown that, regardless of age, this is one of the main concerns of 
females with TS and their parents. For this reason, it is recommended that girls with TS 
are informed early during childhood or adolescence about the possibilities to fulfil their 
wish for a future child. An expectative management approach can be proposed, 
especially in females with regular menstruation cycles. However, the majority of females 
with TS currently depend on assisted reproductive technologies (ART), such as oocyte 
donation, or alternative options to become a parent such as adoption or fostering. 
Quantitative and qualitative research shows a strong need for new options such as 
fertility preservation [17, 19].
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Fertility preservation includes the cryopreservation of the patient’s own gametes, 
either by preserving mature oocytes or ovarian tissue containing primordial follicles. In 
recent years, thanks to the success rates in other patient groups [20-23], physicians are 
often asked by girls with TS and their parents about the options to preserve their 
fertility [24]. However, very little is known about the success rates of different fertility 
preservation options in this specific group of patients. This raises the question if the 
promise of fertility preservation is at present hypothetical, or if these options can be 
realistically offered to females with TS.
Methods
A systematic literature search based on the PRISMA-P methodology for systematic 
reviews [25] was performed in Pubmed in April, 2018 in order to collect all published 
data on fertility preservation in females with TS. A total of 2021 records could be 
identified by using search terms mentioned in Appendix 1. The search was limited to 
studies published in English or Dutch between January 1980 and April 2018 with full 
text availability. This resulted in a total number of 1276 articles. The selection of relevant 
articles was based on title and abstract screening, which was done by four investigators. 
In case of doubt, the titles and abstracts were discussed with the other investigators. 
Additional articles were found by scanning the reference list of each relevant article. 
A total number of 73 articles were screened in full text by two investigators independently, 
which led to the exclusion of 26 articles. Reasons for exclusion were publication in 
other languages than Dutch or English, no full text availability, or being irrelevant to the 
main topic. Additionally, 20 useful publications were included after the screening of 
reference lists.  A total number of 67 records were included in this review and were 
screened for information regarding fertility preservation in females with TS (Figure 1). 
Information was gathered on both cryopreservation of mature oocytes and ovarian 
tissue. Two ongoing trials on fertility preservation in young females with TS were also 
included. Information regarding embryo freezing in patients with TS was not taken into 
account, as this review focuses on fertility preservation in females with TS without a 
male partner. 
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Results
Cryopreservation of mature oocytes in females with TS 
Cryopreservation of mature oocytes (OC) requires ovarian stimulation with exogenous 
FSH administration followed by transvaginal ultrasound-guided oocyte retrieval [26].
OC is an established fertility preservation approach but can be performed only in post 
pubertal females, as it requires ovarian activity and psychological maturity. This means 
that OC is limited to a small percentage of females with TS, namely those who will 
experience a spontaneous onset of menstruation and are emotionally mature enough 
to undergo the procedure.
Over the last ten years, eighteen cases of OC in females with TS have been reported 
[27-34]. Patient characteristics and biochemical profiles are summarized in Table 1. 






















Records identif ied (n=2021)
Records screened (n=1276)
Excluded with reasons (n=26)
Language (n=7)
Topics not relevant (n=12)
No full-text availability (n=7)
Full-text articles assessed for 
eligibility (n=73)
Excluded after abstract and 
title screening (n=1203)





Excluded after applying search 
limitations (n=745)
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All eighteen cases experienced a spontaneous onset of menstruation. Fifteen females 
had a 45, X / 46, XX karyotype with a 45, X percentage between 20 – 93%, two 
females had a 45, X / 47, XXX karyotype with a 45, X percentage between 90 – 98%, 
and one female was diagnosed with 45, X (86%) / 46, XX (3%) / 47, XXX (11%) TS. 
In four patients OC was opted because of an irregular cycle. Thirteen females still had 
a regular menstruation cycle when they decided for OC. In one patient, the regularity 
of the menstruation cycle was not reported. The age of patients during the oocyte 
retrieval ranged from 13 to 28 years. Before ovarian stimulation, eight patients had a 
normal FSH serum level, and ten patients had a serum FSH level of >15 mUI/mL. Serum 
AMH levels ranged from 1.7 to 43.8 pmol/L. Ultrasonic assessment showed an antral 
follicle count between 6 and 40, with a mean number of 13 antral follicles. The stimulation 
medication, dosage, type of trigger and OC outcomes are detailed in Table 1. On average, 
11 oocytes (range 2 – 19) were retrieved per cycle, of which approximately 76% could 
be cryopreserved (range 69 – 100%). All females tolerated the procedure well, and in 
most females OC was performed safely without any complications. However, one 
patient developed a severe ovarian hyper stimulation syndrome. Seven days after the 
administration of 5.000 IU human chorionic gonadotropin (hCG), she had to undergo 
an abdominal paracentesis of 1L of ascites, which resulted in a full recovery. The peak 
estradiol level on the day of the trigger in this patient was high (16.545 pmol/L) compared 
to the peak estradiol levels that was described in the other cases (range 1.241 – 5.956 
pmol/L.
There are no published reports of pregnancies after OC in patients with TS.
Ovarian tissue cryopreservation in females with TS
Ovarian tissue cryopreservation (OTC) requires a surgical procedure, most preferably 
a laparoscopic ovarian biopsy, ovarian wedge resection, or a unilateral ovariectomy. 
OTC can be performed regardless of age or spontaneous onset of puberty, and thus 
appears to be a promising technique to preserve the fertility of young girls with TS [19]. 
It provides the possibility to store a part of the primordial follicles within the ovarian 
tissue before their premature disappearance. Even though OTC in girls facing fertility 
threatening cancer treatment is accepted and established [16-18], there are currently 
no recommendations on fertility preservation in girls with TS. However, OTC has been 
performed experimentally in at least 83 young females with TS aged 6 – 19 years old 
[4, 19, 28, 31, 35]. Study characteristics and outcomes are summarized in Table 2. 
Ovarian tissue could be obtained in approximately 85% of the patients, and no 
complications related to the surgical procedure have been reported. Primordial follicles 
were found in the ovarian tissue of 43% of the cases. Positive predictive markers for the 
presence of follicles were mosaic TS, a spontaneous menarche, a spontaneous thelarche, 
a normal FSH level, and a normal AMH level. One study reported a positive association 
with age (above 12 years old) [19], which might be related to the age distribution within 
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the study group, as 86% of the study population was 12 years or older. None of the 
other studies reported a correlation with the patient’s age. The follicular density in the 
ovarian cortex tissue harvested in young females with TS varied from 0 – 1200 follicles 
per mm3. It is unknown if autotransplantation of earlier cryopreserved ovarian tissue 
has already been performed in patients with TS. There has to date been no follow-up 
data published.
Currently, the data from 47 girls with TS who underwent OTC in France is being 
assessed and will be reported soon (personal communication Lise Duranteau). One 
clinical trial currently in progress in the Netherlands, is recruiting young females with TS 
aged 2 to 18 years (principal investigator Kathrin Fleischer). This cohort will be followed 
from OTC until live birth with the aim to collect long-term follow-up data (Table 3).
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Table 1.  Cryopreservation of mature oocytes in patients with  
Turner syndrome - reported cases.


















1 1 1 1
Age (y) 28 16 16 22
Karyotype 45, X / 46, XX 
(percentages not 
reported)
45, X (20%) / 46, 
XX (80%)
45, X (98%) / 47, 
XXX (2%)
45, X (86%) / 47, 
XXX (11%) / 46, 
XX (3%)
Cells used for chromosome 
analysis 
not reported lymphocytes 
(number not 
reported)
not reported not reported
Spontaneous thelarche yes yes yes yes
Spontaneous menarche yes yes yes yes
Menstruation cycle irregular irregular regular regular
Serum AMH not reported not reported not reported 8.5 pmol/L
Serum FSH 4.3 mIU/ml 9.8 mUI/mL 6.3 mUI/mL 4.6 mUI/mL
Serum LH not reported 1.4 mUI/mL 2.4 mUI/mL not reported
Serum estradiol not reported 119 pmol/L 73.4 pmol/L <44.0 pmol/L
Serum inhibin B not reported not reported not reported not reported








wedge resection of 
the left ovary and 
in vitro aspiration 
of the antral 
follicles, followed 
by the isolation 
of (immature) 
oocytes and in vitro 
maturation from 
germinal vesicle 
















Antral follicle count 40 not reported 6 7
№ of cycles 1 not applicable 1 1
Protocol antagonist not applicable agonist flare-up (agonist)
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United Kingdom United States United States The Netherlands
Cryopreservation 








1 1 3 10
28 14* 13 14* 13 not reported
45, X (93%) / 46, 
XX (7%)
45, X (45%) / 46, 
XX (55%)
45, X (90%) / 47, 
XXX (10%)
45, X (45%) / 46, 
XX (55%)
45, X (20%) / 46, 
XX (80%)
45, X / 46, XX 
(100%)
30 lymphocytes 20 lymphocytes 30 lymphocytes 20 lymphocytes 20 lymphocytes not reported
yes yes yes yes yes not reported
yes yes yes yes yes not reported
regular irregular irregular irregular not reported regular
43.8 pmol/L 2.0 pmol/L 3.6 pmol/L 2.0/3.8 pmol/L ** 1.7 pmol/L not reported
not reported 5.3 mUI/mL 5.7 mUI/mL 5.3 mUI/mL 5.6 mUI/mL > 15.0 mUI/mL
not reported 9.5mUI/mL 3.9 mUI/mL 9.5 mUI/mL 5.3 mUI/mL not reported
not reported 239.3 pmol/L 33.9 pmol/L 146.5 pmol/L 75.3 pmol/L not reported



















































not reported 12 6 12 6 not reported
2 1 1 2 1 not reported
antagonist antagonist antagonist antagonist antagonist not reported
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Table 1.  Continued.








Stimulation medication  
and dose
2.025 IU rFSH  
(sd 1-9)
not applicable 900 IU rFSH  
(sd 1-10) + 150 IU 
hMG (sd 6-10)
825 IU hMG  
(sd 1-11)
Duration of ovarian 
stimulation (days) 
9 not applicable 10 11
Peak estradiol levels on the day 
of trigger
16.545pmol/L not applicable 1.241 pmol/L 5.956 pmol/L
Trigger medication and dose 5.000 IU hCG not applicable hCG, dose not 
reported
10.000 IU hCG
Number of oocytes retrieved  
per cycle
15 not applicable 2 8
Number of mature oocytes 
cryopreserved
13 8 2 8
Total number of mature oocytes 
cryopreserved
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1.350 IU rFSH  
(sd 1-9)
1.800 IU rFSH  
(sd 1-10), 150 IU 
hMG  (sd 8-10)
2.475 IU rFSH + 
150 IU rLH  
(sd 1-11)
1.800 IU rFSH + 
450 hMG (sd 1-10) 
/ 3.750 IU rFSH + 
2.100 hMG  
(sd 1-14)
2.025 IU hFSH + 
75 IU rLH (sd 1-10)
not reported
9 10 11 10 / 14 10 not reported
not reported 5.112pmol/L 3.478 pmol/L 5.112/4.559 pmol/L 3.624 pmol/L not reported
10.000 IU hCG 1 mg luprolide 
acetate
3300 IU hCG 1 mg luprolide 
acetate / 1 mg 
luprolide acetate
250mcg rhCG not reported
12*** / 10 11 19 11 / 7 16 not reported
0*** / 10 8 10 8 / 4 12 not reported
10 8 10 12 12 not reported
none none none none none not reported
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Table 2.  Cryopreservation of ovarian tissue in patients with Turner syndrome 
- reported cases.
Authors Hreinsson et al 2002 Huang et al 2008 Borgström et al 2009
Country Sweden Canada Sweden
Procedure(s) Cryopreservation of ovarian 
tissue   
Cryopreservation of mature 
oocytes and ovarian tissue   
Cryopreservation of ovarian 
tissue   
Surgical intervention Laparoscopic removal of a 
quarter to one whole ovary
Laparoscopic ovarian wedge 
resection
Laparoscopic unilateral 
ovarian biopsies (25-50% of 
the ovarian cortical tissue of 
one of both ovaries) 
Study period not specified not specified not specified
10 1 57
Age (y) 12 – 19 16 8-19 
Karyotype 
(% of participants)
45, X / 46, XX (50%),45, X 
(40%), and 45, X / 46, XX / 
47, XXX (10%)
45, X / 46, XX (100%) 45, X (49%), structural X 
chromosomal abnormalities 
(38%), 45, X / 46, XX (9%),    
45, X / 46, XX / 47, XXX 
(2%), 45, X / 47, XXX (2%)
Cells used for 
chromosome analysis
lymphocytes or skin 
fibroblasts (number not 
reported)
lymphocytes (number not 
reported)
15-105 lymphocytes  
(no case specific reports)
Ovarian tissue  
could be obtained 
(% of participants)
9 (90%) 1 (100%) 47 (82%)
Complications related  
to the surgical procedure
not reported not reported none 
Presence of follicles  
in the obtained ovarian 
tissue (% of participants)
8/9 (89%) 1/1 (100%) 15/47 (32%)
Positive predictive 
markers for the presence 
of follicles (positive 
predictive value,  
statistical significance)
small sample size small sample size Mosaic Turner syndrome 
(0.86, p = 0.0001), 
spontaneous menarches 
(0.62, p = 0.0039), 
spontaneous thelarche 
(0.58, p = 0.0008), normal 
FSH level (0.69, p = 0.0123), 
normal AMH level (0.64,  
p = 0.0003), age 12-16 years 
old (0.31, not significant),  
age above 16 years old (0.24, 
not significant)
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Balen et al 2010 Von Wolff et al 2015 Jadoul et al 2017 Jensen et al 2017
United Kingdom Germany, Switzerland, 
Austria
Belgium Denmark
Cryopreservation of mature 
oocytes and ovarian tissue
Cryopreservation of mature 
oocytes or ovarian tissue 
(not specified)
Cryopreservation of ovarian 
tissue   
Cryopreservation of ovarian 
tissue   
Laparoscopic bilateral 
ovarian biopsies




1998 - 2009 2007-2013 1997-2013 2000-2015
1 8 not reported 6
17 not reported not reported 6-17
45, X / 46, XX (100%) 45, X mosaicism (100%) not reported 45, X (67%), 
45, X mosaicism (33%)
30 lymphocytes not reported not reported not reported
1 (100%) not reported not reported 6 (100%)
none not reported not reported not reported
1/1 (100%) not reported not reported not reported
small sample size not reported not reported not reported
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Table 2.  Continued.
Authors Hreinsson et al 2002 Huang et al 2008 Borgström et al 2009
Negative predictive 
markers for the presence 
of follicles (negative 
predictive value,  
statistical significance)
small sample size small sample size 45, X karyotype  (0.89,  
p = 0.0001), structural X 
chromosomal abnormalities 
(0.73, p = 0.0001),  
no spontaneous menarche 
(0.81, p = 0.0039),  
no spontaneous thelarche 
(0.87, p = 0.0008), elevated 
FSH level (0.77, p = 0.0123), 
low AMH level (0.88,  
p = 0.0003), age below 
12 years old  (0.82, not 
significant)
Follicles per mm3  
in ovarian cortex
0-499 not reported 0-1200
Follow up data not reported not reported not reported
Optimal age to 
discuss ovarian tissue 
cryopreservation
All patients with TS, ideally 
before the age of 12-13 years 
old, especially in females with 
nonmosaic Turner syndrome
All patients with TS, ideally 
aged 12-13 years old
All patients with TS, ideally 
aged 13-14 years old  
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Balen et al 2010 Von Wolff et al 2015 Jadoul et al 2017 Jensen et al 2017
small sample size not reported not reported not reported
not reported not reported not reported not reported
not reported not reported not reported not reported
not reported not reported not reported not reported
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Cryopreservation of mature oocytes and ovarian cortex tissue has been performed 
experimentally in > 150 girls and adolescents with TS [4, 19, 27-37] [Clinicaltrial.org]. 
Thus far, there are no published records of girls with TS who have returned for auto-
transplantation or in vitro fertilization with embryo transfer. Recently, the success rate 
of cryopreservation and subsequent transplantation(s) of ovarian tissue in cancer 
survivors was reported [23]. The FertiPROTEKT study group found a restoration of 
ovarian function in 67% per transplantation. Pregnancy and live birth rates were 33 and 
25% per transplantation, respectively [23], and multiple autotransplantation sessions 
per patient were possible, depending on the number of ovarian strips. However, these 
data cannot be automatically translated to females with TS, as the occurrence of 
pregnancy and live birth after autotransplantation of frozen ovarian cortex strips is 
highly correlated with the number of functional primordial follicles found in the ovarian 
tissue [38]. Women with TS are likely to have a decreased follicular density [19, 39], but 
also show a higher risk of miscarriage [11], and a slightly higher risk of a child with a 
congenital disorder when they conceive spontaneously [11, 40]. If these increased risks 
are related to the functional integrity or the chromosome profile of their follicular cells 
remains unclear. Autotransplantation of ovarian cortex fragments with a low number 
of functional follicles might lead to false hope, as it is unlikely that these cortex strips will 
lead to restoration of ovarian function, pregnancy and live birth. Possibly, in vitro 
activation (IVA) of residual dormant follicles [41-44] prior to autotransplantation can be 
applied to optimize the treatment outcome. However, no cases of IVA in patients with 
TS have been reported so far.
The possible negative effects on future fertility of girls with TS after the removal of one 
ovary are also unknown. Recent studies in other patient groups have shown that the 
surgical removal of one ovary does not affect the menstrual cycle, nor the chances of 
getting pregnant in the future [45-48].  However, removal of an ovary may lead to an 
earlier onset of menopause of up to 3 years in comparison to females who still have 
both ovaries [49]. In these patient groups it has been suggested that one intact ovary 
may compensate for the loss of the other [50].
Hence, fertility restoration by OC or OTC in patients with TS is at present still 
hypothetical, and further research is needed to provide supporting evidence for the 
efficacy of these fertility preservation techniques in this specific group of patients. The 
Oncofertility Consortium states that OTC is a promising approach to provide fertility 
options to girls with TS [51]. In some countries, OTC is already routinely offered to girls 
with TS.
It is fundamental that young females with TS and their parents are not only informed 
about the chances of developing POI and the possibilities to preserve their fertility, but 
also receive information on alternative options to become a future parent (e.g. by 
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oocyte donation, surrogacy, adoption or fostering). Furthermore, they should be 
counselled about the probability of conceiving spontaneously, even if the occurrence of 
spontaneous pregnancies is low (2.0 – 7.6%). In addition, the maternal and fetal risks of 
a future pregnancy should be discussed, including extensive counselling about the 
cardiovascular risks. Needless to say, it is preferable to discuss fertility preservation 
options with girls who are competent to make their own decisions. However, the 
majority of girls are infertile by the end of adolescence. This young age of reaching 
infertility may be a limiting factor in comprehension and emotional maturity required 
to fully understand their fertility status and preservation options. The International 
Turner Consensus Group therefore states that fertility preservation counselling should 
begin at the time of diagnosis to allow the patient and her parent(s) to have enough 
time to consider its implications. However, they recommend against routine fertility 
preservation of young TS girls before the age of 12 years [52].
A decision aid based on the information needs of girls with TS and their parents is 
therefore required to facilitate deliberate decision making. Ideally, this decision aid 
should include a patient-specific a priori calculation of the ovarian reserve, with the aim 
to avoid unnecessary interventions (i.e. in girls without follicles in their ovaries or in 
females with a normal ovarian reserve) and to better pinpoint the urgency of fertility 
preservation. Several studies have been conducted aiming to estimate the ovarian 
reserve in patients with TS at a young age [19, 26]. A spontaneous onset of puberty and 
menstruation, mosaic karyotype, measurable AMH level, and normal FSH level have 
been associated with the presence of follicles [19, 26].
Borgström et al. suggested the following categories of girls to have the highest chance 
of having follicles: 1) girls with a mosaic karyotype; 2) girls with a spontaneous onset of 
puberty and 45, X or 45, X / 46, X and structural anomalies; and 3) girls with normal 
serum FSH and/or normal AMH levels with or without spontaneous onset of puberty. 
By retrospectively applying these criteria  to their cohort [19], 19 laparoscopic 
procedures would have been performed, and 23 girls would have been excluded from 
taking an ovarian biopsy. In 15 girls the surgical procedure would have been postponed. 
No follicles would have been found in 8 out of 19 girls, and 2 girls with follicles would 
have been missed, resulting in a relatively low sensitivity of 0.58 and a specificity of 0.91.
Using these criteria for fertility preservation counselling in females with TS is still 
controversial, as there are, for example, also spontaneous pregnancies reported in 
females with a 45, X monosomy karyotype (classical TS) [10-12, 53-59]. Nevertheless, 
it should be questioned whether these females indeed had a true 45, X karyotype and 
not a low grade 45, X / 46, XX mosaicism karyotype, as the number of cells used for 
chromosome analysis are often not reported.
Thus, optimal discriminative markers to estimate the ovarian reserve in females with TS 
are still lacking. For this reason, and because of its experimental character, experts 
recommend against routine fertility preservation in females with TS [19, 26, 52, 60]
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Future clinical research should focus on both the efficacy of fertility preservation 
options in females with TS including pregnancy rates, pregnancy outcomes, and 
maternal, as well fetal risks, and on the development of a reliable prognostic model for 
the presence of follicles in females with TS.
In vitro studies with the aim to optimize the chances for females with TS of becoming 
biological parents of their own children should focus on oocyte genetics, activation of 
immature oocytes in isolated ovarian tissue [41-44], maturation of immature oocytes 
obtained from cryopreserved ovarian tissue (IVM) [61], and the development of 
artificial gametes from stem cells [62].
Conclusion
Cryopreservation of oocytes or ovarian tissue has been performed experimentally in 
> 150 girls and adolescents with TS since 2002. However, the efficacy of fertility 
preservation procedures in females with TS is still unknown. Future studies with focus 
on efficacy, safety and long-term follow-up are desperately needed.
563903-L-bw-Schleedoorn
Processed on: 26-7-2021 PDF page: 41
41In the literature 
2
References
1. Elsheikh, M., D.B. Dunger, G.S. Conway, and J.A. Wass, Turner’s syndrome in adulthood. Endocr Rev, 2002. 
23(1): p. 120-40.
2. Karnis, M.F., Fertility, pregnancy, and medical management of Turner syndrome in the reproductive years. Fertil 
Steril, 2012. 98(4): p. 787-91.
3. Stochholm, K., S. Juul, K. Juel, R.W. Naeraa, and C.H. Gravholt, Prevalence, incidence, diagnostic delay, and 
mortality in Turner syndrome. J Clin Endocrinol Metab, 2006. 91(10): p. 3897-902.
4. Hreinsson, J.G., M. Otala, M. Fridstrom, B. Borgstrom, C. Rasmussen, M. Lundqvist, T. Tuuri, N. Simberg, 
M. Mikkola, L. Dunkel, and O. Hovatta, Follicles are found in the ovaries of adolescent girls with Turner’s 
syndrome. J Clin Endocrinol Metab, 2002. 87(8): p. 3618-23.
5. Weiss, L., Additional evidence of gradual loss of germ cells in the pathogenesis of streak ovaries in Turner’s 
syndrome. J Med Genet, 1971. 8(4): p. 540-4.
6. Reynaud, K., R. Cortvrindt, F. Verlinde, J. De Schepper, C. Bourgain, and J. Smitz, Numberofovarianfollicles
in human fetuses with the 45,x karyotype. Fertility and Sterility, 2004. 81(4): p. 1112-1119.
7. Modi, D.N., S. Sane, and D. Bhartiya, Accelerated germ cell apoptosis in sex chromosome aneuploid fetal 
human gonads. Mol Hum Reprod, 2003. 9(4): p. 219-25.
8. Pasquino, A.M., F. Passeri, I. Pucarelli, M. Segni, and G. Municchi, Spontaneous pubertal development in 
Turner’ssyndrome.ItalianStudyGroupforTurner’sSyndrome. J Clin Endocrinol Metab, 1997. 82(6): p. 1810-3.
9. Hadnott, T.N., H.N. Gould, A.M. Gharib, and C.A. Bondy, Outcomes of spontaneous and assisted pregnancies 
inTurnersyndrome:theU.S.NationalInstitutesofHealthexperience. Fertil Steril, 2011. 95(7): p. 2251-6.
10. Bryman, I., L. Sylven, K. Berntorp, E. Innala, I. Bergstrom, C. Hanson, M. Oxholm, and K. Landin-Wilhelmsen, 
Pregnancy rate and outcome in Swedish women with Turner syndrome. Fertil Steril, 2011. 95(8): p. 2507-10.
11. Bernard, V., B. Donadille, D. Zenaty, C. Courtillot, S. Salenave, A. Brac de la Perrière, F. Albarel, A. Fèvre, 
V. Kerlan, T. Brue, B. Delemer, F. Borson-Chazot, J.-C. Carel, P. Chanson, J. Léger, P. Touraine, and S. 
Christin-Maitre, Spontaneous fertility and pregnancy outcomes amongst 480 women with Turner syndrome. 
Human Reproduction, 2016. 31(4): p. 782-788.
12. Birkebaek, N.H., D. Crüger, J. Hansen, J. Nielsen, and G. Bruun-Petersen, Fertility and pregnancy outcome 
in Danish women with Turner syndrome. Clinical Genetics, 2002. 61(1): p. 35-39.
13. Hovatta, O., Pregnancies in women with Turner’s syndrome. Ann Med, 1999. 31(2): p. 106-10.
14. Tanaka, T., Y. Igarashi, K. Ozono, K. Ohyama, M. Ogawa, H. Osada, K. Onigata, S. Kanzaki, H. Kohno, Y. 
Seino, H. Takahashi, T. Tajima, K. Tachibana, H. Tanaka, Y. Nishi, T. Hasegawa, K. Fujita, T. Yorifuji, R. 
Horikawa, and S. Yokoya, Frequenciesof spontaneousbreastdevelopmentand spontaneousmenarche in
Turner syndrome in Japan. Clin Pediatr Endocrinol, 2015. 24(4): p. 167-73.
15. da Silva Negreiros Liza, P., R. Bolina Eduardo, and M. Guimarães Marilia, Pubertaldevelopmentprofilein
patients with Turner syndrome, in Journal of Pediatric Endocrinology and Metabolism. 2014. p. 845.
16. Hankus, M., K. Soltysik, K. Szeliga, A. Antosz, A. Drosdzol-Cop, K. Wilk, A. Zachurzok, E. Malecka-Tende-
ra, and A.M. Gawlik, Prediction of Spontaneous Puberty in Turner Syndrome Based on Mid-Childhood
GonadotropinConcentrations,Karyotype,andOvaryVisualization:ALongitudinalStudy. Horm Res Paediatr, 
2018. 89(2): p. 90-97.
17. Sutton, E.J., A. McInerney-Leo, C.A. Bondy, S.E. Gollust, D. King, and B. Biesecker, Turner syndrome: four 
challenges across the lifespan. Am J Med Genet A, 2005. 139A(2): p. 57-66.
18. Sylven, L., C. Magnusson, K. Hagenfeldt, and B. von Schoultz, LifewithTurner’ssyndrome--apsychosocial
reportfrom22middle-agedwomen. Acta Endocrinol (Copenh), 1993. 129(3): p. 188-94.
19. Borgstrom, B., J. Hreinsson, C. Rasmussen, M. Sheikhi, G. Fried, V. Keros, M. Fridstrom, and O. Hovatta, 
Fertility preservation in girls with turner syndrome: prognostic signs of the presence of ovarian follicles. J Clin 
Endocrinol Metab, 2009. 94(1): p. 74-80.
20. Dittrich, R., J. Hackl, L. Lotz, I. Hoffmann, and M.W. Beckmann, Pregnancies and live births after 20 trans-
plantations of cryopreserved ovarian tissue in a single center. Fertil Steril, 2015. 103(2): p. 462-8.
21. Meirow, D., H. Ra’anani, M. Shapira, M. Brenghausen, S. Derech Chaim, S. Aviel-Ronen, and J. Dor, Trans-
plantationsoffrozen-thawedovariantissuedemonstratehighreproductiveperformanceandtheneedtorevise
restrictive criteria. Fertil Steril, 2016. 106(2): p. 467-74.
563903-L-bw-Schleedoorn







22. Jadoul, P., A. Guilmain, J. Squifflet, M. Luyckx, R. Votino, C. Wyns, and M.M. Dolmans, Efficacyofovarian
tissue cryopreservation for fertility preservation: lessons learned from 545 cases. Hum Reprod, 2017. 32(5): 
p. 1046-1054.
23. Van der Ven, H., J. Liebenthron, M. Beckmann, B. Toth, M. Korell, J. Krussel, T. Frambach, M. Kupka, M.K. 
Hohl, K. Winkler-Crepaz, S. Seitz, A. Dogan, G. Griesinger, F. Haberlin, M. Henes, R. Schwab, M. Sutterlin, 
M. von Wolff, and R. Dittrich, Ninety-fiveorthotopic transplantations in74womenofovariantissueafter
cytotoxic treatment in a fertility preservation network: tissue activity, pregnancy and delivery rates. Hum 
Reprod, 2016. 31(9): p. 2031-41.
24. Grynberg, M., M. Bidet, J. Benard, M. Poulain, C. Sonigo, I. Cedrin-Durnerin, and M. Polak, Fertility 
preservation in Turner syndrome. Fertil Steril, 2016. 105(1): p. 13-9.
25. Liberati, A., D.G. Altman, J. Tetzlaff, C. Mulrow, P.C. Gøtzsche, J.P.A. Ioannidis, M. Clarke, P.J. Devereaux, 
J. Kleijnen, and D. Moher, ThePRISMAStatementforReportingSystematicReviewsandMeta-Analysesof
Studies That Evaluate Health Care Interventions: Explanation and Elaboration. PLOS Medicine, 2009. 6(7): 
p. e1000100.
26. Oktay, K., G. Bedoschi, K. Berkowitz, R. Bronson, B. Kashani, P. McGovern, L. Pal, G. Quinn, and K. Rubin, 
Fertility Preservation in Females with Turner Syndrome: A Comprehensive Review and Practical Guidelines. 
J Pediatr Adolesc Gynecol, 2015.
27. Kavoussi, S.K., S. Fisseha, Y.R. Smith, G.D. Smith, G.M. Christman, and L.A. Gago, Oocyte cryopreservation 
in a woman with mosaic Turner syndrome: a case report. J Reprod Med, 2008. 53(3): p. 223-6.
28. Huang, J.Y., T. Tulandi, H. Holzer, N.M. Lau, S. Macdonald, S.L. Tan, and R.C. Chian, Cryopreservation of 
ovarian tissue and in vitro matured oocytes in a female with mosaic Turner syndrome: Case Report. Hum 
Reprod, 2008. 23(2): p. 336-9.
29. Lau, N.M., J.Y. Huang, S. MacDonald, S. Elizur, Y. Gidoni, H. Holzer, R.C. Chian, T. Tulandi, and S.L. Tan, 
Feasibility of fertility preservation in young females with Turner syndrome. Reprod Biomed Online, 2009. 18(2): 
p. 290-5.
30. El-Shawarby, S.A., F. Sharif, G. Conway, P. Serhal, and M. Davies, Oocyte cryopreservation after controlled 
ovarian hyperstimulation in mosaic Turner syndrome: another fertility preservation option in a dedicated UK 
clinic. BJOG, 2010. 117(2): p. 234-7.
31. Balen, A.H., S.E. Harris, E.L. Chambers, and H.M. Picton, Conservation of fertility and oocyte genetics in a 
young woman with mosaic Turner syndrome. BJOG, 2010. 117(2): p. 238-42.
32. Oktay, K., K.A. Rodriguez-Wallberg, and G. Sahin, Fertility preservation by ovarian stimulation and oocyte 
cryopreservation in a 14-year-old adolescent with Turner syndrome mosaicism and impending premature
ovarian failure. Fertil Steril, 2010. 94(2): p. 753.e15-9.
33. Oktay, K. and G. Bedoschi, Oocytecryopreservationforfertilitypreservationinpost-pubertalfemalechildren
at risk for premature ovarian failure due to accelerated follicle loss in Turner Syndrome or cancer treatments. 
Journal of pediatric and adolescent gynecology, 2014. 27(6): p. 342-346.
34. Balkenende, E., T. Dahhan, S. Repping, A.A. de Melker, F. van der Veen, and M. Goddijn, [Oocytevitrification:
for whom?]. Ned Tijdschr Geneeskd, 2015. 159: p. A9361.
35. von Wolff, M., R. Dittrich, J. Liebenthron, F. Nawroth, A.N. Schüring, T. Bruckner, and A. Germeyer, 
 Fertility-preservationcounsellingandtreatmentformedicalreasons:datafromamultinationalnetworkofover
5000 women. Reproductive BioMedicine Online, 2015. 31(5): p. 605-612.
36. Jadoul, P., A. Guilmain, J. Squifflet, M. Luyckx, R. Votino, C. Wyns, and M.M. Dolmans, Efficacyofovarian
tissue cryopreservation for fertility preservation: lessons learned from 545 cases. Hum Reprod, 2017. 32(5): 
p. 1046-1054.
37. Jensen, A.K., C. Rechnitzer, K.T. Macklon, M.R. Ifversen, N. Birkebaek, N. Clausen, K. Sorensen, J. Fedder, 
E. Ernst, and C.Y. Andersen, Cryopreservation of ovarian tissue for fertility preservation in a large cohort of 
young girls: focus on pubertal development. Hum Reprod, 2017. 32(1): p. 154-164.
38. Donnez, J.S.K., S.S. (Eds.), Principles and Practice of Fertility Preservation. , ed. C.U. Press. Vol. 1. 2011, 
Cambridge: Medical. 329.
563903-L-bw-Schleedoorn
Processed on: 26-7-2021 PDF page: 43
43In the literature 
2
39. Duncan, F.E., M.E. Pavone, A.H. Gunn, S. Badawy, C. Gracia, J.P. Ginsberg, B. Lockart, Y. Gosiengfiao, and 
T.K. Woodruff, Pediatric and Teen Ovarian Tissue Removed for Cryopreservation Contains Follicles Irrespective 
of Age, Disease Diagnosis, Treatment History, and Specimen Processing Methods. J Adolesc Young Adult 
Oncol, 2015. 4(4): p. 174-83.
40. Bouchlariotou, S., P. Tsikouras, M. Dimitraki, A. Athanasiadis, I. Papoulidis, G. Maroulis, A. Liberis, and V. 
Liberis, Turner’s syndrome and pregnancy: has the 45,X/47,XXX mosaicism a different prognosis? Own clinical 
experience and literature review. J Matern Fetal Neonatal Med, 2011. 24(5): p. 668-72.
41. Kawamura, K., Y. Cheng, N. Suzuki, M. Deguchi, Y. Sato, S. Takae, C.H. Ho, N. Kawamura, M. Tamura, S. 
Hashimoto, Y. Sugishita, Y. Morimoto, Y. Hosoi, N. Yoshioka, B. Ishizuka, and A.J. Hsueh, Hippo signaling 
disruption and Akt stimulation of ovarian follicles for infertility treatment. Proc Natl Acad Sci U S A, 2013. 
110(43): p. 17474-9.
42. Zhai, J., G. Yao, F. Dong, Z. Bu, Y. Cheng, Y. Sato, L. Hu, Y. Zhang, J. Wang, S. Dai, J. Li, J. Sun, A.J. Hsueh, 
K. Kawamura, and Y. Sun, In VitroActivation of Follicles and Fresh TissueAuto-transplantation in Primary
OvarianInsufficiencyPatients. J Clin Endocrinol Metab, 2016. 101(11): p. 4405-4412.
43. Kawamura, K., N. Kawamura, and A.J. Hsueh, Activation of dormant follicles: a new treatment for premature 
ovarian failure? Curr Opin Obstet Gynecol, 2016. 28(3): p. 217-22.
44. Suzuki, N., N. Yoshioka, S. Takae, Y. Sugishita, M. Tamura, S. Hashimoto, Y. Morimoto, and K. Kawamura, 
Successfulfertilitypreservationfollowingovariantissuevitrificationinpatientswithprimaryovarianinsufficiency. 
Hum Reprod, 2015. 30(3): p. 608-15.
45. Geomini PM, Z.R., Vlemminx M, Mol BW, Coppus SF. . Unilateral ovariectomy, is there a risk for early meno-
pause?[oral presentation]. in European Society for Gynaecological Endoscopy 23rd Annual Congress 2014. 
Brussels, Belgium.
46. Khan Z, G.R., Tabbaa ZM, Laughlin-Tommaso SK, Jensen JR, Coddington CC, 3rd, et al. , Unilateral 
oophorectomy results in compensatory follicular recruitment in the remaining ovary at time of ovarian stimulation 
for in vitro fertilization. Fertility and sterility, 2014 Mar;101(3):722-7.
47. Bellati, F., I. Ruscito, M.L. Gasparri, M. Antonilli, M. Pernice, C. Vallone, G. Morano, P. Chirletti, P.B. Berloco, 
and P.B. Panici, Effects of unilateral ovariectomy on female fertility outcome. Arch Gynecol Obstet, 2014. 
290(2): p. 349-53.
48. Lass, A., The fertility potential of women with a single ovary. Hum Reprod Update, 1999. 5(5): p. 546-50.
49. Bjelland, E.K., P. Wilkosz, T.G. Tanbo, and A. Eskild, Is unilateral oophorectomy associated with age at 
menopause?Apopulationstudy(theHUNT2Survey). Hum Reprod, 2014. 29(4): p. 835-41.
50. Coccia, M.E., F. Rizzello, G. Mariani, C. Bulletti, A. Palagiano, and G. Scarselli, Ovarian surgery for bilateral 
endometriomasinfluencesageatmenopause. Hum Reprod, 2011. 26(11): p. 3000-7.
51. Oncofertility http://oncofertility.northwestern.edu/turner-syndrome. 2017.
52. Gravholt, C.H., N.H. Andersen, G.S. Conway, O.M. Dekkers, M.E. Geffner, K.O. Klein, A.E. Lin, N. Mauras, 
C.A. Quigley, K. Rubin, D.E. Sandberg, T.C.J. Sas, M. Silberbach, V. Söderström-Anttila, K. Stochholm, J.A. 
van Alfen-van derVelden, J. Woelfle, P.F. Backeljauw, and O.b.o.t.I.T.S.C. Group, Clinical practice guidelines 
for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner 
Syndrome Meeting. European Journal of Endocrinology, 2017. 177(3): p. G1-G70.
53. Schwack, M. and A.E. Schindler, [Turner’ syndrome (monosomy) and pregnancy]. Zentralbl Gynakol, 2000. 
122(2): p. 103-5.
54. Platt, L.D., S.R. Korula, G.R. DeVore, and D.R. Mishell, Jr., Altered fetal growth and development in a patient 
with Turner’s syndrome. Am J Perinatol, 1986. 3(3): p. 175-7.
55. Magee, A.C., N.C. Nevin, M.J. Armstrong, D. McGibbon, and J. Nevin, Ullrich-Turner syndrome: seven
pregnancies in an apparent 45,X woman. Am J Med Genet, 1998. 75(1): p. 1-3.
56. Kaneko, N., S. Kawagoe, and M. Hiroi, Turner’sSyndrome–Reviewof theLiteraturewithReference toa
Successful Pregnancy Outcome. Gynecologic and Obstetric Investigation, 1990. 29(2): p. 81-87.
57. Mortensen, K.H., M.D. Rohde, N. Uldbjerg, and C.H. Gravholt, Repeated spontaneous pregnancies in 45,X 
Turner syndrome. Obstet Gynecol, 2010. 115(2 Pt 2): p. 446-9.
58. Cools, M., R.P.A. Rooman, J. Wauters, Y. Jacqemyn, and M.V.L. Du Caju, A nonmosaic 45,X karyotype in a 
mother with Turner’s syndrome and in her daughter. Fertility and Sterility, 2004. 82(4): p. 923-925.
563903-L-bw-Schleedoorn







59. Varela, M., E. Shapira, and D.B. Hyman, Ullrich-Turnersyndromeinmotheranddaughter:prenataldiagnosis
ofa46,X,del(X)(p21)offspringfroma45,Xmotherwithlow-levelmosaicismforthedel(X)(p21)inoneovary. 
Am J Med Genet, 1991. 39(4): p. 411-2.
60. Huang, L., Y. Mo, W. Wang, Y. Li, Q. Zhang, and D. Yang, Cryopreservation of human ovarian tissue by 
solid-surfacevitrification. Eur J Obstet Gynecol Reprod Biol, 2008. 139(2): p. 193-8.
61. McLaughlin, M., D.F. Albertini, W.H.B. Wallace, R.A. Anderson, and E.E. Telfer, Metaphase II oocytes from 
humanunilaminarfolliclesgrowninamulti-stepculturesystem. Mol Hum Reprod, 2018. 24(3): p. 135-142.
62. Costa, J.J.N., G.B. Souza, M.A.A. Soares, R.P. Ribeiro, R. van den Hurk, and J.R.V. Silva, In vitro differentiation 
ofprimordialgermcellsandoocyte-likecellsfromstemcells. Histol Histopathol, 2018. 33(2): p. 121-132.
563903-L-bw-Schleedoorn
Processed on: 26-7-2021 PDF page: 45
45In the literature 
2
Appendix 1. Search terms
((Ullrich Turner Syndrome* [tiab] OR Turner Syndrome* [tiab] OR Turner’s 
Syndrome* [tiab] OR Turners Syndrome* [tiab] OR Gonadal Dysgenesis, 45,X 
[tiab] OR Gonadal Dysgenesis, XO [tiab] OR XO Gonadal Dysgenesis [tiab] OR 
Monosomy X [tiab] OR Bonnevie-Ullrich Syndrome [tiab] OR Status Bonnevie-
Ullrich [tiab] OR TS [tiab] OR “Turner Syndrome*”[Mesh]) AND (“Fertility 
Preservation”[Mesh] OR preservation[tiab] OR Fecundability [tiab] OR Fecundity 
[tiab] OR Subfecundity [tiab] OR Fertility [tiab] OR Infertility [tiab] OR subfertility 
[tiab] OR sub-fertility [tiab] OR fertile [tiab] OR pregnan* [tiab] OR infertile [tiab] 
OR ovarian insuff iciency [tiab] OR Ovarian Failure [tiab] OR ovarian dysfunction 
[tiab] OR ovary insuff iciency [tiab] OR ovary failure [tiab] OR ovary dysfunction 
[tiab] OR “Fertility “[Mesh] OR “Pregnancy”[Mesh] OR “Primary Ovarian 
Insuff iciency”[Mesh]))
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Can reflectance confocal microscopy (RCM) be used to determine follicle density in 
human ovarian cortex fragments that are intended for fertility restoration?
Design
RCM was used on living cortex tissue fragments derived from five bovine ovaries and 
13 human ovaries. All tissue fragments were cryopreserved and thawed before RCM 
analysis. Follicle numbers and distribution were determined by RCM and histology. 
Before and after RCM, general tissue viability and follicle integrity were assessed by a 
glucose uptake assay and neutral red staining, respectively.
Results
RCM can detect all stages of follicle development in living ovarian tissue to a maximum 
depth of 250 µm. In bovine tissue, all follicles were located within this 0–250 µm range. 
In human ovarian tissue, follicles were also present below the 250 µm RCM threshold, 
implying that only a percentage of the total number of follicles could be detected with 
RCM. The percentage of follicles detected by RCM appeared to be age dependent. The 
RCM procedure did not affect the glucose uptake by the tissue, whereas neutral red 
staining indicated a high level of follicle survival.
Conclusion
In this proof of concept study, we have shown that RCM is a promising technique to 
determine the density of follicles ex vivo in living human ovarian cortex fragments, 
apparently without compromising the vitality of the tissue. Safety studies and further 
optimization of the RCM technique with a focus on increasing the penetration depth 
are required before clinical use of RCM.
Key message
Reflectance confocal microscopy (RCM) is a promising technique to visually determine 
the density of follicles ex vivo in living human ovarian cortex fragments without 
compromising the vitality of the tissue. Safety studies and further optimization of the 
RCM technique are required before RCM can be used in a clinical setting.
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Since the first successful autotransplantation of frozen-thawed ovarian tissue was 
reported 14 years ago [1], ovarian tissue cryopreservation (OTC) has become an 
established fertility preservation option for selected groups of patients, as for example 
patients undergoing gonadotoxic treatments [2-4]. After the patient has been cured 
and experiences difficulties to conceive, one or more cryopreserved tissue fragments 
can be thawed and transplanted back into the patient in an attempt to restore her 
fertility. 
In Europe, OTC is routinely performed in 12 countries with an estimated number of 
2500-6500 procedures per year [5]. Several national studies have reported that auto-
transplantation of frozen-thawed ovarian tissue leads to restoration of ovarian function 
in 67-93% of cases [4, 6-8] with reported live birth rates between 25-33% per trans-
plantation [4, 7, 9-12]. In a study with a limited number of patients a live birth rate of 
75% has been reported [8]. To date, more than 130 children have been born following 
autotransplantation of cryopreserved ovarian tissue [3, 4, 7, 13-15]. 
Depending on the size of the ovary, the method used to obtain the ovarian cortex 
fragment(s), and the patient’s age, 11-30 ovarian cortex fragments are prepared for 
cryopreservation [16]. Restoration of ovarian function in the future is most likely related 
to the number of primordial follicles in the autograft [6, 17]. Preferably, the cortex 
fragments with the highest number of primordial follicles should be selected for auto-
transplantation purposes. In addition, the number of cortex fragments transferred 
during a transplantation procedure might be adjusted if the number of primordial 
follicles present in the individual cortex fragments was known in advance. 
Determining the follicular density with conventional histology renders the tissue 
unsuitable for subsequent transplantation. In addition, follicles are not evenly distributed, 
and therefore determining follicle density in one tissue fragment does not necessarily 
reflect the number of follicles in adjacent fragments [18, 19]. Ideally, a non-invasive 
imaging technique is required to determine the number of follicles in each ovarian 
cortex fragment prior to autotransplantation. 
Optical coherence tomography (OCT) has been reported as a promising technique for 
the non-invasive imaging of ovarian tissue at the cellular level [20-23], but unfortunately 
its detection range in ovarian tissue is limited to a maximum depth of 100 µm. 
Alternatively, reflectance confocal microscopy (RCM) [24] could be used to evaluate 
the number of primordial follicles in ovarian cortex tissue fragments. RCM is a 
non-invasive imaging technique that has thus far been used mainly in dermatology for 
the in vivo detection of skin cancer [25]. RCM provides en face, high-resolution images 
and has the potential to cover the complete surface of a standard ovarian cortex tissue 
fragment (40-50 mm2) in minutes. Furthermore, RCM produces images in skin up to a 
depth of 250 µm with a resolution similar to conventional light microscopy [26]. RCM 
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has never been used to analyse human ovarian tissue. Therefore, as a proof of concept, 
we developed an ex vivo method for imaging ovarian cortex fragments. In addition, the 
influence of RCM imaging procedure on tissue viability was evaluated.
Materials and methods
Study design
Reflectance confocal microscopy (RCM) was performed using the commercially 
available and CE-marked Vivascope® 1500 (Lucid Inc., Rochester, BY, USA) imaging 
system (Figure 1). This RCM system uses a diode laser with a near-infrared wavelength 
of 830nm and a tissue penetration up to 200-300 µm in skin [27]. RCM images were 
compared with histological images of the same tissue fragments obtained with 
conventional microscopy of haematoxylin and eosin (HE) stained sections. HE stained 
tissue sections images were digitized using the VisionTek® (Sakura Finetek Europe B.V, 
Alphena.d.Rijn,NL) live digital microscope. The distribution and total number of follicles, 
the follicular density and other histological aspects of the ovarian tissue were assessed 
in both bovine and human ovarian cortical tissue fragments. In addition, the effect of 
RCM imaging on ovarian tissue viability and follicle viability was evaluated. Lastly, the 
percentage of primordial follicles within the detection range of RCM was determined.
Ovarian tissue preparation, cryopreservation and thawing
Intact bovine ovaries of 7-8 months old animals were collected at a local abattoir and 
transported to the laboratory on ice, essentially as described previously [28]. Bovine 
ovarian tissue has been proposed as the best animal model to study human ovarian 
tissue [29] . 
Human ovarian tissue was collected from 13 patients between January 2014 and 
December 2017 after ethical approval (Ethical committee Arnhem and Nijmegen, 
reference numbers: 2016-2894 and 2016-2871, date of approval: 12 October 2016 and 
19 December 2016; Ethical committee Amsterdam, reference number: 2017.168, date 
of approval: 28 March 2017; and Ethical committee Bonn reference number: 007/09, 
date of approval: 11 May 2008) was obtained for patient-related research (Table 1). 
9 patients (aged 5 to 40 years) underwent unilateral ovariectomy for fertility preservation 
purposes at the University Hospital of Bonn or at the Radboud University Medical 
centre. 4 patients (aged 18 to 27 years) underwent bilateral ovariectomy as part of 
their gender affirming surgery at the VU Medical centre Amsterdam. In accordance 
with the Declaration of Helsinki, all 13 patients and/or their parents had provided 
written informed consent for the use of their ovarian tissue for research purposes. 
Ovarian tissue was prepared for cryopreservation and thawing as previously described 
[30]. Cortex fragments of approximately 8x6x1mm were used for RCM imaging. 
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Qualitative analysis – Comparing RCM images of ovarian cortex 
fragments with the corresponding HE stained sections
Since the Vivascope® 1500 was initially designed for in vivo imaging of the skin only, a 
special sample container was designed (Figure 1) to perform ex vivo RCM imaging of 
ovarian tissue. The sample container was sterilized prior to every use. Ovarian cortex 
fragments of standard size (8x6x1mm) could be easily fitted in this sample holder. 
Furthermore, the viability of the ovarian fragment that was examined could be 
safeguarded, as each ovarian tissue fragment was moistened by a sponge soaked in cold 
L15 medium during imaging. The sample holder was placed in a second container filled 
with ice to ensure that the tissue remained at 0oC during the imaging procedure. The 
moistened ovarian tissue fragment was covered by an optical plastic window that was 
subsequently stuck to the steel ring of the sample container. Before imaging, ultrasound 
gel was applied to the centre of the optical window in order to generate the confocal 
image. The laser head was positioned on the steel ring with a magnetic snap. 
Figure 1. The Vivascope 1500 system. Before imaging, the ovarian cortex tissue fragment was 
transferred to the specially designed pre-cooled adaptor for ex-vivo imaging (arrowhead) and 
covered by a sterile plastic window and a magnetic metal ring. Ultrasound gel was applied to the 
window and the objective lens housing was attached to the metal ring. The system allows real- 
time visualization of living tissue and generates black and white images on the computer screen 
that are stored digitally.
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The RCM examination was systematically performed starting from the tunica albuginea 
down to the medulla. Horizontal black-and-white images of 8x8mm (Vivablock) 
(covering the complete surface of the tissue fragment) with an axial resolution of 5.0 
µm and a lateral resolution of 0.5 - 1.0 µm close to optical histology, were obtained by 
capturing a series of confocal images of 500x500 µm with vertical steps of 25 µm using 
the Vivascan Version 7 software (Lucid Inc., Rochester, BY, USA). RCM images were 
constructed based on the specific reflectance index of the single tissue structure due 
to its molecular properties.
After the RCM imaging procedure was completed, the tissue samples were fixed in 
Bouin solution and embedded in paraffin for conventional histological analysis. The 
RCM images were then compared with the corresponding horizontal HE stained 6 µm 
sections by two investigators. Small spots of Indian ink were used to properly align the 
RCM images to the corresponding HE stained sections.  
Table 1. Characteristics of patients from whom ovarian cortex tissue was obtained.
Patient characteristics Human samples (n=13)
Mean age (median age; SD, range) 20,77 years (21,00years;9,24years,range5-40years)
Age group, n (%)
Paediatric (0-11 years) 1 (7,69%)
Adolescent (12-17 years) 4 (30,77%)
Young adult (18-29) 6 (46,15%)
Adult (>30 years) 2 (15,38%)
Indication for OTC, n (%)
Oncologic 7 (53,85%)
Rhabdomyosarcoma 1 (7,69%)
Cervical cancer 2 (15,38%)
Breast cancer 1 (7,69%)
Osteosarcoma 1 (7,69%)
Acute myeloid leukaemia 1 (7,69%)
Hodgkin lymphoma 1 (7,69%)
Gender dysphoria 4 (30,77%)
Other 2 (15,38%)
Bone marrow transplantation 
for hyper eosinophilic syndrome 
(HES)
1 (7,69%)
Metachromatic leukodystrophy 1 (7,69%)
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Viability assays – Determining the viability of ovarian tissue and ovarian 
follicles using glucose uptake assay and Neutral red staining 
The viability of ovarian cortical tissue after RCM imaging
To assess the possible adverse effects of RCM imaging on the quality of the ovarian 
cortical tissue fragments, the viability of the tissue fragments before and after RCM 
imaging was determined by an in vitro glucose uptake assay as previously described [20, 
31]. Frozen-thawed bovine cortical ovarian tissue fragments of 5 individual animals 
were exposed to a complete RCM analysis for the duration of 30 minutes at 0 oC. 
Frozen-thawed bovine cortical ovarian tissue fragments of the same ovaries that were 
not imaged, served as a control and were kept on ice for 0, 30, 60 or 120 minutes. The 
tissue fragments were cut into small (approximately 1x1x1 mm) pieces that were 
subsequently cultured for 3 days in 2 ml Dulbecco’s Modified Eagle’s medium (DMEM) 
culture medium supplemented with 10% Foetal Calf Serum (FCS) and 40 µg/ml 
gentamycin. Glucose content of the culture supernatant was determined and compared 
with fresh culture medium. The weight of each cultured tissue sample was determined 
at the end of culture. Glucose consumption was expressed as nmol glucose per 
milligram of ovarian cortical tissue per hour. Bovine ovarian tissue of two animals, which 
was snap-frozen and thawed in the absence of cryoprotectants, served as a positive 
control for tissue damage. 
The viability of the primordial follicles after RCM imaging
The viability of the primordial follicles before and after the RCM imaging was determined 
by a Neutral red staining assay as previously described, [20, 31, 32]. Neutral red staining 
is a commonly used assay to determine the viability of primordial follicles in vitro. The 
number of viable (red-coloured) follicles and non-viable (non-coloured) follicles was 
calculated by using standard light microscopy. Frozen-thawed bovine cortical ovarian 
tissue fragments of 5 individual animals were exposed to RCM for 30 minutes. 
Frozen-thawed bovine cortical ovarian tissue fragments of the same animals that were 
not subjected to imaging, served as a control.
Quantitative analysis – Determining the percentage of primordial follicles within 
the detection range of RCM
Frozen-thawed ovarian tissue samples from 5 animals and all 13 patients (Table 1) 
were fixed with Bouin solution and embedded in paraffin for conventional histological 
analysis. Follicles were categorized according to predefined criteria [33]. Vertical HE 
stained sections were used to create side-view images for an overview of the localization 
of the primordial follicles throughout the ovarian cortex and more specifically, within 
the detection range of RCM. The number of primordial follicles from the tunica 
albuginea down to the medulla was determined by two investigators independently. 
Afterwards, the total number of primordial follicles at different depths was calculated 
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for several ranges: 0 - 50 µm, 50 - 100 µm, 100 - 150 µm, 150 - 200 µm, 200 - 250 µm 
and deeper than 250 µm.
Statistical analysis
Student t test was used to perform statistical analysis, using SPSS software (version 
22.0, BM, New York). P-values of 0.05 or less were considered to be statistically 
significant. 
Results
RCM imaging of bovine ovarian cortex fragments
In view of the paucity of human ovarian cortex tissue available for research purposes, 
we initially resorted to bovine tissue for the optimization of the RCM imaging procedure. 
Starting at the tunica albuginea, which mostly consists of extracellular matrix fibrils, 
each fragment was scanned down towards the medulla. Using RCM, each ovarian 
cortex fragment could be visualized at the cellular level in black and white images, up to 
a maximum depth of approximately 250 µm (Figure 2). Follicles could be easily 
distinguished from other ovarian tissue structures in bovine ovarian tissue. Whereas 
oocytes appeared as dark circular structures, the surrounding granulosa cells appeared 
as small circular or white oval structures. After passing the tunica albuginea (Figure 2, 
panel B), small (primordial and primary) follicles with a diameter of approximately 
35-40 µm were abundantly present from a depth of 50 µm up to 175 µm (Figure 2, 
panels C-H). In addition to primordial follicles with a flat layer of granulosa cells, we 
also observed primary follicles surrounded by cuboidal granulosa cells. More advanced 
stages of follicular development with a diameter of 80 µm or more showed multiple 
layers of granulosa cells and were located at a depth of 125 µm or deeper (Figure 2, 
panels F-I). Ex vivo RCM imaging up to depth of 250 µm of an ovarian tissue fragment 
with a surface of 8x6mm took about 30 minutes.
To confirm that the RCM images of a tissue fragment corresponded with the HE 
staining of the same fragment, we first produced RCM images of each ovarian cortex 
tissue fragment. Next, several easily recognizable RCM images were selected and 
compared with the HE stained sections taken at the same depth from which the RCM 
images originated. As shown in Figure 3 the follicles in the RCM images corresponded 
well to both size and location of the follicles in the HE stained sections.
To determine the percentage of small follicles in bovine ovarian cortex tissue within the 
detection range (0-250 µm) of RCM, transversal HE stained tissue sections were 
produced from ovarian tissue of 5 animals. In these sections the number of primordial/
primary follicles was determined at various distances from the cortex surface. The small 
follicles were found to be all located within the detection range of RCM (Figure 4). 
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Determining the viability of ovarian tissue and follicles after RCM 
The RCM imaging of each ovarian cortex fragment was performed at 00 C within 30 
minutes using a non-ionizing near-infrared laser. The possible adverse effects of the 
RCM imaging procedure on the viability of ovarian tissue and primordial follicles were 
determined by two viability assays; an in vitro glucose uptake assay to determine overall 
tissue viability and a Neutral Red stain to assess follicle viability [20, 31, 32]. Figure 5a 
shows the mean glucose consumption per mg ovarian tissue per hour over a 3-day 
culture period of ovarian cortex fragments from 5 animals that were exposed to 30 
minutes of RCM imaging at 0oC. Glucose uptake was compared with cortex tissue of 
the same ovary that had not been subjected to RCM imaging but was stored at 0oC for 
various periods of time (0-30-60-120 minutes).  As shown in Figure 5a for cortex 
tissue from 5 individual animals, glucose uptake by the tissue subjected to RCM was not 
Figure 2.  Reflectance confocal microscopic (RCM) images of bovine ovarian cortex tissue. (A) 
A cryopreserved and thawed bovine ovarian cortex fragment of approximately 8x6x 1 mm thick 
was imaged using RCM at different levels (z = 25–225 µm), with steps of 25 µm starting from 
the cortex surface (B–J). After RCM imaging, sections of the tissue were stained with haematoxylin 
and eosin at two different depths (K and L). Arrowheads point to small (primordial and primary) 
follicles, arrows point to more advanced stages of follicular development. Scale bars represent 
100 µm.
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affected by the imaging procedure and statistically not different from tissue that was 
stored on ice for either 0 or 30 minutes (p> 0.05). Even a longer incubation of 60 or 
120 minutes on ice did not influence glucose uptake by the tissue (data not shown). As 
a positive control for tissue damage, ovarian tissue fragments of 2 animals were 
snap-frozen in the absence of cryoprotectants resulting in a strong reduction in glucose 
uptake. In addition to the overall tissue viability, the possible effect of RCM imaging on 
the viability of the primordial follicles within the ovarian tissue fragment was examined. 
To this end, small follicles in frozen-thawed bovine ovarian tissue fragments from three 
individual animals were stained with Neutral Red before and after a 30-minute-long 
RCM imaging session (Figure 5b). In all tissue samples, irrespective of RCM imaging, 
the percentage of Neutral Red stained primordial follicles was between 85-98%. This 
Figure 3. Reflectance confocal microscopic (RCM) images with corresponding haematoxylin 
and eosin stained sections. Several unique RCM images of a bovine ovarian cortex fragment 
were selected showing a large antral follicle (A), two closely located small follicles (C) and small 
follicles close to the edge of the tissue fragment (E). After RCM, a series of haematoxylin and 
eosin stained sections was produced. The location of the follicles with RCM corresponds highly 
to the location of the follicles observed in conventional haematoxylin and eosin histology (B, D 
and F). Arrowheads point to small (primordial and primary) follicles. Scale bars represent 100 µm.
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indicates that RCM imaging for 30 minutes at 0oC does not affect the viability of bovine 
ovarian tissue nor the viability of the small follicles.
RCM imaging of human ovarian cortex fragments
RCM analysis of a cryopreserved/thawed ovarian cortex fragment of a 5-year-old 
patient revealed the presence of many small follicles already at a tissue depth of 25 µm 
(Figure 6, panel B). Similar to the bovine images, the follicles appeared as dark spheres 
surrounded by a lighter coloured ring. In this particular tissue, follicles were abundantly 
present up to a depth of 200 µm (Figure 6, panels B-I), after which the RCM 
resolution became too low for accurate detection of individual follicles. The follicle 
density observed in HE stained tissue sections was in agreement with the density we 
observed using RCM (Figure 6, panels K and I). With RCM, follicles of different sizes 
could also be detected in the ovarian cortex fragments of adult patients, as shown in 
Figure 7 for a 22 years old patient. Up to a depth of 50 µm only a small number of 
follicles were seen (Figure 7, panels A-C), but beyond this depth patches of many 
small follicles could be observed that were unevenly distributed throughout the cortex 
(Figure 7, panels D-H). Interestingly, in this particular tissue, RCM was able to detect 
follicles beyond the 200 µm limit, allowing us to detect larger follicles (with a diameter 
up to 100 µm) at 200 µm or deeper.
Figure 4. Vertical distribution of small follicles in bovine ovarian cortex tissue. The number of 
small (primordial and primary) follicles in transversal haematoxylin and eosin stained sections at 
different levels from the cortex surface was determined in ovarian tissue of five animals (A–E). 
The total number of small follicles counted for each individual animal is indicated.
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Figure 5. A) Viability of ovarian cortex fragments after reflectance confocal microscopic (RCM) 
imaging. In-vitro glucose uptake over a 3-day culture period of ovarian cortical tissue fragments 
derived from five bovine ovaries (A–E) after incubation on ice for 0 or 30 min and after tissue 
was subjected to 30 min of RCM imaging at 0°C (hatched bars). No statistical difference in 
glucose uptake between control tissue (0 or 30 min on ice) and tissue after 30 min of RCM 
imaging was observed (P > 0.05). As a positive control for tissue damage the glucose uptake was 
measured for ovarian tissue from two animals (D and E) that was snap-frozen–thawed in the 
absence of cryoprotectants, leading to a statistically significant reduction in glucose uptake (P < 
0.05). Values presented as mean ± SD; (B) follicles visualized by neutral red staining. Overview 
of follicles from a bovine ovarian cortical tissue fragment subjected to 30 min of RCM imaging at 
0°C stained with neutral red. Viable follicles are red (white arrowhead) and dead follicles remain 
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To determine the percentage of small follicles that were located within the detection 
range of RCM in human ovarian cortex tissue, transversal HE stained sections of 
ovarian cortex tissue of patients of different ages were used. The number of small 
follicles at different depths was counted by 2 investigators independently (Figure 8a). 
We observed that the distance between the small follicles and the cortex surface 
increased with age. In the ovarian cortex fragments derived from 3 patients aged 5, 12 
and 14 years, respectively, 65%, 14% and 47% of the follicles were located within the 
detection range of the RCM. In the patients aged 16 – 33 years old, 10% or less of the 
follicles was located within this detection range, whereas in the oldest patient (40 years 
of age), all remaining small follicles were located 250 µm or deeper, and therefore 
outside the detection range of RCM (Figure 8b).
Figure 6. Reflectance confocal microscopic (RCM) images of ovarian cortex tissue from a 5-year 
old patient. (A) A cryopreserved and thawed human ovarian cortex fragment of approximately 
8x6x1 mm thick of a 5-year old patient was imaged using RCM at different levels (z = 25–225 
µm) with steps of 25 µm starting from the cortex surface (B–J). After RCM imaging, sections of 
the tissue were stained with haematoxylin and eosin at two different levels (K and L). Small 
(primordial and primary) follicles were observed in high numbers at all levels. Scale bars represent 
100 µm.
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Figure 7. Reflectance confocal microscopic imaging (RCM) images of ovarian cortex tissue from 
a 22-year old patient. A cryopreserved and thawed human ovarian cortex fragment of 
approximately 8x6x1 mm thick of a 22-year old patient was imaged using RCM at different levels 
(z = 0–250 µm), with steps of 25 µm starting from the cortex surface (A–K). Arrowheads 
indicate small (primordial and primary) follicles and arrows point to more advanced stages of 
follicular development. Scale bars represent 100 µm.
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Figure 8. Vertical distribution of small (primordial and primary) follicles in human ovarian cortex 
in patients of different ages. (A) Transversal haematoxylin and eosin stained sections of human 
ovarian cortical tissue of patients aged 5 years (A), 19 years (B), 33 years (C) and 40 years (D). 
Note the increase in distance between the remaining small follicles and the ovarian cortex 
surface with advancing age. The detection range of reflectance confocal microscopic images in 
human ovarian cortical tissue (approximately 0–250 µm) is indicated by a double headed arrow. 
Scale bars represent 100 µm; (B) quantitative analysis of the vertical distribution of small follicles 
in human ovarian cortical tissue. Small follicles were counted in transversal haematoxylin and 
eosin stained sections of human ovarian cortical tissue of patients of various ages and categorized 
according to their distance from the ovarian cortex surface. The number of small follicles that lies 
within (0–50 µm, 50–100 µm, 100–150 µm, 150–200 µm and 200–250 µm), and outside (>250 
µm) the detection range of RCM is indicated. Note that, with advancing age, the remaining 












In this proof of concept study, we have investigated whether reflectance confocal 
microscopy (RCM) can be used as a non-invasive imaging technique to determine the 
vertical and horizontal distribution, and the number of follicles in ovarian cortical tissue 
fragments intended for fertility preservation purposes. Our results show that RCM 
could readily detect all follicles in a bovine ovarian cortex tissue fragment of approximately 
45 mm2 in 30 minutes, up to a depth of 250 µm. Ovarian tissue and follicle viability 
were not affected by the imaging procedure. Tissue damage was not expected as RCM 
uses a point light source derived from a near-infrared laser of 830 nm that delivers 5-10 
mW non-ionizing radiation power [27]. Furthermore, RCM imaging was performed in 
a specially designed container under sterile conditions at 00C to avoid microbial 
contamination or additional ischemic damage to the tissue. Incubation of ovarian tissue 
at 00C for up to 120 minutes did not result in a significant reduction in the viability of 
the ovarian tissue and follicles, indicating that the 30 minutes RCM procedure had very 
little effect on the ovarian cortex fragment. However, more research is needed on the 
functional integrity of the ovarian tissue after exposure to RCM.
By comparing RCM images and HE stained sections of the same ovarian tissue fragment, 
we show that RCM is capable of visualizing all stages of follicle development, including 
primordial follicles. Remarkably, the follicle visibility was generally better in bovine 
tissue compared with human tissue. In bovine ovarian tissue, follicles could be easily 
detected up to 250 µm, which is comparable with the maximum imaging depth of RCM 
reported in skin tissue [25, 34-37].
In human ovarian tissue, follicles could be easily detected up to a depth of 100 µm, 
which is comparable to the maximum imaging depth of optical coherence tomography 
(OCT) reported in human ovarian tissue [20-23]. However, between 100 µm and 250 
µm, follicles could still be detected, but were more difficult to distinguish from other 
ovarian tissue structures due to a limited absorption of laser light and scattering. This 
seemed to be related to the thickness of the tunica albuginea which increases with age 
[38]. This layer of extra cellular matrix reduces the tissue penetration of the near-infrared 
laser light, and hence, to a decrease in reflectance [39]. In ovarian cortex tissue from 
young patients, the tunica albuginea was found to be significantly thinner, and RCM was 
capable of detecting up to 65% of the follicle population in the tissue of our 5-year-old 
patient. Thus, RCM seems an appropriate non-invasive imaging method to estimate the 
follicular density in young patients. However, in ovarian cortex from adult patients, only 
a small percentage of the total number of follicles could be detected with RCM, making 
it difficult to determine the follicular density in these patients. 
In theory, the detection range of RCM could be doubled by scanning each ovarian 
tissue fragment from both sides. However, the medullar side of the approximately 1 
mm thick cortex fragment hardly contains any follicles in the first 250 µm and will 
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therefore not significantly contribute to the total number of follicles that can be 
observed by RCM. A further improvement of the RCM technique could increase the 
maximum tissue penetration depth in human ovarian tissue, and hereby increase its 
predictive value. After improvement, RCM could be applied to evaluate the follicular 
density in ovarian tissue fragments of patients who are undergoing ovarian tissue cryo-
preservation, and in the future, ovarian tissue fragments with the highest number of 
primordial follicles could be selected for autotransplantation first. This is of clinical 
importance in all patients undergoing ovarian tissue autotransplantation, especially in 
patients with a diminished ovarian reserve, as the chances of the restoration of their 
fertility critically depends on the number of primordial follicles in the autograft [40]. 
However, more research is required to confirm that the numbers of follicles observed 
with RCM are indeed correlated with the capacity of the tissue to restore fertility after 
autotransplantation. 
The present study is the first to evaluate the use of RCM for the non-invasive selection 
of optimal ovarian cortex fragments for autotransplantation. RCM is a promising 
technique to visually determine the density of follicles ex vivo in living ovarian cortex 
fragments without compromising the vitality of the tissue. RCM is capable of visualizing 
all stages of follicle development, including primordial follicles up to a maximum depth 
of 250 µm, hence leaving the majority of the follicles undetected. Safety studies and 
further optimization of the RCM technique are required before this non-invasive 
imaging technique can be used in a clinical setting.
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What is the standpoint of an international expert panel on ovarian tissue cryopreser-
vation (OTC) in young females with Turner syndrome (TS)?
Summary answer 
The expert panel states that OTC should be offered to young females with TS, but 
under strict conditions only. 
What is known already 
OTC is already an option for preserving the fertility of young females at risk of iatrogenic 
primary ovarian insufficiency (POI). Offering OTC to females with a genetic cause of 
POI could be the next step. One of the most common genetic disorders related to POI 
is TS. Due to an early depletion of the ovarian reserve, most females with TS are 
confronted with infertility before reaching adulthood. However, before offering OTC 
as an experimental fertility preservation option to young females with TS, medical and 
ethical concerns need to be addressed.
Study design, size, duration 
A three-round ethical Delphi study was conducted to systematically discuss whether 
the expected benefits exceed the expected negative consequences of OTC in young 
females with TS. The aim was to reach group consensus and form an international 
standpoint based on selected key statements. The study took place between February 
and December 2018.
Participants/materials, setting, methods 
Anonymous panel selection was based on expertise in TS, fertility preservation or 
medical ethics. A mixed panel of 12 gynaecologists, 13 (paediatric) endocrinologists, 10 
medical ethicists, and 20 patient representatives from 16 different countries gave 
consent to participate in this international Delphi study. In the first two rounds, experts 
were asked to rate and rank 38 statements regarding OTC in females with TS. 
Participants were offered the possibility to adjust their opinions after repetitive 
feedback. The selection of key statements was based on strict inclusion criteria. 
Main results and the role of chance 
A total of 46 participants completed the first Delphi-round (response rate 84%). Based 
on strict selection criteria, six key statements were selected, and 13 statements were 
discarded. The remaining 19 statements and two additional statements submitted by 
the expert panel were re-evaluated in the second round by 41 participants (response 
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rate 75%). The analysis of the second survey resulted in the inclusion of two additional 
key statements. After the approval of these eight key statements, the majority of the 
expert panel (96%) believed that OTC should be offered to young females with TS, but 
in a safe and controlled research setting first, with proper counselling and informed 
consent procedures, before offering this procedure in routine care. The remaining 
participants (4%) did not object but did not respond despite several reminders. 
Limitations, reasons for caution 
The anonymous nature of this study may have led to lack of accountability. The selection 
of experts was based on their willingness to participate. The fact that not all panellists 
took part in all rounds may have resulted in selection bias.
Wider implications of the findings 
This international standpoint is the first step in the global acceptance of OTC in females 
with TS. Future collaborative research with a focus on efficacy and safety and long-term 
follow-up is urgently needed. Furthermore, we recommend an international register 
for fertility preservation procedures in females with TS.
Study funding/competing interest(s) 
Unconditional funding (A16-1395) was received from Merck B.V., The Netherlands. 
The authors declare that they have no conflict of interest. 
Introduction
Removal of one of the two ovaries for cryopreservation followed by autotransplantation 
of ovarian cortex fragments in the future (i.e. ovarian tissue cryopreservation: OTC) 
is already an option for preserving the fertility of young females at risk of iatrogenic 
primary ovarian insufficiency (POI) [1-4]. Offering OTC to females with a genetic cause 
of POI could be the next step. One of the most common genetic conditions related 
to POI is Turner syndrome (TS), affecting 25-50 per 100,000 live-born girls [5]. 
TS is caused by the partial or complete absence of one of the sex chromosomes. 
Missing an X or Y chromosome affects the foetal development. Signs and symptoms 
vary greatly among females with TS but are mostly related to the patient’s karyotype. 
Monosomy 45, X is associated with a more severe lymphatic and skeletal phenotype, 
while the dysmorphic features of patients with a mosaic karyotype can be very mild, 
depending on the level of mosaicism. No association was found between karyotype 
and cardio-aortic malformations [6]. The majority of females with TS are diagnosed 
before the age of 12 years because of growth retardation [7]. TS may be diagnosed 
prenatally by chorionic villus sampling or amniocentesis in cases of foetal cystic hygroma, 
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intra-uterine growth retardation, cardiovascular malformations or advanced maternal 
age, or shortly after birth because of dysmorphic signs such as neck webbing, cubitus 
valgus, and lymphoedema. In a few cases, TS is diagnosed in adolescence because of 
delayed puberty or primary or secondary amenorrhea.
Females with TS are known to have a shorter reproductive lifespan due to an 
accelerated loss of germ cells. This process starts during meiosis I of the foetal oocyte 
and continues until the point when the ovarian reserve is completely exhausted [8, 9]. 
In most females with TS, this point is reached during childhood or early adolescence [9]. 
Up to 33% have some pubertal development and 10-15% experience one or more 
spontaneous menstruation cycles [10-12]. Hence, spontaneous pregnancies in adult 
females with TS are rare, occurring in approximately 2.0 - 7.6% of cases [13-17]. 
As the majority of females with TS is unable to conceive a child naturally, most of them 
depend on alternative parenting options such as adoption, foster care or oocyte donation. 
However, like most women, females with TS prefer a genetically-related child above 
other forms of parenting, as adoption, foster care or oocyte donation have their own 
limitations [18, 19]. The inability to bear biological children is the most prevalent and 
painful challenge experienced by most females with TS, especially at the moment that 
their family and friends begin to procreate [20, 21]. In an interview study with 97 females 
with TS aged 7 – 59 years and 21 parents, uncertainty about their fertility started at a 
young age and was a major concern for both groups [21]. In females with other causes of 
POI, uncertainty about fertility and the inability to have biological offspring was associated 
with a reduction of quality of life and serious psychosocial disorders [22]. 
It is, therefore, unsurprising that physicians are increasingly being asked about fertility 
preservation (FP) options for females with TS [23], especially as research shows that 
oocytes can still be found in the ovaries of some girls with TS [24-38]. 
FP is the process of safeguarding the patient’s own gametes so that these can be used 
to have biological children in the future. In single females, FP can be performed by 
either the vitrification of mature oocytes or by cryopreserving ovarian tissue containing 
primordial follicles. Vitrification of mature oocytes (oocyte cryopreservation, OC) is 
the most established FP approach but is limited to a small percentage of females with 
TS only, i.e. those with a spontaneous menstrual cycle during adolescence or adulthood 
[39]. Furthermore, females interested in OC have to be emotionally mature enough to 
undergo the procedure, which involves a period of at least 2 weeks with daily hormone 
injections, frequent ultrasonographic monitoring, and transvaginal oocyte retrieval 
[39]. In view of these limitations, OTC appears to be a more promising technique to 
preserve the fertility of females with TS, as it can be performed regardless of the 
patient’s age or ovarian activity. This procedure may offer more females with TS the 
possibility to store a number of primordial follicles before their disappearance [26]. 
Since 2002, OTC procedures have been performed experimentally in more than 100 
young females with TS [24-31][ClinicalTrials.gov: NCT01410045]. Unfortunately, 
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optimal discriminative markers for the presence or absence of follicles are lacking, but 
there is a general agreement that females with a mosaic karyotype are the most likely 
group to have ovarian follicles [23, 26, 31, 39].  
Thus far, there are no published records of girls with TS who have returned for auto-
transplantation of cryopreserved ovarian tissue. Hence, the efficacy of OTC in females 
with TS remains unknown. In other patient groups, the occurrence of pregnancy and 
live birth after autotransplantation of cryopreserved ovarian tissue is highly correlated 
with the number of functional primordial follicles found in the ovarian tissue [40]. 
However, even in these patient groups there is limited data regarding the efficacy of the 
procedure when OTC is performed at a very young age [41]. Autotransplantation of 
ovarian cortex fragments with a decreased follicular density combined with the risk of 
re-initiation of accelerated follicle apoptosis might be less effective. Possibly, in vitro 
activation (IVA) of residual dormant follicles [42-45] prior to autotransplantation might 
be helpful in females with TS to optimize their fertility chances. However, no cases of 
IVA in patients with TS have been reported thus far. The isolation and IVM of primordial 
follicles from cryopreserved ovarian tissue could become an effective alternative to 
autotransplantation in the future [46]. However, this method is still experimental and 
not yet available in the clinic. Hence, females with TS who are currently undergoing 
OTC are still depending on autotransplantation.
Even if the follicular density is normal or slightly decreased, it remains questionable if 
autotransplantation of cryopreserved ovarian tissue in females with TS will lead to 
healthy offspring, as females with TS females who conceived spontaneously are known 
to have an increased risk of miscarriages and chromosomal abnormalities among their 
offspring [15]. Whether these increased risks are related to the quality and functional 
integrity, or the chromosome profile, of the follicular cells remains unclear. 
Hence, offering OTC in routine clinical care could give false hope which could lead 
psychological harm in the future. Young patients might not be able to fully understand 
the possible risks and benefits of the procedure [47-49], and thus, parents will be 
burdened with this decision [50]. 
Another concern that should be taken into account is that OTC requires laparoscopic 
surgery under general anaesthesia with a possible risk of complications [51]. 
Furthermore, removing half of the ovarian reserve in females with TS might impact 
their chances for spontaneous puberty, menstruation and pregnancy. The short-term 
and long-term effects of the surgical removal of one ovary in females with TS are 
currently unknown, but recent studies [52-55] have shown that the surgical removal of 
one ovary in females with a normal ovarian reserve does not affect the patient’s 
menstrual cycle, or their chance for spontaneous pregnancies in the future [56]. 
However, the procedure could lead to early menopause, of up to 3 years earlier in 
comparison to a woman who still has both ovaries [57]. 
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Lastly, one should consider that pregnancies in females with TS show more foetal and 
maternal complications compared to pregnancies in healthy females. Pregnant females 
with TS have an increased risk of intra-uterine growth restriction and preterm labour 
[58]. Thyroid dysfunction, diabetes, obesity, hypertension and pre-eclampsia occur in 
approximately 40% of pregnant women with TS [58]. In the past, women with TS were 
advised to avoid pregnancy due to the risk of mortality. Recent studies have shown that 
the risk for aorta dissection and maternal mortality associated with pregnancy have 
decreased from 2.0% to 0.5% due to increased awareness of cardiovascular complications, 
stringent preconception screening, and cardiovascular follow up during pregnancy [5, 
59]. Pregnancies in females with TS should be strictly monitored by a multidisciplinary 
team including high-care obstetricians, and cardiologists and anaesthesiologists with 
expertise in maternal heart disease and/or disease of the aorta. If this care is unavailable, 
pregnancies in females with TS might be contraindicated because of an increased risk 
of complications.
For the above mentioned reasons, FP in females with TS remains a controversial topic 
for clinicians [60]. However, patient organizations are optimistic and demand equal 
access to FP options worldwide [26, 47]. To further explore the opinion of international 
professionals and patient representatives, we conducted a three-stage ethical Delphi 
study to systematically discuss the advantages and disadvantages of OTC in females 
with TS. The aim of this study was to reach group consensus and to form an inter-
nationally accepted standpoint as to whether OTC should be offered to females with 
TS, or not.
Materials and methods 
The RAND/UCLA Delphi procedure [61-63] was used to combine scientific evidence 
with the expertise and opinion of different international experts within the field of TS, 
OTC, or medical ethics. The Delphi procedure is a well-accepted method for attaining 
group consensus. It is a structured process that uses a series of questionnaires or 
rounds to gather information from different experts anonymously. Rounds are held 
until group consensus is reached according to predetermined defined consensus rules. 
In medical research, the Delphi procedure is commonly used to reach consensus on key 
recommendations [64], quality indicators [65], or key statements [66].
In this study, the Delphi procedure was used to determine whether the expected 
benefits exceed the expected negative consequences of OTC in TS [63, 67]. The 
outcome of this study was an international standpoint for or against OTC in females 
with TS, supported by a set of key statements. 
Two questionnaire rounds and one agreement round were performed. Panel members 
were polled individually and anonymously. Participants were offered the possibility to 
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adjust their opinions after repetitive feedback after each round, thus avoiding the 
negative social influences associated with face-to-face discussion [62]. Questionnaires 
were conducted by electronic data capture, using CastorEDC® (Castor, George 
 Westinghousestraat 2, 1097 BA, Amsterdam, The Netherlands). Possibilities to add 
new statements or comments were provided in each questionnaire. Invitations and 
reminders were sent via CastorEDC®. All scores were listed in a database created with 
IBM SPSS Statistics version 25.0 (IBM Netherlands, Johan Huizingalaan 765, P.O. Box 
9999, 1066 VH Amsterdam, Netherlands). The consensus procedure took place 
between February and December 2018.
Identifying ethical issues and formulating statements
A total number of 65 articles were screened for arguments both for and against OTC 
in TS after a comprehensive literature search (Figure 1). Each article was screened 
independently by two researchers from a multidisciplinary research group (i.e. two 
gynaecologists (n=KF, CB), one paediatric endocrinologist (n=AvdV), one medical 
ethicist (EvL), one senior scientist in reproductive biology (n=RP) and one physician in 
reproductive medicine (MS) for arguments regarding OTC in females with TS. None of 
these researchers participated in the Delphi selection procedure. Arguments were 
extracted if both independent researchers agreed.
This selection procedure resulted in a total number of 155 arguments regarding OTC 
in TS. Arguments focusing on a similar topic were grouped and brought together into 
a framework of 38 statements (Supplementary Table SI). These statements were 
divided over the four basic ethical domains [68], i.e. beneficence (n=18), autonomy 
(n=5), non-maleficence (n=8), and justice (n=7). Each statement highlighted a specific 
ethical concern regarding OTC in females with TS. The original 155 arguments are 
presented as additional information below each statement.
Selection of key statements and formulation of a common stand
Step 1: Composition of the expert panel 
To enhance the acceptance of this international standpoint in clinical practice, the 
expert panel consisted of a representative diversity of international professionals and 
patient representatives. Sufficient English language proficiency was an admission 
requirement for all experts. Invitations for the Delphi study were sent out by E-Mail to 
59 international professionals (female professionals n=37, male professionals n=22) with 
expertise in the field of FP, TS, and/or medical ethics. Eligible experts were gynaecologists 
(n=18) and (paediatric) endocrinologists (n=17) with either a prominent role in one or 
more international expert groups (i.e. ESHRE Special Interest Group for Fertility 
Preservation, DSD-Life, Oncofertility, FertiPROTEKT, or Turner Syndrome Guideline 
Group), and/or an author of one or more key publications regarding FP in females with 
TS. Medical ethicists (n=24) were recruited by the ESHRE Task Force Ethics & Law and 
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the personal network of the senior research team members (KF, AvdV, EvL, WN, CB, 
RP, DB). Patient representatives should have had a prominent role in one of the 
international TS patient organizations. Therefore, a request for patient representatives 
(i.e. patients and/or parents of patients) was sent out to 17 patient organizations in 15 
Figure 1. Identifying ethical issues and formulating statements. A detailed process description of 
the comprehensive literature search, extraction of arguments and formulation of statements.
Identifying ethical issues and formulating statements
879 records 
Step 1 – Literature search
Pubmed, Web of Science, ESHRE Ethics and Law, EMBASE,
PsycINFO, and CINAHL 
Step 2 – Applying selection critera
329 records excluded
• Other language than English or Dutch
• Publication date >10 years ago
• No abstract available




• No full text available (n=2)
• Not eligible (n=438)
65 records 
Step 4 – Extraction of arguments regarding OTC in females
with TS by a multidisciplinary panel 
155 arguments
Step 5 – Formulation of statements from arguments
covering a similar topic 
38 statements
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different countries. Contact data from 38 patient representatives were obtained, and 
invitations were sent out to them by E-Mail.
Step 2: First Delphi round
In the first Delphi round, the panel was asked to rate the 38 statements on a 9-point 
Likert scale ranging from 1 (extremely irrelevant) to 9 (extremely relevant). Relevance 
was graded by the experts in response to the following question; “To what extent is the 
following statement an important determinant to offer/discourage OTC in young females with 
TS?”.Participants were encouraged to read the original arguments and were provided 
with supporting evidence and background information. By the end of the questionnaire, 
participants were asked to create a top 5 of their most relevant statements to promote 
discrimination between recommendations with a high Likert score. In addition, they 
were given the option to add comments and new statements. Participants were given 
4 weeks to complete the first round. Reminders were sent after 2 and 3 weeks.
The results of the first round were analysed using predefined consensus criteria based 
on Campbell’s criteria [69]. These criteria include a median score of 8 or higher without 
panel disagreement. Panel disagreement was defined as the case in which 25% or more 
of the individual scores was in the lowest tertile of the scale (Likert score 1-3). Previous 
studies [70-77] have shown that Campbell’s criteria alone are often not discriminative 
enough. Therefore, a third criterion was added, which is commonly used in Delphi 
studies, namely a top 5 score [70-73, 75-77]. Recommendations should have at least a 
top 5 score of 35 points or higher. Points were awarded to each top-five ranking 
position, with number 1 position = 5 points, number 2 position = 4 points, number 3 
position = 3 points, number 4 position = 2 points, and number 5 position = 1 point. 
The authors combined the three criteria as described above and converted them into 
three possible outcomes ‘selected’, ‘rejected’, or ‘no consensus’. Recommendations that 
met all three criteria were classified as ‘selected’, those who met none of the criteria as 
‘rejected’, and the remaining recommendations as ‘no consensus’. The ‘no consensus’ 
recommendations were again discussed in the second questionnaire round. 
Step 3: Second Delphi round 
The second round started with an overview of the selected, rejected and ‘no consensus’ 
recommendations. First, the experts were asked for their approval of the key statements 
that have been selected in the first round. Second, the expert panel was asked to revise 
their opinion for the ‘no consensus’ recommendations in light of the replies of the other 
panel members. The overall median score, the median score of each subgroup, the 
total top 5 score, and their own previous rating was shown for each statement. When 
experts were not able to participate in the first Delphi round (n=9), but wanted to 
participate in the second Delphi round, the overall median score, the median score of 
each subgroup, and the total top 5 score was shown for each statement. Participants 
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were asked once again to score the ‘no consensus’ recommendations on the same 
9-point Likert scale as used in the first Delphi round (ranging from 1 (extremely 
irrelevant) to 9 (extremely relevant)). By the end of the questionnaire, the recommen-
dations that they scored with 8 or higher were shown, and participants were asked to 
select up to three additional statements. 
Participants were given 3 weeks to complete the second round. Reminders were sent 
after 1 week and after 2 weeks. 
The selection of additional key statements during the second round was based on two 
predefined criteria that were used during the first round (i.e. a median score of 8 or 
higher and panel disagreement below 25%). Furthermore, additional key statements 
should be selected by at least 30% of the experts. These three criteria were combined 
and converted into two possible outcomes: ‘selected’ or ‘rejected’. Recommendations 
that met all criteria were classified as ‘selected’ and the remaining recommendations as 
‘rejected’.
After having discussed the medical and ethical aspects of OTC in females with TS, 
the expert panel was asked to form a current standpoint if OTC should be offered to 
young females with TS or not.
Step 4: Final approval
An overview of the selected key statements and the current expert panel’s standpoint 
was sent out by E-mail to all 55 experts who initially gave consent for study participation, 
as 14 out of the 55 experts (25%) did not participate in the second Delphi round. 
They were provided with a last opportunity to make remarks and asked for their 
approval of the final set of key statements and the expert panel’s standpoint in order 
to reach international consensus. 
Results
Selection of key statements and formulation of a common stand
Step 1: Composition of the expert panel 
A total number of 12 gynaecologists, 13 (paediatric) endocrinologists, 10 medical ethicists 
and 20 patient representatives (patients n = 7, parents n = 13) from 16 different 
countries gave consent to participate in this study, forming an international expert 
panel of 55 members (Figure 2). The composition of the expert panel for each Delphi 
round has been visualized in Supplementary Figure S2.
All professionals, except one of the (paediatric) endocrinologists, were employed in 
academic hospitals or were working in an academic setting. Most of them were females 
(n=23), and about one-third of them were male professionals (n=12), Gynaecologists 
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had an average work experience of 23 years (range 9-40 years), (paediatric) endo-
crinologists had an average work experience of 21.4 years (range 7-40 years), and 
medical ethicists had an average work experience of 22 years (range 9-38 years). 
Many professionals (77%) had children themselves, and most of them conceived 
spontaneously. Two professionals conceived using ART and one professional adopted 
a child.
The remaining panel consisted of 20 patient representatives, seven females with TS and 
13 parents of patients with TS. The average age for patients was 32 years (range 18-50) 
and for parents 45 years (range 36-55). 
Most patient representatives were highly educated, with at least an associate degree 
(n=15), while the remaining five patient representatives finished at least high school. 
Figure 2. Members of the TurnerFertility expert panel (n=55) divided by country. 
(Paediatric) endocrinologists (n=13) representing 10 countries: Belgium (n=2), Belarus (n=1), 
Denmark (n=1), France (n=1), Italy (n=1), The Netherlands (n=2), Poland (n=1), Sweden (n=2), 
United Kingdom (n=1), United States (n=1).
Medical ethicists (n=10) representing 3 countries: Belgium (n=3), The Netherlands (n=6), Chile (n=1). 
Gynaecologists (n=12) representing 7 countries: Germany (n=2), France (n=1), Italy (n=1), The 
Netherlands (n=2), Sweden (n=1), United Kingdom (n=3), United States (n=2).
Patient representatives (n=20) (7 patients with TS and 13 parents) representing 8 countries: 
Belgium (n=1), Estonia (n=1), Finland (n=2), Ireland (n=1), The Netherlands (n=5), Norway 




















































































None of the women with TS had children themselves, but all except one expressed a 
desire to have children in the near future. None of them had tried ART. One woman 
with TS tried to adopt a child but was rejected for unknown reasons. One of the 
parents adopted a child, and the others conceived spontaneously.
Step 2: First Delphi round
A total number of 46 participants completed the first Delphi-round (response rate 
84%). Reasons for not participating were: concerns about privacy (n=1), not enough 
time (n=4), not feeling sufficiently involved with the subject (n=2), a conflict of interest 
(n=1), and software problems (n=1). The average time for completing the first survey 
was 30 minutes.
Based on the predefined selection criteria, six of the 38 statements were selected as 
key statements (Fig. 3). These six key statements were divided over the four ethical 
domains (beneficence (n=2), autonomy (n=1), non-maleficence (n=2), and justice 
(n=1)). In the first round, 13 statements could be discarded, and 19 statements remained 
undetermined. In addition, two new statements submitted by the expert panel, were 
added to the second Delphi round (Supplementary Table SI).
Step 3: Second Delphi round 
The remaining 19 statements and the two additional statements submitted by participants 
were re-evaluated in the second round by 41 participants (response rate 75%). Time 
investment was reported as the main reason for not participating. The average time for 
completing the second survey was 10 minutes. 
The analysis of the second survey resulted in the inclusion of two additional key 
statements (Figure 3). The other 19 statements could be discarded. 
By the end of the second Delphi round, 30 experts (75%) believed that OTC should 
be offered to young females with TS in a safe and controlled research setting, one 
participant voted against (2%), and 10 experts chose to remain neutral (24%). 
Step 4: Final approval
The final set of eight key statements (Figure 3) and the current expert panel’s 
standpoint was approved by 53 out of 55 participants (response rate 96%). All experts, 
including those who voted against, remained neutral or did not respond in the second 
Delphi round, now agreed that OTC should be offered to young females with TS, 
but under strict conditions only. The expert panel suggested a research setting, with 
proper counselling and informed consent procedures, and a long-term follow-up to 
study the efficacy of OTC in young females with TS first, before offering this procedure 
in routine care.
Two experts (4%), one gynaecologist and one medical ethicist, did not respond despite 
several reminders. 
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Figure 3. The final set of 8 key statements divided over the 4 basic ethical themes (beneficence, 
autonomy, non-maleficence, and justice). Inclusion was based on predetermined selection 
criteria (i.e. a median of 8 or higher AND panel disagreement below 25%) AND a top 5 score 




































































































1.  Infertility in women with Turner syndrome 
leads to psychological harm. 1 8 8 8 8 7.5 2.2% 46 -
2.   Patients with Turner syndrome rate their own 
infertility as their primary concern. 1 8 8 8 7 8 4.3% 65 -
3.  There are other ways to become a parent 
besides having genetically own children. 2 8 7.5 7 8 7.5 4.9% - 30.5%
Theme 2: Autonomy
4.  Regardless their age, girls with Turner syndrome 
should be included in the consent process. 1 8 8 8 8 7.5 4.3% 38 -
Theme 3: Non-maleficence
5.  Pregnancies in women with Turner syndrome 
are associated with higher rates of maternal 
complications. 
1 8 8 7 9 8 6.5% 52 -
6.  Pregnant women with Turner syndrome are at 
risk of severe cardiac complications and mortality. 1 8 8 6 8 8 6.5% 60 -
Theme 4: Justice
7.  Patients at risk of premature ovarian 
insufficiency should have equal access to 
counselling and fertility preservation options.
1 8 8 8 9 8 6.5% 70 -
Additional statements
8.  Each girl with TS interested in OTC, should 
be discussed within a multidisciplinary expert 
team, after psychosocial and cardiologic 
screening have taken place.
2 8 8 7 9 7.5 7.3% - 44.4%
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The detailed process of study enrolment and response rates by Delphi round is shown 
in Figure 4. A process description of the key statement selection by Delphi round can 













































































































































































































































































































































































































Differences in scoring behaviour between experts
In the first Delphi round, patient representatives mainly highlighted arguments focusing 
on the psychological harm of infertility, and one of the key statements was selected by 
the patient representatives despite a moderate popularity among the professionals. 
This statement focused on the impact of infertility on the quality of life. Medical ethicists 
were more concerned about creating false hope resulting in psychological harm in the 
future. Gynaecologists and (paediatric-) endocrinologists underlined statements 
regarding non-maleficence. The fact that young TS patients might be too immature to 
give informed consent was considered a major issue for both patient representatives 
and (paediatric) endocrinologists but was not recognized by the gynaecologists and 
medical ethicists. Younger participants (<25 years old) expressed the importance of 
including all patients in the consent process, regardless of their age. The statement that 
‘infertility leads to psychological harm’ was selected twice as frequently by participants 
without children compared to participants with children. Male participants were more 
concerned about pregnancy-related complications, whereas the female participants 
highlighted the psychological harm of infertility. Religion, age, and the availability of OTC 
in the participant’s country did not influence the scoring behaviour between participants 
in the first Delphi round.
Differences in scoring behaviour between the various experts were only seen in the 
first Delphi round and disappeared in the following two rounds when opinions were 
exchanged. 
Discussion
In this Delphi study, we demonstrated that an international expert panel of both 
professionals and patient representatives agreed that OTC in patients with TS should 
be offered, but in a safe and controlled research setting only. The expert panel’s 
standpoint was supported by eight key statements (Figure 3). The first two statements 
highlighted that infertility leads to psychological harm, and that patients with TS consider 
this their main concern (key statements 1 and 2). In addition, patients with TS should 
have equal access to FP options, in line with other patient groups (e.g. patients awaiting 
cancer treatments) (key statement 7). However, there were concerns about the 
increased risk of maternal morbidity and mortality associated with TS during a future 
pregnancy (key statements 5 and 6). Patients with TS should be counselled about the 
alternative options for future parenthood (i.e. adoption, fostering, and oocyte donation) 
(key statement 3). Furthermore, the option of voluntary childlessness should be 
discussed. All patients with TS interested in OTC should undergo psychosocial and 
cardiac screening and should be discussed by a multidisciplinary expert team (key 
statement 8). Great caution and restrictive (i.e. more negative, or even discouraging) 
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counselling are recommended if laparoscopic surgery or pregnancy is contraindicated 
(i.e. in patients with severe cardiac comorbidity).
In addition, patients with TS should always be included in the consent process, regardless 
of their age (key statement 4).
To our knowledge, this is the first international standpoint regarding OTC in females 
with TS. To reach international group consensus we used the RAND/UCLA Delphi 
procedure, which is a well-accepted method to perform Delphi studies. A key strength 
of this study was the combination of evidence and expert opinion, involving both 
professionals, and patient representatives from 16 different countries. Furthermore, 
our expert panel represented a robust sample of the most important stakeholders to 
ensure that all the medical and ethical aspects of OTC in females with TS were 
discussed. The literature shows that a diversity of expert panel members leads to the 
inclusion of different perspectives, in turn leading to better overall performance [78]. 
This diversity provided a suitable set of key statements and consensus on a final 
standpoint, which should support broad acceptance in daily practice internationally. 
Remarkably, ours was one of the few studies where a combined panel of medical 
professionals and patient representatives was involved in defining a standpoint regarding 
the indication for medical treatment for a specific patient group. It is well known that 
patient input is invaluable when it comes to clinical practice guideline development [74, 
75, 79]. Essentially, patients are the ultimate experts in patient-centeredness of care 
[80, 81], which is possibly the dominant paradigm in modern health care systems. The 
final set of key statements, and thus the outcome of this Delphi study, could have been 
different if only professionals had been involved in the selection procedure [73, 74, 
82-85]. In the first Delphi round, patient representatives mainly highlighted arguments 
focusing on the psychological harm of infertility, whereas medical ethicists were more 
concerned about creating false hope resulting in psychological harm in the future. 
Gynaecologists and (paediatric) endocrinologists underlined statements regarding 
non-maleficence. This is in line with previous studies reporting that professionals 
underestimate ‘softer’ dimensions of healthcare (e.g. quality of life) and overestimate 
the importance of biomedical outcomes compared to patients [85-89]. 
However, differences in scoring behaviour between the various experts were only seen 
in the first Delphi round and disappeared in the following two rounds when opinions 
were exchanged. Only one of the key statements (Infertility in women with TS leads to 
psychological harm) was selected by the patient representatives, despite having a 
moderate popularity among the professionals.
Although we considered the expert panel to be representative because of their diverse 
backgrounds [82, 90-92], the recruitment of professionals and patient representatives 
based on their expertise, having a leading role in one of the Turner patient’s organizations, 
and willingness to participate may have led to selection bias. As a result, panel members with 
a prominent opinion regarding OTC in females with TS might have been preferentially 
563903-L-bw-Schleedoorn







motivated to participate in this Delphi study. Furthermore, as not all panel members 
took part in all three rounds, there might be some response bias [93] because of time 
constraints or technical problems. Therefore, the final set of key statements and the expert 
panel’s standpoint might reflect the opinion of the most motivated panel members 
[93]. However, we tried to overcome this by inviting all 55 experts who initially agreed 
to participate in this Delphi study to participate in the final approval round. 
The anonymous nature of this study was both a strength and a weakness. The purpose 
of anonymity in a Delphi study is to allow a safe exchange of opinions, without the bias 
of the more influential responders dominating the discussion. External influences are 
eliminated, as participants do not have to worry about their reputation. However, it 
might encourage hasty decision-making and a lack of accountability for their answers.
This study described the systematic selection of key statements and the formulation of 
a final standpoint regarding use of OTC in females with TS by an international panel of 
patient representatives and professionals. International group consensus was reached 
after three rounds. The approval to perform OTC in a safe and controlled research 
setting is the first step in the global acceptance of this FP option in females with TS. The 
eight supporting key statements will contribute to the implementation of and patients’ 
access to this new treatment method. Our results reinforce the importance of involving 
patient representatives in decision making and guideline development.
Future collaborative research with a focus on the efficacy and safety of OTC in females 
with TS is urgently needed before OTC is performed in females with TS in routine care. 
Therefore, we recommend an international prospective cohort study with long-term 
follow-up with a research protocol based on the eight selected key statements. 
Furthermore, we recommend an international register for FP procedures in females 
with TS.
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Supplementary Table S1. Overview of the 38 statements divided over the four 
basic ethical themes that formed the basis of this Delphi study. In the first Delphi 
round 2 new statements were added (statement 39 and 40).
THEME 1: BENEFICENCE
1. Infertility in women with Turner syndrome leads to psychological harm.
2. Patients with Turner syndrome rate their own infertility as their primary concern.
2. The risk of infertility in patients with Turner syndrome has a negative impact on their 
intimate relationships and their chances at marriage.
4. Fertility is an essential element of femininity and is linked to a woman’s sense of identity.
5. There are other ways to become a parent besides having genetically own children.
6. Most women prefer biologic offspring.
7. It is more difficult for women with Turner syndrome to adopt a child.
8. Live birth rates are doubled in woman with Turner syndrome who used donor oocytes 
to become pregnant.
9. Oocyte donation in women with Turner syndrome leads to significantly less 
chromosomal abnormalities in their offspring
10. Intrafamilial oocyte donation offers woman with Turner syndrome an option for 
genetically related offspring with reduced foetal risks.
11. Intrafamilial oocyte donation could lead to imbalances in the relationship between 
patient, donor and child.
12. Cryopreservation of oocytes is an established fertility preservation method for woman 
and post-pubertal girls, whereas ovarian tissue cryopreservation is still experimental.
13. Cryopreservation of oocytes requires ovarian stimulation with exogenous FSH, whereas 
ovarian tissue cryopreservation does not.
14. Cryopreservation of oocytes requires transvaginal ultrasound guided oocyte retrieval, 
whereas ovarian tissue cryopreservation does not.
15. Cryopreservation of oocytes can be performed only in girls who have had a 
spontaneous menarche, whereas ovarian tissue cryopreservation can be performed in 
both pre- and post-pubertal girls.
16. Ovarian tissue preservation has been demonstrated as a successful fertility preservation 
option in other patient groups.
17. The germ cell loss will continue after auto transplantation of cryopreserved ovarian 
tissue.
18. The attempt to preserve a patient’s fertility decreases the patient’s psychological distress 
and promotes her psychological comfort. 
THEME 2: AUTONOMY
19. Most patients diagnosed with premature ovarian insufficiency express a desire for future 
offspring.
20. Patients and parents are motivated to try experimental fertility preservation methods.
21. Young patients with Turner syndrome might be too immature to give informed consent 
for experimental fertility preservation methods.
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Supplementary Table S1. Continued.
THEME 2: AUTONOMY
19. Most patients diagnosed with premature ovarian insufficiency express a desire for future 
offspring.
20. Patients and parents are motivated to try experimental fertility preservation methods.
21. Young patients with Turner syndrome might be too immature to give informed consent 
for experimental fertility preservation methods.
22. Regardless their age, girls with Turner syndrome should be included in the consent 
process for ovarian tissue cryopreservation.
23. Fertility preservation could create expectations for the child to reproduce. 
THEME 3: NON-MALEFICENCE
24. Pregnancies in women with Turner syndrome show higher rates of foetal complications.
25. Oocyte genetics or pre-implantation genetic screening can be used to screen oocytes  
and embryos.
26. Pregnancies in women with Turner syndrome show higher rates of maternal complications. 
27. Furthermore, pregnant women with Turner syndrome are at risk of severe cardiac 
complications and mortality.
28. Ovarian tissue cryopreservation requires laparoscopic surgery.
29. Experimental fertility preservation options could create false hope, which could lead to 
psychological harm in the future. 
30. A decisional conflict between the child and the parents could cause harm to their 
relationship.
31. Performing ovarian tissue cryopreservation in paediatric patients upon parents’ consent, 
may lead to both positive and negative feelings during adolescence of adulthood.
THEME 4: JUSTICE
32. Reproduction is a fundamental human right.
33. Patients at risk of premature ovarian insufficiency should have equal access to counselling 
and fertility preservation options.
34. Fertility preservation is a typical instance of ‘medicalization’. 
35. Ovarian tissue cryopreservation is also performed for non-medical reasons and social 
indications.
36. In some countries, ovarian tissue cryopreservation is already experimentally offered to 
girls with Turner syndrome.
37. Ovarian tissue cryopreservation remains financially out of reach for some patients.
38. Girls with Turner syndrome are less likely to get sexual education from their parents, due 
to their infertility.
ADDITIONAL STATEMENTS
39. Each girl with TS interested in OTC, should be discussed within a multidisciplinary expert 
team, after psychosocial and cardiologic screening have taken place.
40. Fertility preservation options might make us unhappier in the long run, because they 
contribute to a society where tragedy and human limitations are not accepted and are 
insurmountable problems.
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Supplementary Figure S2. Participants of per Delphi round divided by subgroup. A. Participants 
of the first Delphi round (n=46) divided by subgroup; (paediatric)endocrinologists (n=11), 
medical ethicists (n=8), gynaecologists (n=7), and patient representatives (n=20). B. Participants 
of the second Delphi round (n=41) divided by subgroup; (paediatric)endocrinologists (n=10), 























Supplementary Figure S3. Detailed process description of the selection of key statements in 
this 3-round Delphi study.
Selection of key statements









Step 2 - First online questionnaire (Delphi round 1) 
Individual appraisal of the 38 statements





‘No consensus’ recommendations 
n=19
Step 4 - Second online questionnaire (Delphi round 2) 
Reappraisal of the 19 ‘no consensus’ recommendations














Step 6 - Approval of selected statements (Delphi round 3)
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TurnerFertility Trial: PROTOCOL for an Observational Cohort Study 
to Describe the Efficacy of Ovarian Tissue Cryopreservation for Fertility 













To investigate the occurrence of live birth in women with Turner Syndrome (TS) after 
ovarian tissue cryopreservation in childhood followed by auto transplantation in 
adulthood and to find reliable prognostic markers for estimating the ovarian reserve in 
girls with TS in the future.
Setting
An observational cohort study with long-term follow-up in a tertiary fertility clinic in 
the Netherlands. Patients recruitment between January 2018 and December 2021. 
Participants
100 females aged 2 through 18 years with classical Turner (i.e. 45, X) or Turner variants 
(i.e. 45, X mosaicism or structural anomalies). Girls with Y chromosomal content, 
minor X deletions with marginal impact on fertility, active HIV, hepatitis-B or hepatitis-C 
infection, and/or an absolute contra indication for surgery, anaesthesia or future 
pregnancy will be excluded.
 
Interventions 
Ovarian cortical tissue will be harvested by performing a unilateral oophorectomy via 
laparoscopic approach. Ovarian cortex fragments will be prepared and cryopreserved. 
One fragment per patient will be used to determine follicular density by conventional 
histology, and to perform FISH analysis of ovarian cells. Routine chromosome analysis 
will be performed on both lymphocytes and buccal cells. A blood sample will be taken 
for hormonal analysis and all subjects will undergo a transabdominal ultrasound to 
determine the uterine and ovarian size. Patient characteristics, pregnancy rates, and 
pregnancy outcomes will be collected from the patient’s medical record. 
Ethics and dissemination
The study protocol has been approved by the Central Committee on Research 
Involving Human Subjects in November 2017 (CCMO NL57738.000.16). 
Registration details
This study is registered in ClinicalTrials.gov (NCT03381300).  
Strengths and limitations
 Patients were involved in the initiation and design of this study protocol. 
 The long-term follow-up of this study provides the unique opportunity to study the 
efficacy of ovarian tissue cryopreservation and pregnancy outcomes in females with TS.
 The single-centre design could be a limitation.
563903-L-bw-Schleedoorn




Turner Syndrome (TS) is the most common chromosomal abnormality among females, 
affecting 1 in 2,500 live born girls [1-3]. Due to the partial or complete absence of one 
of the two X-chromosomes the foetal development is affected, leading to abnormalities 
in almost all organs including the gonads [4]. Signs and symptoms vary among girls with 
TS, and intelligence is generally normal. The most common phenotypic features are 
infertility, short stature and cardio-aortic malformations.
Females with TS are known to have a limited reproductive lifespan due to an accelerated 
loss of germ cells. This process starts during the fatal period and continues until the 
point when the ovarian reserve is empty [5, 6]. Previous research has shown that 
primordial follicles can still be found in the ovaries of young girls with TS [7]. However, 
in most females with TS the ovarian reserve is exhausted before reaching adulthood 
[6]. Approximately one-third of females with TS have some pubertal development and 
10-15% will experience one or more spontaneous menstruation cycles [8-10]. 
Spontaneous pregnancies occur in approximately 2.0-7.6% of women with TS [11-15]. 
Several interview studies [16, 17] show that, regardless of age, uncertainty about their 
fertility is one of the major concerns for girls and females with TS and their parents. 
While fertility preservation has garnered greater attention in the media, physicians are 
frequently asked whether these methods could also be used to preserve the fertility of 
patients with TS.
Fertility preservation includes the cryopreservation of the patient’s own gametes, 
either by preserving mature oocytes or ovarian tissue containing primordial follicles. 
Cryopreservation of mature oocytes (OC) is a proven fertility preservation approach 
but requires ovarian activity, a good ovarian reserve, and psychological maturity [18]. 
This method is limited to a small percentage of females with TS, namely those who will 
be fertile after a spontaneous onset of puberty and menstruation. Furthermore, the 
patient has to be emotionally mature enough to undergo the procedure, which involves 
ovarian stimulation with exogenous FSH administration followed by transvaginal ultra-
sound-guided oocyte retrieval [18]. 
Because of the limitations of OC in girls with TS, ovarian tissue cryopreservation 
(OTC), appears to be a more promising technique for fertility preservation for this 
condition. The procedure can be performed in patients with TS regardless of their age 
or ovarian activity, and probably offer more females with TS the possibility to store a 
number of primordial follicles before their disappearance [19]. OTC is a proven method 
to preserve the fertility of young females at risk of iatrogenic premature ovarian 
insufficiency (POI) such as females undergoing gonadotoxic cancer treatments [20-22]. 
Auto transplantation of cryopreserved-thawed ovarian cortical tissue in cancer 
survivors has resulted in restoration of ovarian function in 67-93% of cases [23-26] with 
reported live birth rates between 25-33% per transplantation [24, 25, 27, 28]. A recent 
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study with a limited number of patients even reported a live birth rate up to 75% [26]. 
Over the past decades, several clinical guidelines [29-38] and decision tools [39-44] 
for ovarian tissue cryopreservation have been developed for these patients.
From 2002, OTC procedures have also been performed experimentally in at least 
83 young females with TS [7, 19, 45-47]. In approximately one quarter of females with 
TS, follicles were present [19]. Unfortunately, optimal discriminative markers for the 
presence or absence of follicles in females with TS are currently lacking. However, there 
is a general agreement that the mosaic karyotype is the most promising group to have 
ovarian follicles and to benefit from fertility preservation [18, 19, 48, 49].
Furthermore, there are to date no published records of girls with TS who have returned 
for autotransplantation. As long as the efficacy of fertility preservation in females with 
TS regarding future pregnancy and live birth is unknown, experts might be reluctant to 
recommend routine OTC procedures in females with TS [18, 19, 50, 51].
Exploring the efficacy of fertility preservation in females with TS seems a logical next 
step [48]. There is a strong need for a structured observational cohort study with 
long-term follow-up. This study should focus on the efficacy of OTC in females with TS 
including pregnancy rates and pregnancy outcomes, and on the development of a 
reliable prognostic model for estimating the ovarian reserve in females with TS. Ideally, 
a decision aid based on the information needs of females with TS and their parents 
should be developed with the aim to help them to make a deliberate decision between 
OTC and the alternative options for future parenthood. This decision aid should include 
a reliable prognostic model to estimate the ovarian reserve in females with TS. Herewith, 
the urgency of fertility preservation could be determined and unnecessary surgical 
procedures can be avoided. 
Objective
To investigate the occurrence of live birth in women with TS after OTC in childhood 
followed by auto transplantation in adulthood and to find reliable prognostic markers 
for estimating the ovarian reserve in girls with TS in the future.
Methods
Study design
An observational cohort study with long-term follow-up in a tertiary fertility clinic in 
the Netherlands. This study is registered in ClinicalTrials.gov (NCT03381300). The study 
flow is visualised in Figure 1.
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Figure 1. Flowchart of study. TS, Turner Syndrome; 45, X, 45, X Monosomy; r(X), ring 
chromosome X; if(X), isochromosome X; X del, X deletions; HIV, Human Immunodeficiency 
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Recruitment started January 2018. OTC procedures will be performed between 
January 2018 and December 2021. We expect to end this study in 2071. 
Interventions
Based on the international Cincinnati Turner Guideline Consensus Meeting, July 2016 
[52] and the consultation of Dutch cardiologists, paediatric cardiologists and anaesthe-
siologists between 2016-2017, there are no absolute cardiovascular contra-indications 
for surgical intervention and/or pregnancy. Advice against surgical intervention and/or 
pregnancy should be based on the patient-specific cardiovascular risk profile. 
Therefore, all girls will undergo preoperative screening and risk assessment by a 
paediatric cardiologist and paediatric anaesthetist. After this screening, they will be 
defined as either low-risk participants or high-risk participants based on their individual 
risk profile. High-risk patients and their parents will be informed about their risks and 
excluded from this study in order to ensure patient safety. In low-risk participants the 
surgical procedure, followed by a hospital stay of one night, will be planned. 
Ovarian cortical tissue will be harvested by performing a unilateral oophorectomy via 
laparoscopic approach. A collaborating team of well-trained paediatric surgeons, 
gynaecologists specialised in reproductive medicine, and laboratory workers specialised 
in human ovarian cortical tissue cryopreservation, will ensure safe and efficient cryo-
preservation of the ovarian tissue. Cryopreservation of the ovarian tissue fragments 
will be performed according to the Dutch protocol ‘Cryopreservation and transplanta-
tion of ovarian tissue’ (Dutch Network Fertility preservation, September 2012). 
One cortex fragment per patient of approximately 8x5x1mm will be used to determine 
follicular density by conventional histology, and to perform fluorescence in situ 
hybridisation (FISH) analysis of 3 different ovarian cell types (oocytes, granulosa cells 
and stromal cells) [53]. Routine chromosome analysis will be performed on both 
lymphocytes and buccal cells. If follicles are present, additional FISH analysis of urine 
cells will be performed. Furthermore, a blood sample of 3.5 mL will be taken for 
hormonal analysis (i.e. FSH, LH, AMH, oestradiol and inhibin B). All subjects will 
undergo a transabdominal ultrasound to determine the uterine and ovarian size. 
Information such as the patient’s age and the spontaneous onset of puberty and 
menstruation will be collected from the patient’s medical record. In the future, 
orthotropic transplantation of the auto graft is performed via laparoscopic or laparotomic 
approach [21, 54-56]. Pregnancy rates and outcomes will be collected from the patient’s 
medical record. 
Study population
The study population includes 100 females with TS.
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In order to be eligible to participate in this study, a subject must meet all of the following 
criteria:
• Girls and young females with classic Turner (i.e. 45, X monosomy) or Turner variants 
(e.g. 45, X mosaicism, ring X, isochromosome X, X deletions),
• Aged 2 through 18 years,
• Who completed the diagnostic work up phase of TS, according to the international 
guidelines, including routine cardiac screening,
• Whose agreement to participate in this study has been signed by both the parents 
(girls 2-11 years old),
• Whose agreement to participate in this study has been signed by the patient and her 
parents (girls 12-15 years old),
• Whose agreement to participate in this study has been signed by the patient (girls 
16-18 years old).
Exclusion criteria 
A potential subject who meets any of the following criteria will be excluded from 
participation in this study:
• Girls and young females with minor X deletions with marginal impact on fertility or 
Y chromosomal content.
• Girls with an active HIV, hepatitis-B or hepatitis-C infection.
• Girls with an absolute contra-indication for undergoing a laparoscopic unilateral 
oophorectomy under general anaesthesia and/or future pregnancy based on the patient 
specific risk profile (e.g. severe cardiovascular co morbidity and/or BMI >40 kg/m2).
Recruitment of participants and informed consent
Girls with TS and their parents will be informed about this study by their paediatrician 
or by the Dutch TS patient organisation (Turner Contact Nederland). Girls with TS 
who meet the inclusion criteria and are potentially interested, will receive the study 
information for patients and/or parents (https://www.radboudumc.nl/trials/turner) and 
will be invited for a general informative meeting. If the girls / parents are still interested 
after receiving this information, they will be referred to our hospital by their paediatric 
endocrinologist by using a specific form designed for this study. The personal counselling 
is done by a dedicated team of gynaecologists. A paediatric psychologist will be available 
for additional support. In case of comorbidity, a multidisciplinary team of gynaecologists, 
(paediatric)cardiologists and other specialists if needed, will discuss the patient’s specific 
risk profile.
Written consent must be given by the (parents of) patients before study participation. 
Girls and their parents are given time as individually requested to consider participation 
in this study. A pilot decision aid, website and age-specific information flyers have been 
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developed, to help girls and their parents to make a deliberate decision (https://www.
radboudumc.nl/trials/turner). The current decision aid includes a flowchart and 
background information on OTC in comparison with the existing options (i.e. awaiting 
spontaneous pregnancy, vitrification of oocytes, oocyte donation, adoption and/or 
foster ship). When a participant reaches the age of 16 years old, she will be asked for 
reconsent.
Bio banking
All biological material and data will be handled and stored according to the World 
Medical Association (WMA) Declaration of Taipei on ethical considerations regarding 
health databases and biobanks (67th WMA General Assembly. Taipei, Taiwan. October 
2016). All patient data will be coded. Members of the research team, the Data and 
Safety Monitoring Board, and the Health Care Inspectorate are the only persons who 
have access to the key of the code. This key of code is stored in Castor Electronic Data 
capture (EDC). The dignity, autonomy and privacy of the patients will be respected by 
the duty of confidentiality of all who are involved in handling data and biological material. 
There will be no discrimination. 
Castor Electronic Data Capture (EDC) will be used for Good Clinical Practice (GCP)-
compliant data collection. All participant data will be reported in electronic case report 
forms (e-CRF). 
A safe storage of the ovarian tissue and consent forms is provided at our cryobank. This 
cryobank is ISO-accredited (accreditation number M101, ISO 15189), and registered by 
the Dutch Ministry of Health, Welfare and Sport (VWS) (registration number 5515 L/
EO). The cryobank is located at a restricted area in the Radboud University Medical 
Centre, and access is permitted by electronic authorization only.
All subjects will be asked for the continuation of the storage of the ovarian tissue yearly. 
Each individual patient and/or her parents may freely decide about the continuation of 
the storage of the ovarian tissue at our cryobank, transportation of the ovarian tissue 
to another cryobank, donation for research, or the elimination of their cryopreserved 
ovarian tissue. When the participant turns 16 years old, she will be asked for re-consent.
Subjects may withdraw from the trial at any time. Subjects do not need to state a 
reason for withdrawal.
Patient and Public Involvement
This study protocol has been initiated by and conducted with active input and feedback 
of international experts and patient representatives from the Dutch national patient 
organization Turner Contact Nederland (TCN) and the Differences of Sex Differenti-
ation (DSD) patient advisory group of the Radboud university medical centre. Patient 
representatives were also involved in the development of patient information brochures, 
informed consent forms, and website. During the trial, patient representatives will be 
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involved by the development of a decision aid and newsletters. Furthermore, surveys 
and focus groups among all counselled patients are held for continuous process 
improvement. All participants will be informed of the results of the TurnerFertility 
study through post or email.
International consensus to perform this study was achieved in a Delphi study including 
35 medical professionals and 20 patient representatives from 16 different countries. 
This expert panel stated that ovarian tissue cryopreservation (OTC) in patients with 
Turner syndrome (TS) should be offered, but in a safe and controlled research setting 




• Live birth after auto transplantation of cryopreserved-thawed ovarian cortical tissue 
(i.e. live birth rate or LBR)  
Proximate 
• The number of primordial follicles found in the ovarian tissue
Secondary outcomes
• The association between patient’s age at cryopreservation and LBR 
• The association between patient’s genotype and LBR
• The association between patient’s AMH level at cryopreservation and LBR
• The association between patient’s FSH level at cryopreservation and LBR
Tertiary outcomes
• The study participation rate
• The number of eligible participants
• The age of the participant
• The incidence of somatic mosaicism 
• The incidence of germ cell mosaicism 
• Serum hormone levels 
• The number of complications related to the laparoscopic procedure
• The incidence of spontaneous puberty and/or spontaneous menarche after 
laparoscopic oophorectomy
• The incidence of spontaneous pregnancies after laparoscopic oophorectomy
• The incidence of menstruation cycle recovery after auto transplantation of cryopre-
served-thawed ovarian tissue in the future
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• The incidence of pregnancies after auto transplantation of cryopreserved-thawed 
ovarian tissue in the future
• The number of ongoing pregnancies after auto transplantation of cryopre-
served-thawed ovarian tissue in the future
• The number of miscarriages after auto transplantation of cryopreserved-thawed 
ovarian tissue in the future
• The incidence of congenital anomalies in the offspring of women with TS who 
became pregnant after auto transplantation of cryopreserved-thawed ovarian tissue 
• Time to pregnancy after auto transplantation of cryopreserved-thawed ovarian 
tissue in the future
• Time to live birth after auto transplantation of cryopreserved-thawed ovarian tissue 
in the future
Data analysis
All data in this pilot study will be analysed on both intention-to-treat and per-protocol 
analysis. Data of girls who are lost to follow-up will be included as far as possible. 
Missing data will be reported along with the reason. Baseline data will be described 
quantitatively. Continuous variables will be summarised as means with standard deviations 
(SDs) or as medians with inter-quartile ranges (IQRs), depending on their distribution. 
Dichotomous and ordinal data will be summarised as percentages. For all analyses, 
IBM SPSS will be used.
Descriptive statistics will be used to analyse the number of primordial follicles in the 
ovarian tissue, and the number of (ongoing) pregnancies, miscarriages and live born 
children after auto transplantation of cryopreserved-thawed ovarian tissue.
The primary outcome (dichotomous) ‘live birth after auto transplantation of cryopre-
served-thawed ovarian tissue’ will be assessed and reported as a percentage. The number of 
primordial follicles (continuous) will be reported as a mean with standard deviations 
(SDs). The number of pregnancies, ongoing pregnancies, miscarriages, and congenital 
anomalies (dichotomous) will be reported as a percentage. 
The time to pregnancy and the time to live birth after auto transplantation will be 
reported as a mean with standard deviation (SD). 
Furthermore, the relationship between the age of the participant when ovarian tissue 
cryopreservation (OTC) is performed (years), serum FSH level (IU/L), and serum AMH 
level (ng/ml), related to the number of primordial follicles, the incidence of (ongoing) 
pregnancies, live birth, and congenital anomalies will be described using Spearman’s 
correlation coefficient. In addition, the number of primordial follicles, the incidence of 
(ongoing) pregnancies, live birth, and congenital anomalies will be described by the 
patient’s karyotype (i.e. 45, X monosomy or mosaicism).  
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Interim analyses on safety and futility are planned every 6 months until the last 
participant (n=100) has undergone the laparoscopic unilateral oophorectomy followed 
by ovarian tissue cryopreservation. The first interim analysis will be performed after 
the inclusion of the first 10 patients. Each interim analysis will be reported to the 
independent DSMB (Data and Safety Monitoring Board). The percentage of participants 
with follicles in their ovary will be used as a futility indicator. The percentage of 
participants who had one or more complications related to the laparoscopic 
oophorectomy and/or anaesthesia will be used as a safety indicator.
Sample size calculation
The estimated LBR related to OTC in girls with TS is currently unknown. Hence, the 
sample size calculation should be based on LBR in other patient groups. The LBR per 
transplantation of earlier cryopreserved ovarian tissue in cancer survivors is 
approximately 25% [21]. In order to describe the dichotomous outcome live birth rate 
(LBR), we used the sample size calculation of Hulley et al. 2013 [57]. We would need a 
total sample size of 72 participants if the LBR in females with TS would be similar.
However, one should consider that auto transplantation will not be performed in all 
girls who are participating in this study, due to several reasons (e.g. absence of follicles, 
future contra indications and/or on patient’s preference). Furthermore, females with TS 
show an higher risk of miscarriage [13], and a slightly higher risk of a child with a 
congenital disorder when they conceive spontaneously [13, 58]. If these increased risks 
are related to the functional integrity or the chromosome profile of their follicular cells 
remains unclear. On the other hand, performing an exploratory intervention study in 
>100 minors, is unrealistic and inappropriate. Therefore, we aim to include primarily a 
total number of 100 girls with TS in this ‘proof of concept’ study.  
Discussion
This study is an example of patient-initiated research as there is an increasing demand 
for fertility preservation options in girls and young females with TS [48]. This study 
protocol was developed together with patient representatives and gives females with 
TS the possibility to undergo an experimental fertility preservation procedure in a safe 
and controlled research setting. The long-term follow-up of this study up to live birth 
provides the unique opportunity to study the efficacy of ovarian tissue cryopreserva-
tion and pregnancy outcomes in females with TS. Furthermore, this study could 
contribute to the development of a reliable prognostic model for estimating the ovarian 
reserve in females with TS in the future. 
563903-L-bw-Schleedoorn







A limitation of this study could be the single-centre design combined with the relatively 
low expected live birth rate. For the development of a prediction model, more patients 
should be included in the analysis to increase the internal validation. Furthermore, an 
external data validation should be performed. We suggest an international, multicentre 
study with a clear study protocol and a central registration after the results of the 
interim analysis of this pilot study have been published and are open for collaborating 
with other experts within the field of fertility preservation in females with TS.
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What is the X chromosomal content of oocytes and granulosa cells of primordial / 
primary (small) follicles and stromal cells in ovaries of young patients with Turner’s 
syndrome (TS)?
Summary answer
Small ovarian follicles were detected in one-half of the patients studied, and X 
chromosome analysis revealed that most oocytes were normal, granulosa cells were 
largely monosomic, while stromal cells showed a high level of mosaicism.
What is known already
Most women with TS experience a premature reduction or complete loss of fertility 
due to an accelerated loss of gametes. To determine whether fertility preservation in 
this group of patients is feasible, there is a strong need for information on the X 
chromosomal content of ovarian follicular and stromal cells.
Study design, size, duration
Small follicles (<50 µm) and stromal cells were isolated from ovarian tissue of young TS 
patients and analysed for their X chromosomal content. In addition to ovarian cells, 
several other cell types from the same patients were analysed.
Participants/materials, setting, methods 
After unilateral ovariectomy, ovarian cortex tissue was obtained from 10 TS patients 
(aged 2–18 years) with numerical abnormalities of the X chromosome. Ovarian cortex 
fragments were prepared and cryopreserved. One fragment from each patient was 
thawed and enzymatically digested to obtain stromal cells and primordial/primary 
follicles. Stromal cells, granulosa cells and oocytes were analysed by FISH using an X 
chromosome-specific probe. Extra-ovarian cells (lymphocytes, buccal cells and urine 
cells) of the same patients were also analysed by FISH. Ovarian tissue used as control 
was obtained from individuals undergoing oophorectomy as part of their gender 
affirming surgery.
Main results and the role of chance
Ovarian follicles were detected in 5 of the 10 patients studied. A method was developed 
to determine the X chromosomal content of meiosis I arrested oocytes from small 
follicles. This revealed that 42 of the 46 oocytes (91%) that were analysed had a normal 
X chromosomal content. Granulosa cells were largely 45, X but showed different levels 
of X chromosome mosaicism between patients and between follicles of the same 
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patient. Despite the presence of a low percentage (10–45%) of 46, XX ovarian cortex 
stromal cells, normal macroscopic ovarian morphology was observed. The level of 
mosaicism in lymphocytes, buccal cells or urine- derived cells was not predictive for 
mosaicism in ovarian cells.
Limitations, reasons for caution
The results are based on a small number (n = 5) of TS patient samples but provide 
evidence that the majority of oocytes have a normal X chromosomal content and that 
follicles from the same patient can differ with respect to the level of mosaicism of their 
granulosa cells. The functional consequences of these observations require further 
investigation.
Wider implications of the findings
The results indicate that despite normal ovarian and follicular morphology, stromal cells 
and granulosa cells of small follicles in patients with TS may display a high level of 
mosaicism. Furthermore, the level of mosaicism in ovarian cells cannot be predicted 
from the analysis of extra-ovarian tissue. These findings should be considered by 
physicians when offering cryopreservation of ovarian tissue as an option for fertility 
preservation in young TS patients.
Study funding/competing interest(s)
Unconditional funding was received from Merck B.V. The Netherlands (Number A16- 
1395) and the foundation ‘Radboud Oncologie Fonds’ (Number KUN 00007682). The 




Turner’s syndrome (TS) is a heterogeneous genetic disorder in women with one intact 
X chromosome and complete or partial absence of the second X chromosome that 
affects 1 in every 2500 female live births [1, 2]. The presentation of TS is variable and 
includes typical phenotypic features, such as short stature, lymphedema, webbed neck, 
broad shield chest and congenital malformations of the heart and kidneys. The main 
concern for girls and women diagnosed with TS is the reduction or complete loss of 
fertility [3, 4]. Impaired fertility in TS is thought to arise mainly from accelerated germ 
cell apoptosis and impaired folliculogenesis during foetal life, leading to premature 
follicular depletion and gonadal dysgenesis [5, 6]. The degree of oocyte loss, however, 
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is variable, and the remaining function of the ovary after birth is thought to rely on the 
percentage of 46, XX cells in the ovaries [7]. In women from the general population, 
the number of gametes declines from approximately 2 million at birth to about 400 
000 at the start of puberty [8]. In women with TS, the already- diminished oocyte pool 
at birth [5, 6, 9, 10] combined with this subsequent post-natal loss of gametes leads to 
ovarian insufficiency and incomplete sexual development during childhood in more 
than 80% of cases [11]. Several options exist to preserve fertility in women facing 
premature depletion of their gametes [12]. In adult women, these include freezing of 
ovarian tissue, mature oocytes or embryos, while in prepubertal patients ovarian tissue 
cryopreservation (OTC) is currently the only available option. When offering OTC to 
girls with TS who cannot wait until sufficient maturity to undergo oocyte cryopreser-
vation, it should be considered at the earliest age possible in order to store as many 
primordial follicles as possible before their premature disappearance [12, 13]. Although 
OTC is widely and successfully used for fertility preservation/restoration in other 
patient groups [14-16], this does not guarantee that it will also be successful in TS 
patients. OTC is already routinely offered to TS women in several countries [13, 17-20], 
but there are no reports of children born from women with TS after auto-transplanta-
tion of their ovarian tissue [21]. The efficacy of OTC in this particular group of patients 
therefore remains to be confirmed. The success of OTC not only depends on the 
developmental competence of follicles that persist in the ovaries, but also on the ability 
of ovarian tissue from TS patients to support normal ovarian function. The functional 
capacity of the tissue after auto-transplantation might depend on the percentage of 
normal 46, XX cells that are required for follicular growth and ovulation. Aneuploidy in 
oocytes of primordial/primary follicles is also very likely to have functional consequences. 
In addition, genetic abnormalities in the layer of granulosa cells present in small 
(primordial and primary) follicles might impair normal follicular development [22, 23], 
as these cells not only control the arrest of the oocyte during the prophase of meiosis 
I, but also play a crucial role in normal follicular maturation [24]. Very little is known 
about the karyotype of these follicular cells in TS women. This information, however, is 
essential for understanding the mechanisms of premature follicular depletion and 
gonadal dysgenesis in this specific group of patients and, hence, to evaluate if OTC is a 
realistic option to preserve their fertility. As a first step toward the characterization of 
ovarian tissue from TS patients, we determined the X chromosomal content of oocytes 
and granulosa cells of small follicles, and stromal cells of ovarian cortex tissue in a 
cohort of 10 young TS patients with numerical abnormalities of the X chromosome. To 
this end we developed protocols to isolate intact small follicles from ovarian cortex 
tissue and efficiently separate the follicular cells, followed by fluorescence in situ 
hybridization (FISH) analysis of the X chromosome. In addition, a procedure was 
developed for determining the number of X chromosomal sister DNA strands in the 
normally tetraploid oocytes of meiosis I arrested follicles. The karyotype in peripheral 
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blood lymphocytes and cells of buccal smears and urine was determined to assess their 
predictive value for the karyotype of ovarian cells.
Materials and Methods
Patients
The current investigation is part of a nationwide trial ‘Preservation of Ovarian Cortex 
Tissue in Girls with Turner Syndrome’ (ClinicalTrials.gov Identifier: NCT03381300). 
Patients were recruited nationwide and referred to our tertiary fertility clinic between 
January 2018 and December 2018. Patients included in the current study are women 
with TS diagnosed with numerical X chromosome aberrations (45, X or 47, XXX), 
aged 2–18 years. Human ovarian tissue that was used as control was obtained from 
female-to-male transgender individuals undergoing oophorectomy as part of their 
gender affirming surgery.
Ethics
The study was approved by the Dutch Central Committee on Research Involving 
Human Subjects (CCMO NL57738.000.16). Written informed consent was obtained 
from all patients and/or their parents.
Collection of ovarian cortical tissue and estimation of the number 
of follicles per ovary
After unilateral ovariectomy, the ovary was collected in cold L15 medium (Lonza, 
Switzerland), immediately transferred to the laboratory and placed on a pre-cooled 
surface at 4ºC. The medulla was removed from the cortex, after which cortex 
fragments of ~5 × 8 mm were prepared. Fragments were cryopreserved according to 
clinical standards [25]. For each patient, a single representative ovarian cortex fragment 
was available for research purposes. The fragment was thawed and cut in half. One-half 
was used for the isolation of small follicles and stromal cells (see below), the other half 
for histological analysis. The number of follicles was determined by complete serial 
sectioning (4 µm sections) of the tissue followed by haematoxylin–eosin (HE) staining 
of sections at 24 µm intervals. By examining stained sections at 24 µm intervals none of 
the primordial/primary follicles (follicle diameter ~45 µm) could have been missed. 
Since the follicular density in the ovaries of TS patients is low, counting the same follicle 
twice could be easily avoided and staining of all sections was therefore not necessary. 
In addition, in view of the heterogeneous distribution of follicles in the ovary, follicle 
density is expressed as the number of follicles per mm3 of cortex tissue.
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Dissociation of ovarian cortex tissue
Individual small follicles and the stromal cells were isolated as described previously, 
with several modifications [26, 27]. To this end the tissue was cut into small pieces of 
~1 × 1 × 1 mm and enzymatically digested in 4 ml of pre-warmed (37ºC) L15 medium 
containing 0.1 mg/ml Liberase DH, 10 µg/ml DNase I (both from Roche diagnostics, 
Mannheim, Germany) and 1 mg/ml collagenase I from Clostridium histolyticum (Sigma 
life sciences, Israel) for 75 min at 37ºC. The digestion mix was pipetted up and down 
every 15 min. The enzymatic reaction was stopped by the addition of 4 ml of cold L15 
supplemented with 10% of foetal bovine serum (FBS; Life technology, Paisley, UK). The 
dissociated tissue was washed once with 8 ml of cold L15 medium by centrifugation at 
500g and resuspended in 500 µl L15 medium. Next the cell suspension was transferred 
to a Petri dish and examined under a stereomicroscope. Small follicles (<50 µm) were 
manually picked up using a 75 µm plastic pipette (Research instruments, Falmouth, UK) 
and transferred to a droplet of L15 medium supplemented with 10% FBS at 4ºC to 
prevent aggregation of follicles. To improve follicular cell spreading prior to FISH 
analysis, the follicles were treated with a solution of 0.06% trypsin, 1 mg/ml EDTA and 
1 mg/ml glucose for 20 min at 37ºC. Ovarian stromal cells were obtained from the 
cortex cell suspension, taking special care to avoid picking up any remaining follicles.
FISH analysis of lymphocytes, buccal cells, urine cells and ovarian cells 
from TS patients
FISH analysis of extra-ovarian cells was performed following standard protocols [28]. 
Ovarian follicles or stromal cells were transferred to 100 µl droplets of 0.04 mM KCl 
on a slide and incubated for 20 min at 37ºC. Next, slides were allowed to dry and then 
pre-fixed in 300 µl of 0.05 mM KCl/7.5% acetic acid/22.5% methanol for 2 min at room 
temperature. Final fixation was performed by covering the slide with methanol/acetic acid 
(3:1) for 2 min at room temperature. FISH was performed according the manufacturer’s 
instructions with chromosome X and chromosome 18-specific centromeric probes 
(CEP X (DXZ1) and CEP 18 (D18Z1); Vysis, Abbott, IL, USA). Fluorescent images 
were captured, and the signal(s) for the X chromosome was evaluated in somatic cells 
only when two signals of chromosome 18 were visible. In most oocytes, only one 
signal could be detected for each chromosome. Slides were counterstained with 
4,6-Diamidino-2- Phenylindole (DAPI). The presence of different cell lines in the patients 
was determined by routine cytogenetic analysis of peripheral blood lymphocyte 
(30 cells), followed by FISH analysis of buccal cells (100 cells) and urine-derived cells 
(100 cells), following clinical standards.
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Determining the X chromosomal content of peripheral blood lymphocytes and cells 
from buccal smears and urine in patients with TS. From the study population five 
patients with a non-structural, mosaic karyotype 45, X / 46, XX (/ 47, XXX) and five 
patients with a 45, X monosomy were selected based on order of inclusion in the study 
(Table I). In the mosaic patients four out of five were of the 45, X / 46, XX karyotype 
(Patients B–E), while in Patient A three cell lines (45, X / 46, XX / 47, XXX) were 
found.  The ratio between the different cell lines varied considerably between tissues 
of the same patient (Figure 1). For example, in Patient A the majority of lymphocytes 
had a 47, XXX karyotype while in urine comparable numbers of 45, X and 47, XXX 
cells were observed. In Patient E, the ratio between 45, X and 46, XX cells in 
lymphocytes and buccal cells was approximately 1, while in urine only 45, X cells were 
found without any detectable mosaicism.
Macroscopic morphology of ovaries
Intact ovaries were obtained by laparoscopic unilateral ovariectomy and photographed 
before preparation of cortex fragments. As illustrated in Figure 2, the monosomy 
patients showed gonadal dysgenesis with bilateral streak ovaries. The ovaries of the five 
mosaic patients were of normal macroscopic morphology.
Table I.  Characteristics of the patients with Turner syndrome. In this study 
10 patients with Turner syndrome were included.
Patient Age  
(years)
Cell lines  
(lymphocytes and buccal cells)
Number of  
follicles per mm3 tissue
A 8 45, X / 46, XX / 47, XXX 11
B 5 45, X / 46, XX 64
C 15 45, X / 46, XX 45
D 16 45, X / 46, XX 6
E 15 45, X / 46, XX 3
F 14 45, X 0
G 9 45, X 0
H 13 45, X 0
I 3 45, X 0
J 17 45, X 0
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Patient A Patient B
Patient C Patient D
Patient E Patient F-J
= 46, XX = 45, X = 47, XXX
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Designing a protocol for the separation of ovarian cortex cell 
components prior to FISH analysis
To determine the X chromosomal content of ovarian stromal cells, follicular granulosa 
cells and oocytes by FISH, we first designed a protocol to efficiently separate these 
ovarian cell components (Figure 3). To this end ovarian cortex fragments were 
prepared after unilateral ovariectomy. One part of the ovarian cortex fragment that 
was available for research purposes was used for histological analysis to determine the 
number of follicles (Figure 3C and F). The remaining part was enzymatically digested 
to yield a suspension consisting mainly of single stromal cells and, if present, individual 
follicles (Figure 3D and G). When no follicles were observed histologically, part of the 
stromal cells was used directly after the enzymatic digestion for FISH with centromere 
probes specific for the X chromosome and, as a control, chromosome 18. (Figure 3E). 
When small follicles (<50 µm) were present in the cell suspension these were picked 
Figure 1. Mosaicism in extra-ovarian tissues and ovarian stromal cells, granulosa cells and 
oocytes from patients with Turner syndrome. In patients with Turner’s syndrome (TS), 
lymphocytes (n =30), cells from buccal smears (n =100) and urine (n =100) were analysed by 
FISH with an X chromosomal peri-centromeric probe. The percentage of cells with a particular 
karyotype is indicated. In Patient A three different cell lines (45, X / 46, XX / 47, XXX) were 
detected, Patients B–E were mosaic for 45, X and 46, XX cell lines, while in Patients F–J only 45, 
X cells were found. In addition, ovarian cortex components including stromal cells (n = 100), 
granulosa cells (n ≥100) and oocytes were karyotyped. The number of oocytes was 19, 12, 2, 9 
and 4 for Patients A, B, C, D and E, respectively. In Patients F–J no follicles were detected. 
ND=not done; NA= not applicable.
Figure 2. Macroscopic images of ovaries from TS patients. After unilateral ovariectomy intact 
ovaries were transported to the laboratory and photographed. A representative example of an 
ovary from a mosaic 45, X / 46, XX girl (Patient D) with normal morphology and volume is 
shown in panel A. The small fibrous streak ovary shown in photo B is from a girl with 45, X 
monosomy (Patient I). The brown discoloration of the tissue is due to electrocauterization 
during surgery. Bars represent 1 cm.
A B
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up manually and analysed separately by FISH (Figure 3K). After follicle isolation, part 
of the stromal cells from the cell suspension (Figure 3H) was used for FISH analysis on 
separate slides (Figure 3I). Interpretation of the FISH signals of follicles that were 
isolated directly after the enzymatic digestion of the cortex tissue proved to be 
problematic, as nuclei of the granulosa cells of individual follicles were generally not 
sufficiently spaced to unambiguously determine the number of hybridization spots per 
Figure 3. Flow scheme for separating ovarian cortex cellular constituents prior to FISH analysis. 
After the surgical removal of the intact ovary (A), cortical fragments were prepared. Part of one 
representative cortex fragment (B) was analysed by standard haematoxylin–eosin staining for 
the presence of follicles. When no follicles were present (C), the remaining part of the fragment 
was used to make a suspension of stromal cells (D), for interphase FISH with chromosome X 
(green) and chromosome 18 (red)-specific probes (E). When follicles were present (F), the 
remaining part of the cortex fragment was used to make a cell suspension (G) from which small 
follicles were manually picked up. These isolated follicles were subjected to further digestion (J) 
and subsequently analysed by FISH. The white arrowhead points to the signals from the oocyte 
(K). Part of the remaining cell suspension (H) was used for FISH analysis of stromal cells (I). Bars 
represent 1 cm (A and B) or 100 µm (C, D, F–H and J). Original magnification of FISH signals was 
×630 (E, I and K).
A
B C D E
F G H I
J K
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nucleus. In addition, the oocyte-specific FISH signals were frequently obscured by 
granulosa cell DNA (Figure 4A and B). To obtain more dispersed granulosa cell nuclei 
for FISH analysis we introduced an additional enzymatic treatment of isolated follicles 
with trypsin. This treatment visibly affected the follicles, showing partial rounding of 
granulosa cells on the surface of the follicle, but did not lead to detachment of cells from 
the follicle (Figure 3J).  FISH analysis and DAPI counterstaining of these follicles clearly 
showed more dispersed granulosa cell nuclei and, more importantly, oocyte nuclei that 
were not covered by granulosa cell nuclei (Figure 3K, 4C and D).
Determining the karyotype of ovarian stromal cells
In the five patients (F–J) with 45, X monosomy in lymphocytes, buccal cells and urine 
cells, no follicles were found in the HE stained sections of ovarian cortex tissue, nor in 
the cell suspensions used for FISH (Table I, Figure 3C and D). Karyotyping of the 
ovarian stromal cells of these patients showed exclusively 45, X cells (Figure 1). In the 
mosaic TS patients, the karyotype of the stromal cells showed a ratio of cell lines (45, 
X; 46, XX and 47, XXX) that was similar to that of cells from urine (Patients A and B), 
lymphocytes (Patients C and E) or buccal cells (Patients B, D and E).
Karyotyping granulosa cells from small ovarian follicles
The number of X chromosomes was determined in granulosa cells from small follicles 
isolated from ovarian tissue from the five mosaic TS patients (A–E). Although over 98% 
of the follicles in these tissues were either in the primordial or primary stages of 
development (Figure 5A), a small number of secondary follicles was observed as well 
(Figure 5B). After enzymatic digestion of the tissue and subsequent purification of the 
small follicles, the X chromosomal content of their granulosa cells was determined. 
Remarkably, in three out of five patients with a mosaic pattern all granulosa cells were 
45, X (Patients C–E). In the other two mosaic patients, the granulosa cells displayed a 
mosaic karyotype with the majority being 45, X in Patient A, and 46, XX in Patient B 
(Figure1). In Patients B, D and E, efficient spreading of follicular cells allowed us to 
determine the number of X chromosomes in at least 22 granulosa cells from individual 
small follicles (Figure 6). The ratio of the 45, X and 46, XX granulosa cells varied 
considerably between follicles from the same ovary. In Patient B, a follicle was observed 
with exclusively 46, XX granulosa cells, while six other follicles of this patient showed a 
percentage of 45, X granulosa cells varying from 13% to 59%. The granulosa cells of 10 
individual follicles of Patients D and 5 individual follicles of Patient E were all 45, X 
(Figure 1 and 6). Although a large number (45–72%) of the stromal cells of Patients 
C–E was 46, XX, we did not observe any cells with a 46, XX karyotype amongst the 
granulosa cells of these patients, strongly suggesting that stromal cells do not co-purify 
with the follicles. The co-purification of theca cells is also very unlikely since small 
follicles do not yet contain this cell type [29].
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Figure 4. After treatment of isolated follicles with trypsin the follicular cells become more 
available for FISH. Cells of individual small follicles isolated from a suspension of ovarian cortex 
remain clumped during preparation for FISH, obscuring signals of individual granulosa cells and 
the oocyte (panels A and B). Treatment with trypsin of isolated follicles prior to FISH resulted in 
less cell clumping and allowed karyotyping of granulosa cells and oocyte of the same follicle 
(panels C and D). Note that the DAPI counterstain in the trypsin treated follicles reveals that the 
DNA of the oocyte is much more diffuse and can be easily distinguished from DNA of the 
granulosa cells. FISH signals for the X chromosome (green) and chromosome 18 (red) of the 
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Figure 5. Histological sections of ovarian cortex from patients with TS. Haematoxylin–eosin 
stained 4-µm sections were prepared from cortical tissue from ovaries of mosaic (panels A and 
B) and 45, X monosomy TS patients (panel C). In addition to the variable number of small follicles 
in the tissue of the mosaic patients (panel A), a low number (<2%) of secondary follicles were 
observed (panel B). The ovarian tissue of the monosomic 45, X patients contained no follicles 
and showed a fibrous texture with relatively low number of cells (panel C). Bars represent 100 µm.
Figure 6. FISH analysis of granulosa cells from individual follicles. The ratio between 46, XX and 
45, X granulosa cells from the same small follicle varied considerably. FISH analysis of six individual 
small follicles from Patient B revealed that the percentage of 45, X granulosa cells varied from 0% 
to 59% (top row; four follicles are shown). In Patients D (337 granulosa cells from 10 follicles) and 
E (152 granulosa cells from 5 follicles) all granulosa cells were 45, X. For Patients B and D at least 











Karyotyping the oocytes from small ovarian follicles
The FISH signals for the X chromosome and the control chromosome 18 were 
considerably more intense in the nuclei of oocytes than in the granulosa cells. Oocytes 
in primordial/primary follicles are arrested in the prophase of meiosis I and contain four 
copies of each chromosome held closely together by a synaptonemal complex [30]. 
This close proximity results in just a single but strong hybridization signal for the four 
clustered copies of each chromosome (Figure 4 A, B and D). In contrast to somatic 
cells it is therefore not possible to simply count the hybridization spots to determine 
Figure 7. The surface of FISH signals can be used to karyotype oocytes from small follicles. To 
assess whether the surface of FISH signals can be used to determine the X chromosomal content 
of oocytes in the prophase of meiosis I, we measured the surface of split signals for the X 
chromosome (panel A), for chromosome 18 (panel B) or for both chromosomes (panel C) and 
compared these to the signal surface of the other chromosome. The surface ratio is shown in 
panel D and indicates that the surface of a split FISH signal is approximately 0.5 compared to the 
non-split signal of the other chromosome in the same oocyte. A 50% reduction in the number 
of X chromosomal sister chromatids will therefore lead to a reduction in the surface ratio 
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the number of X chromosomes of a particular oocyte. Should an oocyte lack half of its 
X chromosomes it is likely that the corresponding FISH signal becomes less intense. To 
validate this assumption, we analysed the FISH results from a number of oocyte nuclei 
in which the hybridization signal for either the X chromosome or chromosome 18, or 
both, was split into two discrete spots (Figure 7A–C). By determining the surface of 
the hybridization spots as a measure for intensity, we found that the ratio of FISH 
signals between a single spot of a split signal and the control (non- split) signal in the 
same oocyte was approximately 0.6 (mean, 0.6; range 0.4–0.9; Figure 7D). Next we 
analysed the ratio of FISH signals for the X chromosome and chromosome 18 in the 
oocytes of small follicles from TS patients and two non-Turner 46, XX control patients 
(Figure 8). The mean of the ratio of the X chromosome/chromosome 18 FISH signals 
of individual oocytes was between 1.0 and 1.1, which was similar to the oocytes of the 
Figure 8. Most oocytes of small follicles from mosaic TS patients are 46, XX. 
The ratio between FISH signals from the X chromosome and chromosome 18 was measured for 
46 oocytes from 5 mosaic TS patients (pt) and 13 oocytes from 2 controls (ctrl). The ratio in the 
controls varied between 0.9 and 1.5. In TS Patients B, C and E, a similar distribution was seen, 
indicating that these oocytes had a normal X chromosomal content. In Patients A and D, the 
majority of the oocytes displayed a normal ratio, while in three oocytes from Patient A and one 
oocyte from Patient D, the ratio varied between 0.4 and 0.6, which is indicative of a reduction in 




























control patients. This indicates that most oocytes from the patients with a mosaic 
pattern had the normal number of four X chromosomal sister DNA strands. However, 
in Patients A and D the FISH signal ratio was found to be approximately 0.5 in 3 out of 
19 oocytes and 1 out of 9 oocytes, respectively. This implies that in these oocytes 
probably only half of the normal X chromosomal DNA content was present.
Discussion
Fertility preservation by cryopreservation of ovarian cortex tissue is being performed 
on an experimental basis in young women with TS in several countries [13, 17-20]. 
However, very little is known about the genetics of ovarian cells in this group of patients, 
and this may well determine the final outcome of this fertility preservation procedure. 
In this study, we have therefore developed methods to analyse the X chromosomal 
content of both oocytes and granulosa cells from small (primordial and primary) 
follicles, and stromal cells from ovaries of young TS patients. Determining the number 
of chromosomes in diploid somatic cells is relatively straightforward. FISH with a cen-
tromere-specific probe will give two signals in each cell representing a pair of 
homologous chromosomes. However, analysis of oocytes from small follicles is more 
challenging as these oocytes are arrested in the prophase of meiosis I, and therefore 
tetraploid. At this stage of meiosis, each pair of homologous maternal and paternal 
chromosomes is held together by a synaptonemal complex [30]. The very close 
proximity of the homologous chromosomes in these complexes prevents the 
identification of individual chromosomes by FISH analysis. This unique organization of 
genetic material in the oocytes, as present in small follicles, explains why we observed 
only a single strong signal after hybridization with chromosome-specific probes, which 
was more intense compared to the signals in the nuclei of granulosa cells or stromal 
cells. Determining the karyotype of these oocytes is therefore not possible by simply 
counting the number of signals for each chromosome. Instead, the intensity of the FISH 
signal should be used for analysis, assuming that a reduction in number of a certain 
chromosome in the tetraploid oocyte will lead to a less intense FISH signal. To evaluate 
whether the number of sister DNA strands of a certain chromosome is indeed 
reflected by the intensity of the FISH signals in oocytes, we analysed images of oocytes 
of both TS patients and controls, in which the FISH signal for the X chromosome, 
chromosome 18 or both chromosomes was separated into two discrete spots. In these 
oocytes, the synaptonemal complex holding the four chromatids together was probably 
disrupted, resulting in not one (as in most oocytes) but two signals, each containing half 
of the genetic material. By using the surface area of the FISH spots as a measure for 
spot intensity, we found that intensity for each of these spots was indeed reduced by 
50% and concluded that the surface area of FISH signals can be used to determine the 
563903-L-bw-Schleedoorn
Processed on: 26-7-2021 PDF page: 127
127Genetic aspect
6
number of X chromosomal sister DNA strands in oocytes. There are several other 
techniques described for quantitative analysis of fluorescent intensity in microscopy 
images, such as epifluorescence imaging of FITC signals relative to their associated 
DAPI-stained signals [31], or by determining the ratio between two different FISH 
signals in the same cell [32]. However, most of the techniques suffer from lack of 
precision in the results and complexity of existing software and are therefore not 
straightforward for a researcher to use [33]. Furthermore, these techniques are 
optimized for cells during interphase or metaphase and have never been used to 
analyse the FISH signals of the tightly clustered chromosomes of a tetraploid human 
oocyte.
Karyotyping oocytes of TS patients from follicles at more advanced stages of maturation 
has been presented in a case report [19]. However, the oocytes analysed in that study 
already had demonstrated their capacity for development and might be part of a subset 
of gametes capable of progressing through meiosis and may therefore not be 
representative for the resting pool of small follicles in the ovary. The results of our 
oocyte FISH analysis seem reassuring; of the 46 oocytes from small follicles isolated 
from TS patients, 42 oocytes appeared to have a normal number of X chromosomes. 
Four oocytes with an 50% reduction of the FISH signal for the X chromosome were 
observed in two patients, suggesting that these oocytes were 45, X. In 45, X oocytes 
the X chromosome lacks a homologue and can therefore not achieve homologous 
synapsis during diplonema of prophase I. The finding of 45,X oocytes in humans is 
remarkable since this asynapsis is known to lead to oocyte elimination through meiotic 
silencing of unsynapsed chromatin [30]. Our findings may be explained by a process 
observed in mice, in which the 45,X oocytes evade elimination by non-homologous 
self-synapsis of the X chromosome [34]. The complete absence of follicles in ovarian 
tissue of the 45, X patients in our study argues against rescue of 45, X oocytes through 
self-synapsis. However, in contrast to the mosaic TS patients, the ovaries of the 45, X 
patients had a fibrous streak-morphology with a large amount of extracellular matrix 
that may not allow 45, X oocytes to develop or persist. Low numbers of follicles have 
been reported in ovaries of TS patients with 45,X monosomy, but karyotyping of the 
oocytes was not performed and cryptic mosaicism in these patients cannot be fully 
excluded [13]. Although most oocytes from TS patients we analysed had a normal X 
chromosomal content, this is not a guarantee that these follicles are truly functional. 
The human primordial/primary follicle is a multicellular structure in which the oocyte is 
surrounded by a single layer of granulosa cells. The oocyte depends on this layer of 
granulosa cells for its long-term arrest in meiosis I. During follicular growth there is 
extensive bidirectional signalling between the oocyte and its surrounding granulosa 
cells to ensure normal follicular development [24]. Our observation that all granulosa 
cells were 45, X in three of the five mosaic TS patients may have functional consequences 
for follicular development. In addition to follicles containing only 45, X granulosa cells, 
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we observed heterogeneity in the ratio of 45, X / 46, XX granulosa cells between 
different follicles from the same patient. This low-level or absence of mosaicism in 
granulosa cells that populate the small follicles suggests that these cells originate from a 
relatively small number of ovarian surface epithelium derived progenitor cells [35]. 
During follicle maturation the single layer of granulosa cells surrounding the oocyte in 
small follicles undergoes at least 10 mitotic divisions to produce the more than 2000 
cells of the mature antral follicle [36]. As 45, X cells show an increase in apoptosis and 
have a prolonged cell cycle, the timing of expansion of the granulosa cell layer during 
maturation may be distorted [37-39]. The apparent histologically normal follicles 
populated with a high percentage of, or exclusively, 45, X granulosa cells could therefore 
be functionally impaired. Although the functional consequences of our observations 
require additional research, it could be possible that the mere presence of small follicles 
in the ovarian cortex tissue of TS patients does not guarantee normal ovarian function. 
No obvious correlation was found between the number of follicles in the ovary and the 
patient’s karyotype of either the somatic cells or the oocytes. However, estimating the 
follicular density in a single piece of cortex should be interpreted with care in view of 
their uneven distribution throughout the cortex [40, 41]. In addition to the karyotype 
of the oocyte and the granulosa cells, the karyotype of the stromal cellular compartment 
may be of importance for the formation and persistence of a functional ovary as well. 
Stromal cells not only support the growing follicle physically and metabolically, but also 
provide the theca cells during follicular development [42, 43]. In the fibrous streak 
ovaries of the 45, X patients we found no evidence of mosaicism, which may well have 
contributed to their abnormal morphology. However, a certain degree of aneuploidy in 
the ovarian stromal cells does not seem to drastically influence the morphology of the 
ovary. Macroscopically, ovarian morphology was normal in the 45, X / 46, XX mosaic 
patients with 45–97% 46, XX stromal cells. Remarkably, normal ovarian macroscopic 
morphology was also found in a patient presenting a mosaic with only 10% 46, XX 
stromal cells. These findings are in line with previous published results. Ovarian stromal 
cells from a 45, X / 46, XX patient, from which normal 46, XX oocytes were retrieved 
after FSH stimulation, also showed 60% of 45, X cells [19]. This indicates that follicular 
development is possible even as the majority of the ovarian stromal cells are aneuploid.
In this study, the analysis of extra-ovarian cells (lymphocytes, cells from buccal smears 
and urine) in TS patients with mosaicism does not seem to have any predictive value 
for the X chromosomal content of the ovarian cells (oocytes, granulosa and stromal 
cells). This substantiates the difference in levels of mosaicism, not only between patients 
but also between tissues, follicles and cells of the same type of a particular patient. 
Although the number of patients we investigated is relatively low, it is likely that the 
analysis of additional patients will only further support the notion that no two TS 
patients are the same with regard to the variation in mosaicism. In none of the 
extra-ovarian tissues of the 45, X patients did we find evidence of mosaicism. This 
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suggests that analysis of not only lymphocytes but also buccal and urine cells, all 
revealing a 45, X pattern, might be indicative of presence of a non-functional ovary. 
Over the years the presence of oocytes and even pregnancies in apparently 45, X 
women have been reported [44, 45]. However, the karyotyping methods in these cases 
were not clearly defined, and one can assume that these apparently 45, X women were 
in fact individuals with cryptic mosaicism [46, 47].
In this paper, we have confined our study to patients with numerical abnormalities of 
the X chromosome. Structural abnormalities (e.g. isochromosome X, ring chromosome 
X, X-deletions or translocations) are also frequently found in TS. Karyotyping cells of 
TS patients with structural abnormality of the second X chromosome is not possible 
with the probes we used, as these are directed at repetitive pericentromeric sequences 
and will not reveal chromosomal aberrations that leave these sequences intact. 
Structural aberrations of the X chromosome can be detected with probes against 
single copy sequences in somatic cells. However, due to the unique organization of the 
genetic material in meiosis I arrested oocytes, karyotyping with single copy probes is 
likely to be more difficult due to their less intense hybridization signal compared to the 
centromere-specific probes. In conclusion, we believe this to be the first report that 
presents a detailed analysis of the X chromosomal content of oocytes, granulosa cells 
and ovarian stromal cells from ovaries of young patients with TS. We show that the 
majority of oocytes from small follicles of mosaic TS patients are normal, but all or part 
of the granulosa cells of individual follicles may be aneuploid. Follicles derived from the 
same ovary can differ regarding the level of mosaicism of their granulosa cells. High-level 
mosaicism was found in ovarian stromal cells without deviant macroscopic morphology 
of the ovary. The level of mosaicism observed in lymphocytes, buccal cells or 
urine-derived cells did not correlate with that of ovarian cells. These new findings 
suggest that despite the presence of morphologically normal ovaries and follicles in 
mosaic TS patients, the aberrant karyotype of their granulosa cells and ovarian stromal 
compartment may limit their capacity to support fertility. As a consequence, caution 
should be taken when counselling TS patients and their parents about fertility 
preservation options, to avoid unrealistic expectations regarding the success rate of this 
treatment. Clearly more research is required to reveal the functional consequences of 
high-level monosomy in ovarian tissue cells. With these data, a better-informed decision 
can be made on whether OTC should be offered to girls and women with TS, and 
whether the procedure is able to restore fertility.
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Expect the Unexpected: Hidden Ovarian Mosaicism and 
Macroscopically Perioperative Left-Right Differences of the Ovaries 












One of the most reported positive prognostic factors for fertility in females with Turner 
syndrome is 46, XX mosaicism. However, routine genetic testing of lymphocytes, 
buccal cells or urine cells does not rule out the presence of a cryptic 46, XX cell line in 
the ovarian tissue, as the sex chromosome content may vary between different tissues 
from the same patient.
In this case report we show a hidden 46, XX cell line in the ovary and a perioperative 
left-right difference in ovarian morphology in a 13-year-old female who recently 
underwent laparoscopic surgery for ovarian tissue cryopreservation. She had been 
diagnosed with 45, X monosomy, or classical Turner syndrome at the age of 8 years old 
but presented with spontaneous pubertal development. Ovarian tissue could be 
cryopreserved successfully, but few follicles were found. One year after the unilateral 
ovariectomy, she continued to have regular periods of vaginal bleeding with normogo-
nadotropic laboratory findings, except for unmeasurable AMH and inhibin-B 
concentrations.
These unusual findings might be of interest for clinicians involved in fertility preservation 
counselling for patients with Turner syndrome.
Keywords
Turner syndrome, fertility preservation, ovarian tissue cryopreservation, ovarian genetics, 
ovarian morphology
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One of the major concerns for young females with Turner syndrome (TS) is the 
increased risk of infertility [1, 2]. Advanced technology and international consensus now 
allows physicians to discuss fertility preservation (FP) options in this group of patients 
[3]. However, the most difficult aspect of the counselling is the variability and unpre-
dictability in the current presentation and future progress of TS for each individual 
female [4]. 
TS is caused by the partial or complete absence of one of the sex chromosomes in 
some cell lines (i.e. mosaicism) or all cells. A reduction of the X chromosomal content 
may affect the cell metabolism and hence tissue functionality. Consequently, the 
presentation of TS includes a variety of phenotypic features [5]. 
In the ovarian tissue, TS leads to premature ovarian insufficiency with minimal chances 
of spontaneous conception [6]. In addition, the likelihood of healthy offspring is 
decreased as compared to the general population, because of the increased risk for 
miscarriage, and a slightly higher chance of giving birth to a child with a congenital 
malformation [6, 7]. 
It is assumed that patient’s fertility, but also the efficacy of FP in females with TS is 
mostly depending on the percentage of ovarian cells with a 46, XX karyotype [8, 9]. 
Preferably, the karyotype of the ovarian cells should be taken into account when 
patients are counselled for FP, but in routine care the genetic testing is mostly limited 
to peripheral blood lymphocytes. In some cases, the karyotype analysis is extended by 
the analysis of buccal cells or urine cells. However, a recent study showed that the 
karyotype of extra-ovarian cells (e.g. lymphocytes, buccal cells or urine cells) in patients 
with TS is not representative for the karyotype of their ovarian cells [8]. This indicates 
that the percentage of normal 46, XX cells not only varies between patients, but also 
between different types of tissues from the same patient, between different cell types 
within the same tissue and even between cells of the same cell type [8, 10].
Case report
We report the case of a 13-year-old female with TS, who recently underwent 
laparoscopic surgery for ovarian tissue cryopreservation in our centre. She had been 
diagnosed with TS by the age of 8 years upon a diagnostic work-up for growth 
retardation. Chromosome analysis on peripheral blood lymphocytes revealed a 45, X 
monosomy, or classical TS karyotype. No other TS-associated problems were detected 
and growth hormone therapy was started. To exclude Y-chromosome-specific sequences, 
a FISH analysis was performed on buccal cells following the standard protocols [11]. 
Surprisingly, a 47, XXX [78] / 45, X [33] / 46, XX [7] karyotype was reported for these cells. 
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The first signs of spontaneous puberty, i.e. breast gland development (thelarche), were 
seen by the age of 10 years. Two years later she reported monthly periods of vaginal 
bleeding (5-7 days). Endocrinological investigation showed normal-slightly increased 
Follicle Stimulating Hormone (FSH) levels (6.1-9.5 E/l; ref 1.7–21.5 E/l), normal 
Oestradiol (E2) levels (74-100 pmol/l; ref 45–1461 pmol/l), normal Luteinizing Hormone 
(LH) levels (1.2-2.0 E/l; ref 1.0–95.6 E/l), and a low Anti-Müllerian hormone (AMH) 
level (0.2 ug/l; ref 0.56–8.4 µg/l).
By the age of 13 years, she was referred to the gynaecologist of our centre to discuss 
FP options together with her parents. At that moment, she was having irregular vaginal 
bleedings since a few months. As a regular part of counselling, serum hormone 
concentrations were determined, revealing an AMH level <0.1 ug/l (ref 0.56–8.4 µg/l), 
and an FSH level of 8.1 E/l (ref 1.7–21.5 E/l). LH & oestradiol were not determined. The 
uterus and left ovary could be visualized with transabdominal sonography. The uterus 
appeared to be anteverted, with a normal size for the patient’s age and an endometrial 
thickness of 11 mm. The antral follicle count (AFC) in the left ovary was 4, and no cysts 
or free fluid was reported. After comprehensive counselling, the girl and her parents 
decided for ovarian tissue cryopreservation in an experimental setting (Trial registration 
number NCT03381300) with the aim to preserve her fertility. Although transabdominal 
sonography is not conclusive for the presence of ovaries, we discussed the plausible 
scenarios of an absent or streak ovary. Informed consent was obtained to remove the 
‘normal-looking’ ovary in the case that an ovarian left-right difference or single ovary 
would become apparent during the laparoscopic intervention.
During laparoscopy, four months later, a normal sized uterus was seen and a difference 
in ovarian volume was confirmed with a macroscopically ‘normal-looking’ left ovary and 
a streak right ovary (Figure 1). The left ovary could be removed for FP purposes 
without any complications. The resected ovary measured 30*20*15 mm (Figure 2-A). 
Serum hormone concentrations were measured before the ovariectomy was 
performed and showed an elevated FSH serum concentration of 23 E/l (ref 1.7–21.5 
E/l), normal LH level of 7.3 E/l (ref 1.0–95.6 E/l.), low AMH level 0.1 ug/l (ref 0.56–8.4 
µg/l), and an E2 level and inhibin-B level under the laboratory detection level (i.e. < 18 
pmol/l and <10 ng/l).
Directly after the unilateral ovariectomy, the ovary was collected in cold L15 medium 
(Lonza, Switzerland) and transferred to the laboratory where it was placed on a 
pre-cooled surface at 4°C. The medulla was removed from the cortex after which 
cortex fragments of approximately 8*8*1 mm were prepared. Fragments were 
cryopreserved according to the local protocol [12]. Ten ovarian cortex fragments of 
approximately 8*8*1mm could successfully be cryopreserved for FP purposes. 
According to the protocol, one representative fragment was kept aside, divided into 
two and cryopreserved for research purposes. After thawing, one part was used for 
histological analysis, and the other part for performing FISH analysis on ovarian cells as 
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Fig. 1. Laparoscopic images of the genitalia interna. (A) Normal left ovary (arrow) and uterus 
(arrow head) (B) streak right ovary (arrow).
Fig. 2. Macroscopic, histologic and FISH analysis of ovarian tissue. (A) Macroscopically normal 
left ovary directly after unilateral ovariectomy. Length 3.0 cm Width 2.0 cm Height 1.5 cm. (B) 
Haematoxylin-eosin stained section of cortex tissue with empty follicles (arrows) and follicles 
with missing granulosa cells (arrow heads). The inset shows a multilaminar follicle with no 
recognizable oocyte. FISH analysis of cortex stromal cells (C) and of cells from a single follicle (D) 
with X-chromosome (green) and chromosome 18 (red) specific probes. Arrows point to 45, X 
cells, white arrow heads to 47, XX cells and yellow arrow heads to 46, XX cells. The FISH signals 

















described previously [8]. Although histological analysis revealed a normal ovarian 
morphology, no follicles were found in this fragment. The results were discussed with 
the patient and her parents during the check-up 2 months later, and they agreed to 
thawing 1-2 additional fragments for additional research.
In the first fragment, again, no follicles were found. The second fragment showed a 
decreased number of follicles with a follicular density of 7.0 follicles/mg tissue. 
Remarkably, several empty primordial follicles were seen, and even a multilaminar 
follicle without a recognizable oocyte. Furthermore, the tissue contained multiple 
primordial follicles with an incomplete layer of granulosa cells (Figure 2-B). 
The second research fragment was enzymatically digested to yield a cell suspension 
consisting of stromal cells and primordial follicles. Stromal cells and individual primordial 
follicles were picked up manually and prepared for FISH analysis on separate slides. 
FISH analysis was performed with centromere probes specific for the X-chromosome, 
and a probe for chromosome 18 served as a control. The X-chromosome content of 
80 stromal cells (Figure 2-C), 6 oocytes and 262 granulosa cells from 8 individual 
primordial follicles (Figure 2-D) could successfully be determined with FISH analysis. 
Karyotyping of the stromal cells (n=80) showed a mosaic pattern with 3 cell lines 45, X 
[68] / 47, XXX [18] / 46, XX [14], and a full-blown 45, X karyotype was seen in the 
granulosa cells (n=262) (Figure 3). Remarkably, all 6 oocytes that were analysed 
showed a normal (tetraploid 92, XXXX) karyotype (Figure 3).
In order to check if the X chromosome content of other cell types than lymphocytes 
or buccal cells was more representative for the karyotype of the ovarian cells, we also 
performed a FISH analysis on 100 urine cells according to the local protocol [8]. 
However, all cells that were investigated (n=100) showed a 45, X karyotype (Figure 3), 
and were thus, representative for the karyotype of the granulosa cells, but not for the 
oocytes and stromal cells in this patient. 
The first year after surgery, the patient continued to have monthly vaginal bleeding 
periods of approximately 7 days. She had normal gonadotropic hormone levels (FSH 
8.8 E/l; ref 1.7–21.5 E/ and, LH 2.3 E/l; ref 1.0–95.6 E/l) although E2 was relatively low 
(89 pmol/l, ref 45–1461 pmol/l.). AMH and Inhibin B levels remained unmeasurable. No 
other specific details were reported. Two years after surgery, the patient reported 
irregular blood loss (periods of six-day-long vaginal bleeding, every two months). 
Transabdominal sonography showed a normal uterine size for the patient’s age and an 
endometrial thickness of 4 mm. The right ovary could not be visualized. Physical 
examination now showed complete breast development. Unfortunately, the serum 
hormone concentrations revealed hypergonadotropic hypogonadism with elevated 
FSH (84 E/l, ref 1.7–21.5 E/l) and LH (40 E/l, ref 1.0–95.6 E/l) levels, and an unmeasurable 
E2 concentration (<18 pmol/l). Therefore, oestrogen replacement therapy was started.
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In this case report, we describe a second case [13] of a girl who had been diagnosed 
with classical monosomy TS (45, X), but presented with a hidden X mosaicism in her 
ovarian cells and a perioperative left-right difference in ovarian morphology during 
laparoscopic surgery. However, this is the first case reporting on the presence of both 
a streak ovary and normal ovary in a young female with TS. These unusual findings 
might be of interest for clinicians involved in FP counselling and TS care. Especially, since 
the efficacy of FP in this group of patients remains to be confirmed. 
Our patient had been diagnosed with 45, X monosomy but presented with spontaneous 
monthly periods of vaginal bleeding by the age of 12. Ovarian tissue could be 
cryopreserved successfully, but a decreased follicular density was found as compared 
with the ovarian tissue of same-aged non-TS females undergoing FP [14]. One year 
after the unilateral ovariectomy, she continued to have regular periods of vaginal 
bleeding with normogonadotropic laboratory findings except for unmeasurable AMH 
and inhibin-B levels. 
Figure 3. Mosaicism in extra-ovarian tissues and ovarian stromal cells, granulosa cells and 
oocytes. Lymphocytes (n=30), cells from buccal smears (n=100) and urine (n=100) were analysed 
by FISH with an X chromosomal peri-centromeric probe. The percentage of cells with a 
particular karyotype is indicated. In addition, the X-chromosomal content of ovarian cortex 
components including stromal cells (n=80), granulosa cells (n=262 from 8 individual unilaminar 
follicles) and oocytes (n=6) is shown. Three different karyotypes (45, X / 46, XX / 47, XXX) 













The karyotype of the non-ovarian cells (i.e. buccal cells, peripheral lymphocytes and 
urine cells) was somewhat representative for the stromal cells and granulosa cells but 
not for the karyotype of the oocytes that were found. Interestingly, all primordial 
follicles that were investigated, contained normal tetraploid 92, XXXX oocytes but 
were exclusively surrounded by diploid 45, X granulosa cells. Recently, similar findings in 
other females with TS have been reported [8, 13]. This might have functional consequences 
for the follicular development as the oocyte depends on the layer of granulosa cells for 
meiotic arrest but also for later stages of folliculogenesis [15].  However, in this patient, 
cryptic mosaicism in the oocytes and granulosa cells cannot be fully excluded because 
of the small number of primordial follicles (n=8) that was investigated. 
The different macroscopic aspect of the ovaries may indicate a difference in X 
chromosome content between both ovaries. Although left–right differences in ovarian 
volume and antral follicle count have been reported before in healthy females of 
reproductive age and females with subfertility [13, 16, 17], there are no reports 
describing the presence of both a streak ovary and normal ovary in a young female with 
TS. We believe it is important to include the possibility of this rare finding during 
laparoscopic surgery, and how to deal with it, in the counselling for FP, even if we do 
not know yet what the clinical consequences are. 
In this patient, the left-right difference in ovarian volume and aspect was already seen 
during transabdominal ultrasound (TUS). However, distinguishing precisely between 
anatomically normal ovaries and streak ovaries is not easy, and there might even be a 
chance that the ovaries cannot be visualized at all [18]. A Danish study showed that 
ovaries could be detected in 37% of young females with TS by TUS and in 55% by MRI 
(P = 0·1) [19], but they did not confirm their findings with laparoscopic surgery, which 
is considered to be the gold standard. 
In routine care, karyotyping of lymphocytes is the standard technique used to determine 
TS. In most centres, the diagnosis is based on 20-30 lymphocytes only, although it has 
been recommended to determine the karyotype of at least 50 metaphases to exclude 
<10% of mosaicism (CI 0.99) [20]. Interestingly, a recent cohort study in 142 adult 
patients with TS, revealed that the percentage of 45, X cells in lymphocytes and buccal 
cells was identical in less than one third of cases [21]. Therefore, these authors 
recommend adding buccal cell FISH analysis for a better global chromosomal evaluation, 
and, thus better care and follow-up. 
Missing X chromosomal content in ovarian cells is likely to result in germ cell apoptosis 
and impaired folliculogenesis during foetal life [22, 23]. Therefore, one could assume 
that the described cases where follicles were found or pregnancies have occurred in 
females with 45,X monosomy are actually examples of undetected germ cell mosaicism 
[24, 25]. Unfortunately, key papers that are describing the presence or absence of 
follicles in females with TS [9, 26-29] generally do not report the methods used for 
karyotyping or the number of cells that were analysed.
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Some clinicians are suggesting to make FP available for females with a mosaic karyotype 
only. For now, we believe it is too preliminary to close the doors for FP already for 
some subgroups with TS, purely based on the karyotype of 20-30 lymphocytes. We 
recommend other researchers within the field of TS and fertility to include a proper 
genetic analysis of different cell types and an imaging method, either US or MRI, to their 
research protocol, so that the predictive value of these diagnostic markers can be 
further explored and more knowledge regarding TS and fertility can be obtained. 
Ethical approval 
The study protocol for performing ovarian tissue cryopreservation and additional 
genetic testing in young females with TS has been approved by the Central Committee 
on Research Involving Human Subjects in November 2017 (CCMO NL57738.000.16). 
Written informed consent was obtained from the patient and her parents.
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In this thesis, the various challenges of ovarian tissue cryopreservation (OTC) in young 
females with Turner syndrome (TS) were explored. This thesis served as the 
groundwork for a long-term international cohort study (TurnerFertility trial, CCMO 
NL57738.000.16, ClinicalTrial ID NCT03381300) that started including the first 
patients in January 2018. 
In this chapter the main findings are summarized, and discussed in a multidimensional 
approach, including the clinical implications and suggestions for future research. 
Furthermore, the importance of patient-involvement in medical research is pointed out 
and our research is positioned on Arnstein‘s [1] ‘ladder of engagement’ (Figure I).
Main findings and interpretation
I. What is currently known about the presence of follicles in the ovaries of young females 
with TS? (Chapter 2: In the literature)
For many years, it was thought that girls with TS were born infertile due to non-functional 
ovaries. However, scientists questioned this theory as increasing numbers of 
spontaneous pregnancies in females with TS were described. In 2002, a Swedish study 
group reported the presence of primordial follicles in the ovaries of 8 young females 
Figure 1. Arnstein’s ‘ladder of engagement’
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with TS [2]. However, the number of follicles found was significantly lower as compared 
to the follicular density in unaffected girls undergoing laparoscopic ovarian biopsy. This 
new insight, combined with earlier research on TS foetuses [3-5], led to the hypothesis 
that a complete or partial loss of one sex chromosome in females causes an accelerated 
degeneration of germ cells, starting at the 13th week of foetal age. Due to this rapid 
loss, most females with TS reach menopause during childhood or adolescence. The 
timeline at which this occurs differs in every individual with TS [4]. 
II. What is current state of art regarding (experimental) fertility preservation (FP) outcomes 
in females with TS? (Chapter 2: In the literature)
Cryopreservation of mature oocytes (OC) and ovarian cortex tissue (OTC) has been 
performed experimentally in > 150 girls and adolescents with TS [4, 19, 27-37] 
[Clinicaltrial.org]. Thus far, there are no published records of girls with TS who have 
returned for autotransplantation or devitrification of oocytes and fertilization with 
embryo transfer. Hence, the efficacy of FP in females with TS is to date still unknown.
Since 2002, OTC has been performed experimentally in at least 83 young females with 
TS aged 6 – 19 years old [2, 6-9]. Ovarian tissue could be obtained in approximately 
85% of the patients and no complications related to the surgical procedure have been 
reported. Primordial follicles were seen in the ovarian tissue of 43% of the cases. 
Positive predictive markers for the presence of follicles were mosaic TS, a spontaneous 
menarche, a spontaneous thelarche, a normal FSH level, and a normal AMH level. 
Over the last ten years, eighteen cases of OC in females with TS have been reported 
[6, 8, 10-15]. The age of patients during the oocyte retrieval ranged from 13 to 28 years. 
On average, 11 oocytes (range 2 – 19) were retrieved per cycle, of which approximately 
76% could be cryopreserved (range 69 – 100%). Remarkably, one patient developed a 
severe ovarian hyper stimulation syndrome with ascites. She fully recovered after 
abdominal paracentesis. The other females tolerated the procedure well, and no other 
complications were reported.
III. Canwe optimize the efficacy ofOTC by using a non-invasive imaging technique to
determine the density of follicles in human ovarian cortex fragments that are intended 
for fertility restoration? (Chapter 3: Laboratory aspect)
In a proof of concept study, we investigated whether reflectance confocal microscopy 
(RCM) could be used as a non-invasive imaging technique to determine the vertical and 
horizontal distribution, and the number of follicles in human ovarian cortical tissue 
fragments intended for FP purposes. Our results show that RCM is a promising 
technique to determine the density of follicles ex vivo in living ovarian cortex fragments, 
apparently without compromising the vitality of the tissue. Safety studies and further 
optimization of the RCM technique with a focus on increasing the penetration depth 
are required before clinical use of RCM. After improvement, RCM could be applied to 
563903-L-bw-Schleedoorn
Processed on: 26-7-2021 PDF page: 149
149General discussion 
8
evaluate the follicular density in ovarian tissue fragments of patients who are undergoing 
OTC. Ideally, ovarian tissue fragments with the highest number of primordial follicles 
could be selected for autotransplantation first. This is of clinical importance in all 
patients undergoing OTC, but especially in patients with a diminished ovarian reserve 
such as TS patients, because the effectiveness of OTC critically depends on the number 
of primordial follicles in the autograft.
IV. Which ethical aspects should be considered regarding OTC in young females with TS? 
(Chapter 4: Ethical aspect)
For some clinicians, performing OTC in females with TS remains a controversial topic. 
Therefore, we conducted an ethical Delphi study with international professionals and 
patient representatives to systematically discuss the advantages and disadvantages of 
OTC in females with TS. The aim of this study was to identify the most important 
ethical issues, formulate statements and reach group consensus.
In this international ethical Delphi study, patient representatives mainly highlighted 
arguments focusing on the psychological harm of infertility, whereas medical ethicists 
were more concerned about creating false hope resulting in psychological harm in the 
future. Gynaecologists and (paediatric-) endocrinologists underlined statements regarding 
non-maleficence (’do no harm’).
After three rounds, the expert panel reached a consensus on eight key statements 
based on the most important ethical issues. The first two statements highlighted that 
infertility leads to psychological harm, and that patients with TS consider this their main 
concern (key statements 1 and 2). In addition, patients with TS should have equal 
access to FP options, in line with other patient groups (e.g. patients awaiting cancer 
treatments) (key statement 7). However, one should be aware of the increased risk of 
maternal morbidity and mortality associated with TS during a future pregnancy (key 
statements 5 and 6). Patients with TS should be counselled about the alternative 
options for future parenthood (i.e. adoption, fostering, and oocyte donation) (key 
statement 3). Furthermore, the option of voluntary childlessness should be discussed. 
All patients with TS interested in OTC should undergo psychosocial and cardiac 
screening and should be discussed by a multidisciplinary expert team (key statement 8). 
Great caution and restrictive (i.e. more negative, or even discouraging) counselling are 
recommended if laparoscopic surgery or pregnancy is contraindicated (i.e. in patients 
with severe cardiac comorbidity). Lastly, patients with TS should always be included in 
the consent process, regardless of their age (key statement 4).
V. What is the standpoint of an international expert panel regarding OTC in young females 
with TS? (Chapter 4: Ethical aspect)
Based on the set of 8 key statements that were mentioned above, our expert panel 
agreed that OTC in patients with TS should be offered, but only in a safe and controlled 
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research setting. This approval marks the first step in global acceptance of performing 
OTC in females with TS. 
VI. Which research should be performed to better inform TS patients about the feasibility 
andefficacyofOTC?(Chapter 5: Clinical aspect)
We believe it is unethical but also logistically impossible to perform laparoscopic 
surgery followed by experimental OTC in minors in a randomized controlled trial 
research setting including randomization, blinding or treatment allocation. We suggest 
to perform a pilot study instead, i.e. an observational intervention study with long-term 
follow-up in a tertiary fertility clinic in the Netherlands including 100 females aged 2 
through 18 years with classical Turner (i.e. 45, X monosomy) or Turner variants (i.e. 45, 
X mosaicism or structural anomalies, except Y-chromosomal material). The aim of this 
study is to investigate the occurrence of live birth in women with TS after OTC in 
childhood followed by auto transplantation in adulthood and to find reliable prognostic 
markers for estimating the ovarian reserve in girls with TS in the future. 
Therefore, one fragment per patient is used to determine follicular density by 
conventional histology, and to perform FISH analysis of ovarian cells. Routine 
chromosome analysis is performed on both lymphocytes and buccal cells. A blood 
sample will be taken for hormonal analysis and all subjects will undergo a transabdominal 
ultrasound to determine the uterine and ovarian size. Patient characteristics, pregnancy 
rates, and pregnancy outcomes will be collected from the patient’s medical record. 
VII. Is it possible to determine the X chromosomal content of various ovarian cells in young 
patients with TS? (Chapter 6: Genetic aspect)
In an experimental laboratory study, we developed a method to analyse the X 
chromosomal content of oocytes and two supporting cell types (i.e. granulosa cells and 
stromal cells) in the ovarian tissue of young TS patients with fluorescence in situ 
hybridization (FISH) analysis. First, we developed a protocol to isolate intact small 
(primordial and primary) follicles and stromal cells from ovarian cortex tissue. A second 
protocol was developed to efficiently separate the follicular cells (i.e. the oocyte and 
surrounding layer of granulosa cells). Figure 2 shows the three ovarian cell types that 
were analysed. 
Determining the number of chromosomes in the diploid (i.e. containing two complete 
sets of chromosomes) somatic ovarian cells (i.e. granulosa cells and stromal cells) was 
relatively straightforward. FISH with a centromere-specific probe gave two signals in 
each cell representing a pair of homologous chromosomes. However, analysis of 
oocytes from small follicles was more challenging as these cells are arrested in the 
prophase of meiosis I, and therefore tetraploid (i.e. containing four complete sets of 
chromosomes). At this stage of meiosis, each pair of homologous maternal and paternal 
chromosomes is held together by a synaptonemal complex. The very close proximity 
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of the homologous chromosomes in these complexes prevents the identification of 
individual chromosomes by FISH analysis. Determining the karyotype of these oocytes 
is therefore not possible by simply counting the number of signals for each chromosome. 
Therefore, we developed an additional procedure for determining the X chromosomal 
content in the normally tetraploid oocytes of meiosis I arrested follicles, based on the 
intensity of the FISH signal.
VIII.  What is the X chromosomal content of the ovarian cells in young patients with TS? 
(Chapter 6: Genetic aspect)
In addition, we performed a pilot study including the ovarian cortex fragments of ten 
young females with TS (mosaic TS n=5; classical TS n=5). Follicles were only found in 
the ovarian tissue of the five females with mosaic TS. 
This ‘proof of concept’ revealed that in these TS patients, 42 of the 46 oocytes (91%) 
that were analysed had a normal X chromosomal content. Granulosa cells were largely 
45, X but showed different levels of X chromosome mosaicism between patients and 
between follicles of the same patient. The karyotype of the stromal cells showed a ratio 
of cell lines (45, X; 46, XX and 47, XXX) that was somewhat similar to that of cells from 
urine, lymphocytes and/or buccal cells. 
Figure 2. Haematoxylin and eosin stained section of human ovarian cortical tissue showing 
several small (primordial and primary) follicles (blue arrow heads) and stromal cells (green arrow 












In the five patients with classical TS, no follicles were found, and the karyotyping of the 
ovarian stromal cells showed exclusively 45, X cells.
IX. Is the X chromosomal content of the ovarian cells in young females with TS correlated 
with the X chromosomal content of other cell types? (Chapter 6: Genetic aspect)
In the same pilot study, we showed that the analysis of extra-ovarian cells (lymphocytes, 
cells from buccal smears and urine) in TS patients with mosaicism does not seem to 
have any predictive value for the X chromosomal content of the ovarian cells (oocytes, 
granulosa and stromal cells). This substantiates the difference in levels of mosaicism, not 
only between patients but also between tissues and cells of the same type of a particular 
patient. 
X. Is FP also feasible in patients with 45, X monosomy? (Chapter 7: Patient-specific 
aspect)
Some clinicians are suggesting making FP available for females with a mosaic TS only. 
For now, we believe it is too preliminary to close the doors for FP already for other TS 
genotypes, purely based on the karyotype of 20-30 lymphocytes. 
In a case report, we report on a 13-year-old female who had been diagnosed with 45, 
X monosomy, or classical TS at the age of 8 years old but presented with spontaneous 
pubertal development. Ovarian tissue could be cryopreserved successfully, and follicles 
were found. This case of hidden ovarian mosaicism in a patient diagnosed with classical 
TS is not unique. Over the years the presence of oocytes and even pregnancies in 
several (apparently) 45, X women have been reported. However, the karyotyping 
methods in these cases were not clearly defined, and one can assume that these 
apparently 45, X women were in fact individuals with cryptic mosaicism.
As a clinician
As a clinician, I have experienced that humans are curious and always seeking for new 
technologies to improve their life. As clinicians, we bear the responsibility of practicing 
medicine to the best of our ability, where transparency to our patients is one of the 
most fundamental factors. If a medical technology is proven to be successful for one 
patient group (such as OTC in young cancer patients), it is logical that other patient 
groups such as those with TS also search for possibilities to benefit from this technique. 
However, the effectiveness of OTC in females with TS should be confirmed first, before 
it can be offered in daily practice. Nonetheless, OTC procedures have been performed 
in single TS patients without evidence of benefit and most of the time, without the 
insurance covering the costs of the surgical intervention and additional cryopreserva-
tion procedure. 
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I believe, just like our TurnerFertility expert panel [16], that it is better to offer OTC to 
females with TS in a safe and controlled research setting first. Most preferably, in a 
university medical centre with high experience in FP techniques and a dedicated team 
of counsellors and surgeons. 
I am proud that with this research project, specialized consultation hours at Radboud 
university medical centre were launched. We are now one of the first centres in the 
Netherlands where Dutch patients with TS and their parents are structurally and fully 
counselled about fertility, FP and alternative options to become a parent in the future. 
I believe it is extremely important that patients are informed about this as soon as 
possible, following their diagnosis. The consultation should be patient-specific and 
age-specific and can be extended with additional counselling sessions in the future.
I really hope that this will lead to less psychological burden and thus, better health care, 
because patients are now better informed. 
Qualitative research, including interviews and focus groups with patients and other 
stake holders, and health care evaluations could improve future counselling. 
Furthermore, our ‘static’ option grid should be further optimized to a real decision aid. 
In the future, a prediction model could help me and my colleagues to specify the 
counselling. In the meanwhile, I recommend other clinicians to add at least a buccal cell 
FISH analysis in patients diagnosed with 45, X monosomy or low-grade mosaicism. In 
most centres, karyotyping of 20-30 lymphocytes is the standard technique used to 
determine TS. We believe that in these particular patients, the analysis of 1) 2 different 
cell types, and 2) more cells, will result in a higher chance of identifying additional cell 
lines and thus, a better chromosomal evaluation. 
Lastly, I hope that this thesis will generate more knowledge about TS in the general 
population, and lead to more equality and justice for TS patients regarding FP options. 
It would be grateful if in twenty years, when I am still working as a clinician, this thesis 
has led to a cascade of research, new insights regarding the early loss of the ovarian 
reserve in females with TS, and novel options to preserve the fertility in this specific 
group of patients.
As a researcher
As a researcher, I realize that we are still standing at the beginning of a long road. At this 
moment, FP in females with TS is still theoretical. This means, that we do not know yet 
if the cryopreserved ovarian tissue of females with TS is functional, and if autotransplan-
tation in the future will lead to healthy offspring. In the worst-case scenario, we will 
perform a long-term intervention study in 100 young females, and none of them will 
profit from it. 
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This sounds controversial, especially as good clinical practice (GCP) is based on primum 
non nocere (‘first, do no harm’), but we should also not forget the importance of the 
3 other basic principles autonomy (what do patients want?), beneficence (how can we 
help these patients the best?) and justice (equal access to medical treatment options for 
all patients worldwide).
We should realize that only a few years ago our Oncofertility colleagues were standing 
at the same crossing. It takes imagination and dedication to introduce new treatment 
options, but also some courage and patience. You should be prepared for lots of 
criticism, and in the first few years, you will not have clear answers yet. 
To ensure the safety of participants and the validity and integrity of study data, a data 
and safety monitoring board (DSMB), data monitor and an independent confidential 
advisor were appointed. Our research protocol underwent a lengthy process to 
become ethically approved. This long waiting time, we used to publish an overview of 
the existing literature regarding OTC in females with TS [17], to optimize the logistical 
processes and to improve the laboratory aspects of OTC, specifically for females with 
TS [18, 19]. Ethical approval was obtained by the end of November 2017, and thanks to 
our preparations we could start including the first patients January 2018. This long-term 
follow-up study will focus on the efficacy of OTC in females with TS including pregnancy 
rates, pregnancy outcomes and maternal, as well as foetal risks. 
As it will take years for the final results of the main project (long-term follow-up study) 
to be expected, in vitro and in vivo studies could be performed in the meantime. These 
studies should focus on oocyte genetics, activation of immature oocytes in isolated 
ovarian tissue [20-23], maturation of immature oocytes obtained from cryopreserved 
ovarian tissue (IVM) [24], and the development of artificial gametes from stem cells 
[25] to optimize the chances for females with TS of becoming biological parents. 
Furthermore, qualitative research should focus on the optimization of counselling and 
the development of a decision aid. In cooperation with our team of paediatric surgeons, 
retrospective data regarding the surgical outcomes and the recovery of OTC in females 
with TS should be collected, evaluated and reported.
In case that OTC has proven to be a successful technique to preserve the fertility of 
(some) females with TS, it is essential to avoid unnecessary surgical interventions in the 
future. Ideally, a reliable prognostic model for estimating the ovarian reserve in females 
with TS as early as possible in life should be developed. The data of the TurnerFertility 
trial can be used for the development of this prognostic model but should also be 
validated in an external cohort. This model can be expanded with the data of an 
additional cohort study of our research group, i.e. the Minipuberty study, in which we 
focus on early indicators of exhaustion of the ovarian reserve in young children with TS.
The effectiveness of other FP techniques in females with TS, such as vitrification of 
mature oocytes, should also be studied and reported. Furthermore, more information 
regarding the pros and cons of (intra-familiar) oocyte donation in females with TS 
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should be gathered and compared with the pros and cons of FP techniques. 
Lastly, I would recommend future researchers to include a proper genetic analysis (i.e. 
the cell type(s) used for chromosome analysis and the number of cells that were 
determined), when reporting on TS and fertility outcomes. This important information 
is currently lacking in most published papers. 
Patient and Public Involvement
As a researcher with little experience, I am proud to have contributed to the 
establishment of a new research theme (TurnerFertility) at the Radboud university 
medical centre. I believe we performed our research in a deliberate and thoughtful 
manner, especially since we actively involved patients in the research process. In 2014, 
the Lancet published the series Research: increasing value, reducing waste. Chalmers and 
his colleagues [26] covered the issue of how to decide which future research questions 
need answering, suggesting a few research approaches, particularly patient engagement 
in medical research. This thesis is an example of patient-initiated research as there was 
an increasing demand from patients and their parents to explore the possibilities of 
(experimental) FP options in girls and young females with TS. In 2016, the TurnerFer-
tility research project started with a brainstorm meeting with patients and patient 
representatives in collaboration with the Dutch patient organization (Turner Contact 
Nederland). Afterwards, the research protocol [27] and patient information brochures 
were developed together with patients and patient representatives. Furthermore, 
patients and patient representatives were actively involved in the ethical approval and 
ethical Delphi study. Interim results were published in plain language on our website 
and in a newsletter, so that patients and their parents were well informed. Furthermore, 
regular information evenings were held to inform newly diagnosed patients and their 
parents about our research projects. Lastly, surveys were sent out and focus groups 
with patients and patient representatives were organized to evaluate our research, to 
discuss experiences and to share ideas about future projects. 
Arnstein’s [1] ‘ladder of engagement’ is commonly used by both patients and researchers 
to describe or explain the level of patient engagement in medical research (Figure 1). 
I hope that our research project can be positioned on one of the upper four rungs 
(Placation, Partnership, Delegated Power, Citizen Control). However, to move from 
tokenism to patient empowerment, the patient involvement in our research project 
should be further progressed by overcoming the barriers and enablers. For example as 
suggested by Ocloo et al. [28], by involving a more diverse group of patients and by 
making our meetings more attractive, inclusive and enjoyable, or by using different 
methods of involvement that go beyond traditional methods (i.e. meetings and surveys) 
such as supportive activities and informal venues. Furthermore, our research team 
should be easily accessible, and we could focus more on speaking slowly, avoid jargon, 
and communicate in other ways than speech / printed material (our E-mail box, 
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information letters and brochures), e.g. an interactive website including multimedia and 
visual materials. 
Finally, I hope that in the future, more patients will be involved in the design and 
evaluation of medical research projects, because patient-involvement will contribute to 
a fresh perspective on research and meaningful healthcare improvements [26].
As a policy maker
The WHO states that all individuals have the right to decide freely the number, spacing 
and timing of their children and that patients should have access to all medical treatments 
[29]. Some people believe that FP services should be available for everybody, without 
discrimination. A few years ago, this has led to a debate to expand FP options to other 
patient groups (e.g. transgenders and girls with TS) than girls undergoing gonadotoxic 
cancer treatments. After ethical approval was obtained to perform FP in Dutch 
trans-males, it was expectable that also girls with TS would be a patient group 
demanding for the possibility to undergo FP in a research setting. However, expanding 
FP to other patient groups might raise some ethical concerns especially in females with 
TS, as its efficacy is still unknown, while performing surgery in very young children is 
required. In such complex situations, the Delphi method is used for decision-making. As 
stated in this thesis, an international expert panel of gynaecologists, (paediatric) endo-
crinologists, (medical) ethicists, patients and patient representatives stated that OTC 
should be offered to females with TS, but not yet in routine care. The efficacy should 
first be studied in a safe and controlled research setting. As a policy maker, I would 
initiate an international register, containing clinical information of all cases of FP in 
females with TS, including details on fertility outcomes and predictive markers. 
Secondly, further steps should be made in order to find a balance between good quality 
care and the economic burden to the society. These cost-benefit analyses should also 
focus on the psychological burden of infertility in females with TS, alternative options 
for biologically own children (e.g. oocyte donation or adoption) and the costs associated 
with this. 
As a female
Unfortunately, I have met several adult TS patients who were not informed about their 
infertility or had received outdated information. 
I believe that all humans would like to be well-informed about their body, health and 
reproductive system. This information should be age-specific and up to date. General 
information about the reproductive system can be given by parents and schoolteachers. 
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Most preferably it is provided from a young age onwards, frequently repeated, and 
extended with additional age-specific information at the appropriate moment. 
In girls and females that have been recently diagnosed with TS, the specific information 
regarding TS and fertility should be provided by a dedicated team of caregivers. It is 
important that the girl and her parents receive this information as soon as possible after 
the diagnosis. Especially, since infertility, but also the uncertainty about their fertility is 
one of the major concerns for TS patients and their parents [30, 31]. This information 
should mainly focus on the pathogenesis of the early loss of germ cells or ovarian 
reserve, and ideally be extended with a patient-specific risk profile based on the best 
available evidence. Furthermore, the alternative options to become a parent should be 
discussed, such as foster ship, adoption or (intrafamilial) oocyte donation. Lastly, 
information should be given about TS and pregnancy, especially in high-risk patients. 
After all these issues have been addressed, FP can be suggested including the possible 
benefits and risks of the procedure. 
Depending on the girl’s personal situation, her age, and the communication with her 
parents, additional counselling from a paediatrician or a specialized paediatric 
psychologist could be considered. Furthermore, it could be helpful if she receives the 
information in different ways (i.e. presentation, personal counselling, brochures, 
internet, images) from different perspectives (i.e. paediatrician, gynaecologist, paediatric 
surgeon, paediatric psychologist, and/or peers). 
Final conlusion
OTC could be a promising method to preserve fertility in females with TS. However, 
the efficacy of OTC in young females with TS is at present theoretical. Therefore, we 
suggest that OTC in females with TS is offered solely in a safe and controlled research 
setting. The TurnerFertility trial (CCMO NL57738.000.16, ClinicalTrial ID 
NCT03381300) emerged from the preparations that were made in this thesis. In this 
long-term follow-up study, we will focus on the efficacy of OTC in females with TS 
including pregnancy rates, pregnancy outcomes and maternal, as well as the foetal risks. 
Hence, it will take years for the final results to become available. In the meanwhile, my 
colleagues will focus on gathering more knowledge regarding the factors and pathways 
associated with the increased loss of germ cells in females with TS. In the future, 
targeted interventions could be developed to increase the chances for females with TS 
of becoming biological parents. In addition, qualitative studies are needed to improve 
the current health care, optimize the counselling process, prevent decision-regrets and 
psychological burden of counselling. 
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Summary
In this thesis, the various challenges of ovarian tissue cryopreservation (OTC) as a 
fertility preservation procedure for girls and young females with Turner syndrome (TS) 
were explored. 
In Chapter 2 we show that experimental fertility preservation (FP) procedures such 
as OTC and the vitrification of mature oocytes (OC) have been reported in more than 
150 girls and adolescents with TS, but that the efficacy is still unknown due to the lack 
of follow-up data. 
In young cancer patients, OTC is already an established fertility preservation method. 
Autotransplantation of cryopreserved ovarian tissue in cancer survivors has resulted in 
restoration of ovarian function, pregnancies and more than 130 live-births. The efficacy 
of ovarian function restoration is highly related to the number of follicles in the autograft. 
So preferably, the ovarian fragments with the highest number of follicles should be 
selected for autotransplantation purposes. This is of clinical importance in all patients 
undergoing autotransplantation of cryopreserved ovarian tissue, but especially in 
patients with a reduced ovarian reserve during OTC such as TS patients. However, 
determining the follicular density with conventional histology renders the tissue 
unsuitable for subsequent transplantation. In addition, follicles are not evenly distributed 
across the ovarian cortex surface, and therefore determining follicle density in one 
tissue fragment does not necessarily reflect the number of follicles in adjacent 
fragments. Ideally, a non-invasive imaging technique is used to determine the number 
of follicles in each ovarian cortex fragment, so that the fragments with the highest 
follicle density can be selected for autotransplantation first.
In Chapter 3 we investigated whether reflectance confocal microscopy (RCM) could 
be used as a non-invasive imaging technique to determine the number of follicles, and 
the vertical and horizontal distribution, in human ovarian cortical tissue fragments. In 
this proof of concept study, we show that RCM is a promising technique to determine 
the density of follicles ex vivo in ovarian cortex fragments, apparently without 
compromising the vitality of the tissue. Safety studies and further optimization of the 
RCM technique with a focus on increasing the penetration depth in ovarian tissue are 
required before RCM can be applied in routine care. 
Expanding OTC to girls and young females with TS raises complicated medical and 
ethical questions, and therefore remains a controversial topic for many clinicians. 
However, patient organizations are optimistic and demand equal access to FP options 
worldwide. In Chapter 4 we explored the opinion of an international panel including 
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both professionals and patient representatives whether OTC should be offered to girls 
and young females with TS, or not. In a three-stage ethical Delphi study, the advantages 
and disadvantages of OTC in females with TS were systematically discussed. The aim of 
this study was to reach group consensus and to form an internationally accepted 
standpoint regarding OTC in girls and young females with TS. Our expert panel agreed 
that OTC should be offered to patients with TS, but only in a safe and controlled 
research setting. This approval marks the first step towards the global acceptance of 
performing OTC in females with TS.
A randomized controlled trial (RCT) is considered as the best research strategy when 
testing the effectiveness of new treatments. However, in our opinion, it is unethical but 
also logistically impossible to perform laparoscopic surgery followed by experimental 
OTC in minors in a randomized controlled trial research setting including blinding and 
treatment allocation. In Chapter 5, we suggest to perform a pilot study instead, i.e. an 
observational intervention study with long-term follow-up in a tertiary fertility clinic in 
the Netherlands including 100 females aged 2 through 18 years with classical Turner 
(i.e. 45, X monosomy) or Turner variants (i.e. 45, X mosaicism or structural anomalies, 
except the presence of Y-chromosomal material). The aim of this study is to investigate 
the occurrence of live birth in women with TS after OTC in childhood followed by 
autotransplantation in adulthood. In addition, the study results can be used to find 
prognostic markers for the presence or absence of follicles, so that ovarian reserve in 
girls with TS can be estimated better in the future, and/or at a young age.
If follicles are found in the ovarian tissue of a female with TS, the question arises if these 
follicles are truly functional, i.e. if they will lead to pregnancies and (healthy) offspring in 
the future. As the tissue functionality in TS appears to be largely dependent on the 
karyotype of the cells, we developed a method (Chapter 6) to analyse the X 
chromosomal content of oocytes and two supporting cell types (i.e. granulosa cells and 
stromal cells) in human ovarian tissue with fluorescence in situ hybridization (FISH). In 
addition, we performed a pilot study including the ovarian cortex fragments of ten 
young females with TS. 
In the five patients with mosaic TS, a total number of 46 oocytes could be analyses, and 
42 (91%) had a normal X chromosomal content. Surprisingly, the surrounding granulosa 
cells were largely 45, X but showed different levels of X chromosome mosaicism 
between patients and between follicles of the same patient. The karyotype of the 
stromal cells showed a variety of cell lines (45, X; 46, XX and 47, XXX) that was 
somewhat similar to that of cells from urine, lymphocytes and/or buccal cells. This 
substantiates the difference in levels of mosaicism, not only between patients but also 
between tissues and cells of the same type of a particular patient. In the five patients 
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with classical TS, no follicles were found, and the karyotyping of the ovarian stromal 
cells showed exclusively 45, X cells. 
The chance that follicles are found in a 45, X monosomy patient is relatively small 
according to previous research. Some clinicians therefore suggest making OTC available 
for females with a mosaic TS only. For now, we believe it is too preliminary to close the 
doors already for some TS subtypes, purely based on the karyotype of 20-30 
lymphocytes. To illustrate this, we report on a case (Chapter 7) of cryptic mosaicism 
in a 13-year-old female who had been diagnosed with 45, X monosomy, or classical TS 
at the age of 8 years old. She presented with spontaneous pubertal development, and 
recently underwent laparoscopic surgery for OTC. Ovarian tissue could be 
cryopreserved successfully, and follicles were found. All primordial follicles that were 
investigated, contained oocytes with a normal tetraploid 92, XXXX karyotype but 
were surrounded exclusively by diploid 45, X granulosa cells. Karyotyping of the stromal 
cells showed a mosaic pattern with 3 cell lines 45, X / 47, XXX / 46, XX, indicating the 
presence of additional cell lines besides 45, X.
In conclusion, OTC is a promising method to preserve fertility in females with TS. 
However, the efficacy of OTC in young females with TS is at present hypothetical. 
Therefore, we suggest that OTC in patients with TS is offered solely in a safe and 
controlled research setting. The TurnerFertility trial (CCMO NL57738.000.16, 
ClinicalTrial ID NCT03381300) emerged from the preparations that were made in this 
thesis. 
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Samenvatting
In dit proefschrift lichten we vanuit verschillende perspectieven toe welke uitdagingen 
er komen kijken bij het invriezen van ovariumweefsel (OTC) ten behoeve van fertiliteit-
spreservatie bij meisjes en jonge vrouwen met het syndroom van Turner (TS).
In Hoofdstuk 2 beschrijven we dat bij meer dan 150 meisjes en jonge vrouwen met TS 
reeds gepoogd is om de vruchtbaarheid te sparen middels OTC of het invriezen van 
rijpe eicellen (OC). Helaas is de effectiviteit van deze technieken voor deze specifieke 
patiëntengroep vooralsnog onbekend door een gebrek aan follow-up data.
Bij jonge kankerpatiënten is OTC al wel een gevestigde methode om de vruchtbaarheid 
te sparen. Autotransplantatie van gecryopreserveerd ovariumweefsel bij overlevenden 
van kanker heeft geresulteerd in het herstel van de ovariële functie, zwangerschappen 
en meer dan 130 levendgeborenen. De kans op het herstel van de ovariële functie is 
grotendeels gerelateerd aan het aantal follikels in het autotransplantaat. Idealiter 
worden daarom de ovariumfragmenten met het hoogste aantal follikels geselecteerd 
voor autotransplantatie. Dit is van klinisch belang voor alle patiënten die autotransplan-
tatie van gecryopreserveerd ovariumweefsel ondergaan, maar vooral voor patiënten 
die bij OTC al over een verminderde ovariële reserve beschikken zoals patiënten met 
TS. Het bepalen van de folliculaire dichtheid met conventionele histologie maakt het 
weefsel echter ongeschikt voor autotransplantatie. Bovendien zijn de follikels niet 
gelijkmatig verdeeld over het oppervlak van de ovariële cortex, en daarom geeft het 
bepalen van de follikeldichtheid in één weefselfragment niet noodzakelijkerwijs het 
aantal follikels in de andere fragmenten weer. Idealiter wordt daarom gebruik gemaakt 
van een niet-invasieve beeldvormende techniek om het aantal follikels in elk ovarium-
cortexfragment te bepalen, zodat de fragmenten met de hoogste follikeldichtheid als 
eerste geselecteerd kunnen worden voor autotransplantatie. In Hoofdstuk 3 hebben 
we onderzocht of reflectanceconfocalmicroscopy (RCM) een geschikte niet-invasieve 
beeldvormende techniek is om het aantal follikels, en de verticale en horizontale 
verdeling, in humaan ovariumweefsel te bepalen. In deze proof of concept-studie laten 
we zien dat RCM een veelbelovende techniek is om de dichtheid van follikels ex vivo in 
ovariumweefsel te bepalen zonder de vitaliteit van het weefsel in gevaar te brengen. 
Veiligheidsstudies en verdere optimalisatie van de RCM-techniek, met name het 
vergroten van de penetratiediepte in ovariumweefsel, zijn vereist voordat deze techniek 
in de routinezorg kan worden toegepast. 
Het uitbreiden van de doelgroep voor vruchtbaarheidssparende technieken zoals OTC 
met meisjes en jonge vrouwen met TS is een ingewikkeld medisch en ethisch vraagstuk 
en blijft daarom een  controversieel onderwerp voor veel clinici. Patiëntenorganisaties 
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zijn echter optimistisch en eisen een gelijke toegang tot vruchtbaarheidssparende 
technieken wereldwijd. In Hoofdstuk 4 onderzochten we de opinie van een inter-
nationaal expert panel, bestaande uit zowel professionals als patiëntenvertegenwoor-
digers, of OTC al dan niet moet worden aangeboden aan meisjes en jonge vrouwen 
met TS. Tijdens dit Delphi-onderzoek werden eerst de voor- en nadelen van OTC bij 
meisjes en jonge vrouwen met TS systematisch in 3 rondes bediscussieerd. Het doel 
hiervan was om panel consensus te bereiken en een internationaal aanvaard standpunt 
te vormen met betrekking tot OTC bij meisjes en jonge vrouwen met TS. Ons expert - 
panel concludeerde vervolgens dat OTC moet worden aangeboden aan patiënten met 
TS, maar alleen in een veilige en gecontroleerde onderzoekssetting. Deze goedkeuring is 
de eerste stap naar de wereldwijde acceptatie van OTC bij meisjes en jonge vrouwen 
met TS.
Een gerandomiseerde gecontroleerde studie (RCT) wordt beschouwd als de beste 
onderzoeksstrategie voor het testen van de effectiviteit van een nieuwe behandeling. 
Echter, is het, naar onze mening, niet alleen onethisch maar ook logistiek onmogelijk om 
een laparoscopische ingreep gevolgd door experimentele OTC uit te voeren in een 
gerandomiseerde gecontroleerde onderzoekssetting (inclusief blindering en behande-
lingstoewijzing) bij een minderjarige. In Hoofdstuk 5 stellen we daarom voor om een 
pilotstudie uit te voeren in plaats van een RCT. We stellen een observationele inter-
ventiestudie voor met langdurige follow-up in een tertiaire vruchtbaarheidskliniek in 
Nederland waarbij een cohort van 100 vrouwen van 2 tot 18 jaar met klassieke Turner 
(dwz 45, X monosomie) of Turner-varianten (dwz 45, X-mozaïcisme of structurele 
anomalieën, behoudens de aanwezigheid van Y-chromosomaal materiaal) zal worden 
geïncludeerd. Het doel van deze studie is om te kijken of OTC op jonge leeftijd, gevolgd 
door autotransplantatie op volwassen leeftijd, bij vrouwen met TS ook zal leiden tot 
levendgeboren kinderen. Daarnaast kunnen de studieresultaten gebruikt worden om 
prognostische markers te vinden voor de aan- of afwezigheid van follikels, zodat de 
ovariële reserve bij meisjes met TS in de toekomst wellicht beter, en/of al op jonge 
leeftijd kan worden ingeschat.
Als er follikels worden gevonden in het ovariumweefsel van een meisje of jonge vrouw 
met TS, rijst vervolgens de vraag of deze follikels ook daadwerkelijk functioneel zijn, dat 
wil zeggen of ze ook tot zwangerschappen en (gezonde) nakomelingen zullen leiden. 
Omdat de weefselfunctionaliteit bij patiënten met TS voor een groot deel afhankelijk 
lijkt te zijn van het karyotype van de cellen, hebben we een methode ontwikkeld 
(Hoofdstuk 6) om het X-chromosomale gehalte van oöcyten en twee ondersteunende 
celtypen in het ovarium (granulosacellen en stromacellen) te analyseren met behulp 
van Fluorescentie in situ hybridisatie (FISH). Vervolgens hebben we een pilotstudie 
uitgevoerd met ovariële cortexfragmenten afkomstig van tien jonge meisjes met TS. 
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Bij de vijf patiënten die gediagnosticeerd waren met 45,X mozaïcisme konden er in 
totaal 46 eicellen geanalyseerd worden, hiervan hadden 42 eicellen (91%) een normaal 
X-chromosomaal gehalte. Verrassend genoeg waren de omliggende granulosacellen 
grotendeels 45, X, maar vertoonden de andere granulosacellen grote verschillen in 
X-chromosoommozaïcisme tussen patiënten maar ook tussen follikels van dezelfde 
patiënt. Het karyotype van de stromacellen bestond uit verschillende cellijnen (45, X, 
46, XX en 47, XXX) en was enigszins vergelijkbaar met het karyotype van de verkregen 
cellen uit urine, lymfocyten en/of buccale cellen. Deze resultaten laten zien dat de mate 
van X-chromosoommozaïcisme bij patiënten met TS sterk varieert, niet alleen tussen 
patiënten maar ook binnen de verschillende weefsels en celtypes van een dezelfde 
patiënt. Bij de vijf patiënten met klassieke TS werden geen follikels gevonden en de 
karyotypering van de ovariële stromacellen vertoonde uitsluitend 45, X-cellen. 
De kans dat er bij een 45, X monosomiepatiënt follikels worden gevonden, is volgens 
eerder onderzoek ook relatief klein. Sommige clinici stellen daarom voor om OTC 
alleen beschikbaar te maken voor vrouwen met mozaïek TS. Op dit moment denken 
we dat het te voorbarig is om de deuren al voor bepaalde subgroepen te sluiten, puur 
gebaseerd op het karyotype van 20-30 lymfocyten. Om dit te illustreren, beschrijven 
we een casus (Hoofdstuk 7) van cryptisch mozaïcisme bij een 13-jarige meisje bij wie 
op 8-jarige leeftijd de diagnose 45, X-monosomie of klassieke TS was gesteld. 
Desondanks trad er een spontane puberteitsontwikkeling op en onderging zij recentelijk 
een laparoscopische operatie ten behoeve van OTC. Ovariumweefsel kon met succes 
worden gecryopreserveerd en er werden daadwerkelijk follikels gevonden. Alle 
primordiale follikels die werden onderzocht, bevatten oocyten met normaal tetraploïde 
92, XXXX karyotype, maar waren uitsluitend omgeven door diploïde 45, X granu-
losacellen. Karyotypering van de stromacellen vertoonde een mozaïekpatroon met 3 
cellijnen 45, X / 47, XXX / 46, XX, wat wijst op de aanwezigheid van extra cellijnen 
naast 45, X. 
Concluderend is OTC een veelbelovende methode om de vruchtbaarheid bij vrouwen 
met TS te sparen. De effectiviteit van OTC bij meisjes en jonge vrouwen met TS is 
momenteel echter hypothetisch. Daarom stellen we voor dat OTC bij patiënten met 
TS uitsluitend wordt aangeboden in een veilige en gecontroleerde onderzoeksomge-
ving. De TurnerFertility trial (CCMO NL57738.000.16, ClinicalTrial ID NCT03381300) 
is voortgekomen uit de voorbereidingen die in dit proefschrift zijn getroffen.
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List of abbreviations 
AMH Anti-Müllerian Hormone
ART Assisted Reproductive Technology
BMI Body Mass Index
BROK Basiscursus Regelgeving En Organisatie Voor Klinisch Onderzoekers
CCMO Centrale Commissie Mensgebonden Onderzoek
CE Conformité Européenne
CEP Centromere Specific Probe
CV Curriculum Vitae
DAPI 4’,6-Diamidino-2-Phenylindole
DMEM Dulbecco’s Modified Eagle Medium 
DSD Disorders Of Sexual Differentiation
DSMB Data Safety Monitoring Board
E2 Estradiol
EDC Electronic Data Capture
EDTA Ethylenediaminetetraacetic Acid 
Et al. Et Alii, And Others
FBS or FCS Foetal Bovine Serum Or Foetal Calf Serum
FFPE Formalin Fixated And Paraffin Embedded
FISH Fluorescence In Situ Hybridization
FP Fertility Preservation
FSH Follicle-Stimulating Hormone
GCP Good Clinical Practice
HE Haematoxylin And Eosin Stain
HIV Human Immuno-Deficiency Virus
IBM International Business Machines Corporation 
IC Informed Consent
IQR Interquartile Range 
ISO International Organization For Standardization
IVA In Vitro Activation
IVM In Vitro Maturation
IVF In Vitro Fertilisation
KCL Potassium Chloride
LBR Live Birth Rate
LH Luteinizing Hormone
METC Medisch Ethische Toetsing Commissie
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OC Cryopreservation Of Mature Oocytes
OCT Optical Coherence Tomography
OTC Ovarian Tissue Cryopreservation
PhD Doctor (Of Philosophy), Academic Title
POI Premature Ovarian Insufficiency
PRISMA-P Preferred Reporting Items For Systematic Review And Meta-Analysis Protocols
RAND / UCLA Research And Development / University Of California Los Angeles
RCM Reflectance Confocal Microscopy
(S)AE (Serious) Adverse Event
SD Standard Deviation
SPSS Statistical Package For The Social Sciences
SUSAR Suspected Unexpected Serious Adverse Reaction
TS Turner Syndrome
TCN Turner Contact Nederland
VWS Ministerie Van Volksgezondheid, Welzijn En Sport
WMA World Medical Association
WHO World Health Organization
WMO Wet Medisch-Wetenschappelijk Onderzoek Met Mensen
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Research data management 
This thesis is based on the results of human studies, which were conducted in 
accordance with the principles of the Declaration of Helsinki, the Medical Research 
Involving Human Subjects Act (WMO), the Guideline for Good Clinical Practice, and 
all other applicable regulatory requirements. 
For Chapter 2 and 4, no ethical review board approval was obtained, as these studies 
did not involve human subjects or tissue. The study conducted in Chapter 3 was 
approved by three local ethical committees for patient-related research, i.e. the 
Ethical committee Arnhem and Nijmegen, reference numbers: 2016-2894 and 
2016-2871, date of approval: 12 October 2016 and 19 December 2016; the Ethical 
committee Amsterdam, reference number: 2017.168, date of approval: 28 March 
2017; and the Ethical committee Bonn reference number: 007/09, date of approval: 11 
May 2008. Chapter 5, 6 and 7 are part of the TurnerFertility trial, for which ethical 
approval was obtained by the Dutch Central Committee on Research Involving 
Human Subjects in 2017 (CCMO NL57738.000.16).
All biological material and data is handled and stored according to the World Medical 
Association (WMA) Declaration of Taipei on ethical considerations regarding health 
databases and biobanks (67th WMA General Assembly. Taipei, Taiwan. October 
2016). All patient data is coded. Members of the research team, the Data and Safety 
Monitoring Board, and the Health Care Inspectorate are the only persons who have 
access to the key of the code. This key of code is stored in Castor Electronic Data 
capture (EDC). 
A safe storage of the ovarian tissue and consent forms is provided at our cryobank. 
This cryobank is ISO-accredited (accreditation number M101, ISO 15189), and 
registered by the Dutch Ministry of Health, Welfare and Sport (VWS) (registration 
number 5515 L/EO). The cryobank is located at a restricted area in the Radboud 
University Medical Centre, and access is permitted by electronic authorization only. 
All patients and/or their parents had provided written informed consent. 
Research data and study scripts are stored on the Radboudumc department server 
(H:)\\Umcfs049\verlgyndata$\Onderzoek\VPG- FP and Turner. Published data 
generated of analysed in this thesis are parts of published articles. All published 
articles in this thesis are saved in the Radboud Repository. Chapter 5 and 6 are 
published open access. Additional files are available from the corresponding author 
on request.
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